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Abstract 
Rett Syndrome (RTT) is an X-linked genetic disorder and a major cause of 
intellectual disability in girls. Mutations in the methyl-CpG binding protein 2 
(MECP2) gene, are the primary cause of the disorder. Despite the dominant 
neurological phenotypes that characterise RTT, MECP2 is expressed ubiquitously 
throughout the body and a number of peripheral phenotypes such as growth 
retardation (reduced height and weight), skeletal deformities (scoliosis/kyphosis), 
reduced bone mass and low energy fractures are also common yet under-reported 
clinical features of the disorder.  
In order to explore whether MeCP2 protein deficiency results in altered structural 
and functional properties of bone and to test the potential reversibility of any such 
defects, I have conducted series of histological, imaging and biomechanical tests 
of bone using an accurate genetic (functional knockout) mouse model of RTT. 
Initial experiments using a GFP reporter mouse line demonstrated the presence of 
MeCP2 in bone cells and the effective silencing on the gene in functional knockout 
mice. Different aspects of the study were conducted in different types of bone 
tissues that were especially suited for individual assays. For instance, 
biomechanical three point bending tests were conducted in long bone (femur) 
whilst trabecular geometry measures were measured in spinal vertebrae. 
Both hemizygous Mecp2stop/y male mice in which Mecp2 is silenced in all cells and 
female Mecp2stop/+ mice in which Mecp2 is silenced in ~50% of cells as a 
consequence of random X-chromosome inactivation (XCI), revealed, lighter and 
smaller long bones and significant reductions in cortical bone mechanical 
properties (~ 39.5% reduction in stiffness, 31% reduction in ultimate load and 37% 
reduction in Young’s modulus respectively in Mecp2stop/y male mice; %) and 
material properties (microhardess reduced 12.3% in Mecp2stop/y male mice and 
14% inMecp2stop/+ female mice) as compared to age wild type control mice. Micro 
structural analysis conducted using µCT also revealed a significant reduction in 
cortical (54% reduction in cortical thickness, 30% in bone volume, 20% in total 
area, and 38% in marrow area) and trabecular (~30% in trabecular thickness) 
bone parameters as compared to age matched wild-type controls MeCP2-deficent 
mice. Histological analysis using Sirius red staining as a marker of collagen 
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revealed a ~25% reduction in collagen content in MeCP2 deficient mice as 
compared to age matched wild type controls.  
In experiments designed to establish the potential for reversal of MeCP2-related 
deficits, unsilencing of Mecp2 in adult mice by tamoxifen-induced and cre-
mediated excision of a stop cassette located at the endogenous Mecp2 locus 
(male; Mecp2stop/y, CreER and female; Mecp2+/stop, CreER), resulted in a 
restoration of biomechanical properties towards the wild-type levels. Specifically, 
Male Mecp2stop/y, CreER mice displayed improvement in mechanical properties 
(stiffness 40%, ultimate load 10%, young’s modulus 61% and micro hardness 
12%) and structural bone parameter (trabecular thickness 80%) as compared to 
Mecp2stop/y male mice. Female Mecp2+/stop, CreER, displayed a significant 
improvement (19%) in microhardess measures as compared to Mecp2 deficient 
mice.  
Overall, the results of my studies show that MeCP2-deficiency results in overt, but 
potentially reversible, alterations in the biomechanical integrity of bone and 
highlights the importance of targeting skeletal phenotypes in considering the 
development of pharmacological and gene-based therapies for Rett Syndrome.  
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Chapter 1  
General Introduction 
  
Andrea Rett, an Austrian physician, first noticed Rett syndrome (RTT) in 2 young 
girls as they sat in the waiting room of his clinic. He observed that the children 
were making the same repetitive hand-washing motions. In 1966, he conducted a 
comparative review of 22 young females exhibiting similar symptoms and 
compulsive stereotyped behaviours (Rett, 1966). He proposed the unusual brain 
atrophy of RTT affected girls is linked to the hyper ammonia in childhood. Later on 
after a gap of 17 years (in 1983)  similar finding were described by Hagberg et al 
(Hagberg et al., 1983). Dr Hagberg highlighted the findings presented by Andrea 
Rett including the classical normal growth followed by developmental delay, 
autism, gait abnormalities, atypical hand movements and microcephaly. He also 
proposed that the particular occurrence of this syndrome in girls could be linked to 
the X-linked genetic inheritance of this syndrome. However, of inspite of his great 
interest, the cause of Rett syndrome remained unknown (Hagberg et al., 1983). Dr 
Hagberg paper did manage to enhance the awareness of Rett syndrome in 
worldwide scientific community. Three years later in 1986, Suzuki et al found same 
clinical picture of RTT in their study of seven girls. They agreed with Rett’s and 
Hagberg’s description of signs and symptoms of the disorder but they could not 
found any abnormalities in blood chemistry of these young patients and found 
ammonia levels to be normal in these females (Suzuki et al., 1986). 
From 1983 until late 1990s, many studies were conducted not only to discover the 
root cause of syndrome but also to define the clinical picture and different 
treatment options especially in scientific communities of countries like Spain, 
Germany, United Kingdom, Norway, Japan and Tunisia (Glaze et al., 1987; 
Campos-Castelló et al., 1988; Keret et al., 1988; Roberts and Conner, 1988; Loder 
et al., 1989; Holm and King, 1990; Yano et al., 1991; Witt Engerström, 1992; 
Budden, 1995; Plöchl et al., 1996; Haas et al., 1997; Glasson et al., 1998). 
Nearly three decades after the first discovery of RTT, in 1999 the disorder was   
21 
 
shown to be caused primarily by mutations in the X-linked gene, MECP2 (Amir et 
al., 1999). Amir et al used a systemic gene screening approach and identified 
mutations in the gene (MECP2) encoding X-linked methyl –CpG-binding protein 2 
(MeCP2) as the primary cause of RTT. Their study also suggested aberrant 
epigenetic regulation as potential mechanism underlying the RTT pathology. 
The discovery of the genetic cause of RTT enhanced the scientific research 
interest and number of groups had developed Mecp2 knockout mouse models 
(Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 2002b) in order to explore 
the underlying biology and pathophysiology of Rett syndrome. 
In addition to neurological phenotypes, a number of overt ‘peripheral’ phenotypes 
are also common in RTT. For instance spinal deformity (principally scoliosis and 
excessive kyphosis) is a very common feature with approximately 50-90% of 
patients developing severe scoliosis, (Keret et al., 1988; Huang et al., 1994; 
Lidström et al., 1994; Percy et al., 2010) many of whom require corrective surgery. 
Other prominent skeletal anomalies include early osteoporosis, osteopenia, 
increased risk of low energy fracture and hip deformities (Keret et al., 1988; 
Roberts and Conner, 1988; Harrison and Webb, 1990; Leonard et al., 1999c; 
Cepollaro et al., 2001; Downs et al., 2008a; Hofstaetter et al., 2010; Leonard et al., 
2010). 
In my thesis I have used Mecp2 knockout mice to analyse these skeletal 
anomalies. Various anatomical and biomechanical techniques have been 
employed to evaluate the bone structure and strength. Additionally, I have tested 
the reversibility of biomechanical phenotypes following un-silencing of the Mecp2 
gene. Evaluation of the outcomes of these experiments should provide information 
about challenges, benefits, drawback and prospects of gene-based therapies in 
targeting bone phenotypes in Rett syndrome. 
1.1 Clinical picture of Rett syndrome 
Rett syndrome (RTT) is a severe neurodevelopmental disorder which almost 
exclusively affects females, with prevalence between 1in 10,000 and 1 in 15,000 
female births (Hagberg et al., 1983; Neul et al., 2010). Rett syndrome is an X-
linked dominant disorder as more than 95% of RTT cases arise de novo (Webb 
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and Latif, 2001). RTT is lethal in hemizygous males, who die around birth, and if 
they do survive beyond birth then males present a different clinical picture from 
that shown in young females with Rett syndrome (Hagberg et al., 1983; Webb and 
Latif, 2001). 
The uncertainty of diagnosis of Rett syndrome associated with the occasional 
presence of apparently affected males, is further  complicated by the very wide 
clinical spectrum presented by females, which ranges from the severely affected 
‘classical’ cases through a wide range of disability to a milder variant forms. This 
variability has been partly ascribed to the particular type of mutation (Neul et al., 
2010) but also the degree to which skewing of X chromosome inactivation favours 
the expression of the normal MECP2 allele (Webb and Latif, 2001).  
The Rett syndrome not only affects the neurological system but also the 
respiratory, gastrointestinal and skeletal systems (figure 1-1).  
RTT was sometimes co-classified with other autism spectrum disorders with 
features differentiating Rett syndrome from the former including an initial period of 
6-18 month of apparently normal growth (low mean birth weight and head 
circumference were also observed in few cases) (Leonard and Bower, 1998; 
Huppke et al., 2003), followed by rapid destructive phase between 1-4 years 
during which patients display loss of hand skills, impaired mobility and speech, 
development of stereotypic hand movement (continuous repetitive wringing, 
twisting, clapping hand automatism during wakefulness) and difficulties in social 
interactions (figure 1-1). 
This rapid deterioration phase is followed by plateau stage during which patients 
get no worse or their intensity lessens. Late motor deterioration starts between 5 
and 25 years of age and can last for decades (Engerström, 1992; Neul et al., 
2010).  
Autistic features also form the frequent part of RTT clinical spectrum including 
hypersensitivity to sound, expressionless face, and indifference to the surrounding 
environment and un responsiveness to the social cues (Nomura, 2005) and mental 
retardation (Chahrour and Zoghbi, 2007).  
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                  Figure1-1  Systemic manifestations of Rett syndrome 
 
                  
  
24 
 
Musculoskeletal abnormalities of RTT includes scoliosis, which starts at an early 
school age, and distal lower limb abnormalities (Hagberg et al., 2002). In a recent 
study in an Australian cohort, investigators also showed the development of 
scoliosis in majority (85.5%) of cases (Anderson et al., 2014).Radiographic studies 
on RTT patients have demonstrated osteopenia (Leonard et al., 1995; Leonard et 
al., 1999c; Cepollaro et al., 2001).  
Females with Rett syndrome are at increased risk of fracture as it is stated that 
about one third had sustained a fracture by the age of 15 years, compared with 
only 15% of control population of age 20 years (Leonard et al., 1999c). In another 
population based study the fracture risk in RTT patients was found to be nearly 
four times the population rate (Downs et al., 2008a). Decrease in bone volume has 
been reported in RTT patients, and it was concluded that the slow bone creation at 
a young age eventually causes low bone density, pointing towards the possible 
direct effect of MECP2 mutations on bone development (Gonnelli et al., 2008; 
Leonard et al., 2010). 
Rett syndrome patients also suffer from breathing difficulties including episodic 
hyperventilation and apnoea during wakefulness (Kerr et al., 1997; Julu et al., 
2001). In a study on Australian cohort, abnormal breathing pattern were reported 
for two thirds of women (66.4%) including 74.2% who suffered from 
hyperventilation and 88.7% with apnoeic episodes (Anderson et al., 2014) 
Epilepsy also occurs commonly during the plateau phase (Hagberg et al., 
2002).Risk of epilepsy is also thought to be genotype related (Jian et al., 2006). 
Gastrointestinal problems including swallowing dysfunction, gastro oesophageal 
reflux, constipation and distension are also observed in RTT patients (Reilly and 
Cass, 2001; Hagberg, 2002; Oddy et al., 2007; Motil et al., 2012; Anderson et al., 
2014). 
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According to Neul et al RTT diagnostic criteria is as below: 
  Table1-1 Revised diagnostic criteria for RTT 2010 
 
Clinical presentation and severity of RTT display a wide variation and patients may 
exhibit all the essential features necessary for the RTT diagnosis or they may 
show differences leading to their assignment in atypical RTT diagnosis (Neul et al., 
2010) See table below ( table1-2).
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Table1-2  Clinical criteria for diagnosis of “Classic and Atypical” 
RTT 
 
 
1.2 Rett syndrome and the MECP2 gene 
The search for the genetic cause of Rett syndrome was seriously hampered by a 
lack of familial cases as majority of cases of the syndrome were found to be 
sporadic but with series of linkage analysis on the few familial cases the region of 
interest was found to be Xq28 in 1998 (Lewis et al., 1992; Sirianni et al., 1998; 
Webb et al., 1998; Xiang et al., 1998; Berg and Hagberg, 2001) (figure 1-2). 
This discovery lead to intense screening of the Xq28 region for likely candidate 
genes until in 1999 Amir et al finally published first report, establishing mutations in 
MECP2 gene in 5 out of 21 cases of Rett syndrome (Amir et al., 1999). 
Rett syndrome is not a heritable disorder and most common mutations in MECP2 
arises de novo in germ cells, commonly on the paternal side (Trappe et al., 2001). 
Since the original report by Amir et al, there have been a multiple confirmatory 
studies to detect mutations in the MECP2 gene in the young girls with Rett 
syndrome from worldwide and found that the more than 95% of RTT cases are 
usually the result of dominantly acting , de novo (Girard et al., 2001) mutations in 
the X-linked  gene MECP2, which encodes methyl-CpG-binding protein 2 (MeCP2) 
(Wan et al., 1999; Bienvenu et al., 2000; Cheadle et al., 2000; Girard et al., 2001; 
Guy et al., 2011b; Zhang et al., 2012) other variant includes FOXG1,CDKL5 etc. 
More than 600 pathogenic MECP2 mutations have been reported, including 
missense, nonsense, frameshift and large deletion mutations (RettBase: 
http://mecp2.chw.edu.au/mecp2/). 
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Studies have shown a genotype-phenotype relationship between phenotype and 
MECP2 mutation and it is fascinating because it gives the opportunity to explore 
mutations in a single gene (Amir et al., 2000; Ben-Ari and Spitzer, 2010). 
Truncation mutations within the MECP2 gene for example show relation with more 
severe RTT phenotypes (Weaving et al., 2003). Since MECP2 gene  is an X-linked 
gene, the X-chromosome inactivation patterns ( whether they are skewed or 
random or whether the mutant allele is of paternal or maternal origin ) are linked to 
the severity of RTT phenotypes and this has been established by various groups 
(Ishii et al., 2001; Gibson et al., 2005; Xinhua Bao et al., 2008).     
 
Figure1-2  The MECP2 gene location and MeCP2 protein structure 
with the most frequent sites of mutations 
(A) MECP2 gene is located in X-chromosome (Xq28), flanked by the RCP and 
IRAK genes. (B) The schematic figure showing the distinct functional domains of 
MeCP2. Apart from the N terminus, both MeCP2 isoforms are identical and 
contain several functionally distinct domains: NTD, N-terminal domain; MBD, 
methyl binding domain; ID, inter domain; TRD, transcription repression domain; 
CTD, C-terminal domain; NLS; nuclear localisation signals. Most common point 
mutations are also shown (red arrows). 
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Males typically inherit a mutant MECP2 allele, resulting in more severely affected 
phenotype, presenting with infantile encephalopathy and usually not surviving 
infancy. These differences between the heterozygous female and hemizygous 
male RTT phenotype are due to the proportion of cells in the nervous system 
expressing the mutant allele. 
1.3 MeCP2 Structure, Expression and Function 
 
1.3.1 MeCP2 Structure 
MeCP2 is basically a nuclear protein with high affinity for DNA sequences 
containing methylated 5’-CpG-3’ dinucleotides (Lewis et al., 1992). MeCP2 
belongs to Methyl-CpG binding protein family that binds to methylated DNA 
through their unique Methyl Binding Domain (MBD) (Singh et al., 2008). 
In both human and mouse the MECP2/Mecp2 gene is composed of four major 
exons (exon 1-4) and three introns (Intron 1-3). MeCP2 protein structure is 
composed of five important domains, N-terminal Domain (NTD), Methyl Binding 
Domain (MBD), Inter Domain (ID), Transcription Repression Domain (TRD) and C-
terminal Domain (CTD) and is approximately 53 kDa to 75 kDa in size (Nan et al., 
1996; Jones et al., 1998; Zachariah and Rastegar, 2012; Olson et al., 2014). 
These domains combine to form a tertiary structure and this structural 
arrangement of MeCP2 provides a better understanding of MeCP2 
multifunctionality in vitro and in vivo (Adams et al., 2007) (Figure 1-2) MeCP2 has 
two major splice isoforms, e1 and e2, that encode the proteins with different N-
termini. MECP2_e2, which is the first discovered isoform uses a translational start 
site within exon 2, whereas the newer (and more abundant) isoform MECP2_e1 
derives from mRNA in which exon 2 is found to be excluded (Mnatzakanian et al., 
2004) (figure 1-3). 
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Figure1-3  Splicing and composition pattern of MECP2 gene 
(A) Figure showing the splicing of Human MECP2 gene. Two mRNA isoforms are 
generated; MECP2_e1 and MECP2_e2(B) The two isoforms generate two protein 
isoforms of MeCP2 with differing N-termini due to the use of alternative translation 
start sites (bent arrows). Yellow and green shadows refer to the amino acid 
differences in the N-terminal of both MeCP2_e1 (GenBank accession no. 
NM_001110792.1) and MeCP2_2 isoforms respectively (GenBank accession no. 
NM_004992.3). 
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1.3.2 MeCP2 Expression 
MeCP2 is widely expressed in many organs and its highest expression is found in 
brain, lung and spleen, compared to the expression levels in liver, heart, kidney 
and small intestines (Shahbazian et al., 2002b). 
Mecp2 mRNA transcripts are highly expressed in skeletal muscle and heart, lung, 
moderate in brain and low in liver and spleen (D'Esposito et al., 1996; Reichwald 
et al., 2000; Adachi et al., 2005; Zhou et al., 2006). 
The expression of MeCP2 in brain has been extensively studied, as the majority of 
Rett syndrome phenotypes are neurological. However MeCP2 mis-expression 
results in peripheral phenotypes as well for example the bone phenotype 
(scoliosis/ limb movements), breathing and respiratory abnormalities, cardiac 
problems, difficulty in feeding (Matarazzo et al., 2004; Smrt et al., 2007; Alvarez-
Saavedra et al., 2010). Over expression of MeCP2 in the mouse heart leads to 
cardiac septum hypertrophy and the mutated expression of MeCP2 in the skeletal 
tissue produces detrimental deformities (Alvarez-Saavedra et al., 2010). 
In brain, both the distribution and levels of MeCP2 show regional variation as 
recently demonstrated by studies in the adult murine brain regions, specifically in 
the cortex, striatum, olfactory bulb, hippocampus, thalamus, cerebellum, olfactory 
bulb and brain stem (Olson et al., 2014). The highest MeCP2 expression was 
found in the cortex and cerebellum among the studied brain regions (Zachariah 
and Rastegar, 2012). 
Among the MeCP2 expressing cells, neurons show the highest MeCP2 
expression, while lower amounts of MeCP2 are found in glial cell types (Ballas et 
al., 2009; Zachariah and Rastegar, 2012). For normal maturation (Kishi and 
Macklis, 2004; Singleton et al., 2011) and proper function of neurons a normal 
MeCP2 expression is required (Shahbazian et al., 2002b; Nguyen et al., 2012). 
MeCP2 expression has also been demonstrated in astrocytes, oligodendrocytes 
and microglia (Ballas et al., 2009; Zachariah and Rastegar, 2012; Liyanage et al., 
2013; Olson et al., 2014).    
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1.3.3 MeCP2 molecular mechanism and function 
MeCP2 is found to be a multifunctional protein as different domains of MeCP2 
have been assigned to facilitate multiple functions either by direct DNA binding, or 
by interaction with protein partners or recruiting other factors (Guy et al., 2011b). 
Cells undergo differentiation mostly without alternating the sequence of the DNA 
but rather the changes in their transcriptional activity. In mammals, the joint action 
of chromatin remodelling complexes and epigenetic modifications at the level of 
DNA and histones sets the different cell- and development-specific transcriptional 
programs. Also the mammalian DNA is found to be covalently modified by the 
supplementation of a methyl group to cytosines that occur predominantly in CpG 
dinucleotides (Bird, 2002). Over the years lots of evidence has been gathered that 
DNA Methylation plays a very important role in normal mammalian development 
and also for the survival of differentiated cells (Jackson-Grusby et al., 2001; Goll 
and Bestor, 2005). The methyl mark is interpreted by the family of methyl-CpG 
binding proteins via a methyl-CpG-binding domain (MBD) (Hendrich and Bird, 
1998). MeCP2 which is the founding member of the MBD family (Nan et al., 
1998a) mediates its interaction with chromatin remodelling complexes including 
Swi-independent 3a (Sin3a) and Histone deacetylase inhibitor (HDAC1/2) ( (Jones 
et al., 1998; Nan et al., 1998a), the histones methyltransferase, Suv39H (Fuks et 
al., 2003), the DNA methyltransferase I (Kimura and Shiota, 2003) and the 
silencing mediator for retinoid and thyroid hormone receptors (SMRT) (Stancheva 
et al., 2003) through transcriptional repressor domain (TRD). 
Over twenty years ago MeCP2 was first identified as a transcriptional repressor 
that binds to methylated CpG dinucleotides (Lewis et al., 1992; Wakefield et al., 
1999). MeCP2 binds DNA directly through its N-terminal methyl-CpG binding 
domain (MBD), whereas its C-terminal transcriptional repression domain (TRD) 
allows it to interact with co repressors such as Sin3a, HDAC1, and HDAC2 (Nan et 
al., 1998b). Recent studies have shown that MeCP2 is expressed at higher levels 
than expected for classical site-specific transcriptional repressors. MeCP2 binds 
as abundantly and widely throughout the genome as histone H1, which suggest 
that the protein might have additional functions in chromatin biology (Skene et al., 
2010). Transcriptional studies in mouse brains as well as human embryonic stem 
cell-derived neurons, have shown that most genes are actually down regulated in 
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RTT models that lack MeCP2 (Ben-Shachar et al., 2009; Li et al., 2013b). One 
possible explanation to this is that MeCP2 acts as a “transcriptional noise 
dampener”, such that loss of MeCP2 function results in the diversion of basal 
transcriptional machinery to repetitive elements, indirectly leading to global 
transcriptional down regulation (Skene et al., 2010). 
Previous research has shown that membrane depolarization induces de novo 
phophorylation of MeCP2 at serine amino-acid residue 421 (S421) that may 
regulate Bdnf transcription (Chen et al., 2003; Zhou et al., 2006) although activity-
dependent DNA Methylation involving dissociation of the MeCP2 repression 
complex may also regulate Bdnf transcription (Martinowich et al., 2003).  Neuronal 
activity induces differing phosphorylation states of MeCP2 and may be an 
important mechanism through which MeCP2 regulates neuronal plasticity through 
activity-dependent gene transcription. Tao et al have suggested that MeCP2 
phosphorylation may provide a regulatory switch such that at rest S80 
phosphorylation binds MeCP2 to chromatin but during depolarization S421 
phosphorylation allows MeCP2 to dissociate from chromatin thereby providing a 
transcriptionally permissive state (Tao et al., 2009).  
MeCP2 is implicated as a key regulator of activity-dependent gene expression; 
there is still much work needed to do, to identify the target genes involved in these 
critical processes. Moreover there is a possibility of identification of other 
phosphorylation sites on MeCP2, impacting its activity and ultimately gene 
expression that mediates effects on short- and long term synaptic plasticity as well 
as behavioural processes (Tao et al., 2009). 
Significant insight into the functional consequences of MeCP2 in the brain has 
come from the study of transgenic mice. Studies of mice with various temporal and 
spatial deletions of Mecp2 have revealed numerous morphological changes and 
alterations in synaptic transmission and plasticity that likely underlie the observed 
cognitive and behavioural deficits reminiscent of human Rett syndrome (Moretti 
and Zoghbi, 2006; Calfa et al., 2011; Na and Monteggia, 2011).  
Various studies have identified and explored a role of MeCP2 in specific brain 
areas. The anxiety and impaired motor coordination phenotypes observed in 
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Mecp2 mutant mice point to the amygdale and cerebellum as particular regions of 
interest (Gemelli et al., 2006; Pelka et al., 2006). 
1.3.3.1 MeCP2 as a Transcriptional Regulator 
Although traditionally considered a global transcriptional repressor, the precise 
role of MeCP2 as a transcriptional repressor (Nan et al., 1998a) or transcriptional 
activator (Chahrour et al., 2008) is paradoxical. Therefore recent studies have 
categorized MeCP2 as a genome-wide epigenetic modulator rather than a 
transcriptional regulator (Della Ragione et al., 2012). As mentioned previously, 
MeCP2 is a methyl binding domain protein which binds to DNA following the 
addition of a methyl group to carbon-5 of the cytosine pryimidine ring (DNA 
Methylation); principally at CpG dinucleotides (cytosine and guanine separated by 
a phosphate). Once bound, the proteins are traditionally thought to involve a larger 
repressor complex and chromatin remodelling proteins such as HDAC proteins 
which suppresses gene transcription by chromatin compaction (Jones et al., 
1998). However, it is suggested the transcriptional repression of MeCP2 could be 
chromatin independent too by means of inhibiting the basal transcriptional 
machinery through interaction with general transcription factors IIB (Kaludov & 
Wolffe 2000). Furthermore, repression is also thought to occur by MeCP2 
mediated chromatin remodelling. This involves MeCP2 acting to form a loop of 
inactive, methylated chromatin which regulates gene expression by containing 
deacetylated histones which condense the DNA and restrict transcription (Horike 
et al. 2005). Either way, mutations in MECP2 could affect any area of this process 
resulting in a partially functioning protein or a complete breakdown of operation 
MeCP2 involvement in chromatin structure. 
In 2008 Chahrour et al decided to analyse the gene expression profiles in the 
hypothalami of mice that have no Mecp2 present (Mecp2 null) or those that over 
express MECP2 under the control of its endogenous promoter (MECP2-Tg) in the 
hope of deciphering more information into the molecular mechanism of MeCP2 
(Chahrour et al., 2008). Through the use of microarray analysis, a variety of genes 
expressions were found misregulated in both mouse models.  Surprisingly around 
eighty five percent of these genes expressions were found upregulated in 
transgenic hypothalami and dowregulated in Mecp2-null hypothalami suggesting 
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that many of these genes expression are likely activated by increased MeCP2 
activity. 
ChIP work with the antibody for Mecp2 confirmed that Mecp2 bound to the 
promoter region of six of the activated genes (Sst, Oprk1, Mef2c, Gamt, Grpin1 
and A2bp1). The same group also identified Mecp2 to bind to the promoter region 
of the transcriptional activator CREB1 and also associate with this protein at the 
promoters of activated target gene (Chahrour et al., 2008). This data collected 
suggested in favour of the idea that MeCP2 has a role in activating target genes 
and not just repressing them. One explanation for these results might be that 
MeCP2 is repressing a transcriptional repressor therefore activation of the target 
of this repressor would occur. However there is a possibility that changes 
observed might be secondary to the physiological properties of the hypothalamus. 
Overall these results propose a more complex mechanism of transcriptional 
regulation by MeCP2 with a variety of genes being either positively or negatively 
regulated. 
MeCP2 has also been found to be involved in controlling chromatin structure 
(Zlatanova, 2005; Chadwick and Wade, 2007). Significant differences have been 
found in the chromo centres in Mecp2 –deficient and Mecp2-WT neurons, further 
supporting role of MeCP2 in organisation of chromatin (Singleton et al., 2011). 
MECP2 mutation causing Rett syndrome have been found to disrupt the functions 
of higher order chromatin structure (Nikitina et al., 2007). 
Recent studies have demonstrated that the DNA Methylation-dependent binding of 
MeCP2 to the exons sequences modulates alternative splicing (Miyake et al., 
2013) . Altered RNA splicing of synaptic genes have been found in autism as well 
as Rett syndrome (Smith and Sadee, 2011). MeCP2 plays a role to regulate the 
alternative splicing of NMDA receptors subunit NR1 (Young et al., 2005). 
1.3.3.2 MeCP2 role in other biological functions 
Recent research has demonstrated now that the MeCP2 plays a role in regulating 
protein synthesis and it is postulated that the reduced protein synthesis in MeCP2-
deficient cells is contributing to the RTT phenotypes detected in these cells (Li et 
al., 2013b). This finding confirmed the involvement of MeCP2 in Rett syndrome 
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pathogenesis, the aforesaid functions are deteriorated in RTT patients (Kim et al., 
2011). 
Recent biophysical studies have probed the binding specificity of MeCP2 and have 
reported the interaction (via hydration within the major groove) with methylated 
DNA and also the interaction with nucleosomes (Ho et al., 2008). Despite this 
knowledge, the precise biological function of MeCP2 remains unclear. As 
described previously proposed additional or alternative functions include selective 
enhancement/activation of gene expression (Chahrour et al., 2008), chromatin 
regulation (Nikitina et al., 2007), and RNA processing (Young et al., 2005).  
In summary MeCP2 is distributed across the genome very much in parallel with 
Methylation density, and to the exclusion, in neurons, of histon H1 (Skene et al., 
2010). This conclusion suggest that MeCP2 play a major role in the suppression of 
transcription throughout very large scale genome-wide actions; in this way it may 
be best to ascribe MeCP2’s function in terms of global dampening of 
transcriptional noise. 
1.4 Bone phenotypes in Rett syndrome 
The frequent occurrence of bone anomalies like osteoporosis (Haas et al., 1997; 
Leonard et al., 1999c), scoliosis (Amir et al., 2000; Ager et al., 2006; Bebbington et 
al., 2012), increase risk of fracture (Downs et al., 2008a; Hofstaetter et al., 2010) 
and generalized growth failure (Schultz et al., 1993) has raised questions between 
the possible links of MECP2 gene mutations at chromosome Xq28 on bone growth 
and attainment of peak bone mass.   
1.4.1 MeCP2 expression and bone development` 
Alternation of the normal pattern of expression of MeCP2 in skeletal tissues can 
lead to detrimental effects on normal bone development and later on results into 
severe malformations (Alvarez-Saavedra et al., 2010). 
Although accumulating evidence suggests that the most of the RTT-like 
phenotypes are caused specifically by dysfunction of mature neurons (Matarazzo 
et al., 2004; Smrt et al., 2007) resulting from mis-expression of MeCP2 target 
genes in the brain, however a role for MeCP2 in peripheral cells has not been 
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ruled out. For example in case of bone tissue, their usually observed decreases in 
bone mineral density have been ascribed to abnormal activity of osteoblasts. The 
commonly observed dysmorphic features (scoliosis/kyphosis) of MeCP2 
duplication patients (Van Esch et al., 2005; Friez et al., 2006; Smyk et al., 2008) 
could stem from MeCP2 dysfunction in peripheral tissues. 
 The slow bone creation at a young age in Rett syndrome patients may eventually 
cause low bone density, showing that the influence of MECP2 is not restricted to 
damaging brain tissues, but has a direct effect on bone development (Budden and 
Gunness, 2001). 
1.4.2 Factors affecting bone remodelling and their relevance to 
Rett syndrome Patients 
Most of the females with RTT suffer from growth retardation (early deceleration of 
head growth, followed by weight and height deceleration) (Schultz et al., 1993; 
Reilly and Cass, 2001; Oddy et al., 2007; Jefferson et al., 2011). Inspite of this 
description, other bone related symptoms such as fractures and bone mass are 
not included in clinical scales evaluating severity scores in Rett syndrome 
(Bebbington et al., 2008) . 
In 1999, an Australian, population based study revealed that girls with Rett 
syndrome showed a 4 times higher rate (Downs et al., 2008a) of fracture as 
compare with a sample of control children (Leonard et al., 1999c). Moreover nearly 
one third had sustained a fracture by the age of 15 years as compared with only 
15% of girls and women in the general population of 20 years age (Cooley and 
Jones, 2002).    
Factors effecting the bone mineral density and increase fracture risk in the general 
population include genetic predisposition (subjects with p.R168 and p.R270 
mutations in MECP2 gene) (Downs et al., 2008a), hormonal factors (Huppke et al., 
2001), previous fractures, lack of soft tissue padding, lack of bone strength 
(Zysman et al., 2006), weight bearing exercise, vitamin D levels (Motil et al., 2011) 
and use of antiepileptic drugs (AECs) (Downs et al., 2008a; Leonard et al., 2010; 
Jefferson et al., 2011).  
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Greater frequency of fractures of lower limb fractures have been reported within 
RTT (Leonard et al., 1999c; Jones et al., 2002; Cooper et al., 2004; Downs et al., 
2008a; Roende et al., 2011b) and vertebral fractures were not found commonly 
(Roende et al., 2011b). 
 
 
Figure 1-4  Several different dysmorphic skeletal features of Rett 
syndrome: (A, B) Bruxism and pragmatism in an adult patient; (C) severe 
scoliosis in a 14-year-old patient; (D) segmental dystonia; (E, F) the same peculiar 
dystonic feet posture in two different patients aged 2 and 16 years, respectively; 
(G) dystonia of the left inferior limb that interferes with gait; (H, I) two different 
patients with feet dystonia; (J) severe fixed feet in an adult patient; (K) dystonia of 
the hands in a 12-year-old patient (L); hand athetosis in a 14-year-old patient. 
(Temudo et al., 2008). Figure included with permission. Copyright © 2008, 
Movement Disorder Society. License Number obtained after permission: 
3510771178758. Licensed publish content by John Wiley and Sons. 
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Individuals with RTT are at risk of developing osteoporosis (Haas et al., 1997; 
Leonard et al., 1999b; Motil et al., 2006) and mild hypercalciuria in Rett syndrome 
has been reported (Motil et al., 2006). This suggests that the RTT-pathogenesis 
might lie in bone resorption contributing to osteopenia. 
Radiological studies on RTT patients (Carter et al., 1992; Cepollaro et al., 2001; 
Gonnelli et al., 2008; Motil et al., 2008; Nazarian et al., 2008; Shapiro et al., 2010; 
Jefferson et al., 2011; Roende et al., 2011a) have shown low bone mass from an 
early age, with fewer studies showing similar findings in patients over 30 years of 
age (Zysman et al., 2006; Motil et al., 2008; Shapiro et al., 2010). 
Several different dysmorphic skeletal features have also been observed in 
individuals suffering from Rett syndrome including severe scoliosis (Percy et al., 
2010; Riise et al., 2011), bruxism and pragmatism in an adult patient,  (Temudo et 
al., 2007), facial features at infancy and childhood includes microcephaly, flat 
occiput/brachycephaly, broad face, hypertelorism, wide mouth and pointed chin 
(Allanson et al., 2011) (figure 1-4 A-L). 
Scoliosis is exceedingly common in Rett syndrome developing 50-90% of 
individuals with the condition (Keret et al., 1988; Bassett and Tolo, 1990; Harrison 
and Webb, 1990; Holm and King, 1990; Guidera et al., 1991b; Huang et al., 1994; 
Lidström et al., 1994; Brunner and Gebhard, 2002; Ager et al., 2006; Downs et al., 
2009; Koop, 2011; Gabos et al., 2012). Scoliosis becomes apparent at an early 
age and worsens rapidly during adolescence and continue to deteriorate further 
even after the skeletal maturation (figure 1-4C).  
Risk of Scoliosis is appeared to be link to specific chromosomal changes and 
among the numerous mutations of MECP2, only two mutations (R294X and 
R306C) are found to have reduced risk of developing scoliosis (Ager et al., 2006; 
Percy et al., 2010). Rett syndrome patients tend to have long single curves in 
which the pelvis might act as an end vertebra, resulting in pelvic obliquity (Riise et 
al., 2011). Cases of milder skeletal phenotype found associated with balancing 
double curves, usually of smaller magnitude (Riise et al., 2011). 
Skeletal deformities and increased likelihood of fractures may reflect abnormalities 
in adult bone structure or in the process of bone formation or in the cells and 
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mechanisms linked to bone turnover and remodelling. In next section I will briefly 
review the basic biology of bone and its formation. 
1.5 Bone Structure and Composition 
Bone is a highly specialized and dynamic connective tissue and its properties 
depend largely on the unique nature of its extracellular matrix. Throughout life, it is 
being continuously removed and replaced. 
1.5.1 Bone tissue  
Bone is composed of a hierarchical structure and can be divided as follow (Yuan 
et al., 2011): 
Table1-3   Bone hierarchical structure 
 
At the macroscopic level, bone is divided into cortical and cancellous bone 
Trabecular bone in comparison to cortical bone is more active metabolically, is 
remodelled more often than the cortical bone and on this basis considered 
younger on average than the cortical bone. Every year 25% of trabecular bone is 
replaced compared to only 2-3% of cortical bone (Swaminathan, 2001). 
At the microscopic level, bone can be either described as lamellar or non-lamellar. 
All the mature bone is mostly lamellar. Non lamellar bone is rarely present in the 
normal human skeleton after the age of 4 or 5 years old (Buckwalter, 1995). 
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1.5.1.1 Cortical bone 
The cortical bone forms the hard bone shell at the outer surface of each bone and 
composed of a thick and a dense layer of calcified tissue (compact bone tissue) 
(Fratzl, 2007). It is also known as compact bone tissue due to its minimal gaps and 
spaces. In humans and many other mammals, the porosity of normal cortical bone 
is below 3% at the optical microscopic level. Cortical bone is composed of 
haversian systems known as osteons. Osteons are circular or oval in cross section 
and contain central blood vessels in a cylindrical canal known as a Haversian 
canal. The blood vessels are surrounded by three to eight concentrically arranged 
lamellae. Osteons run parallel to the long axis of the bone (major loading 
direction). Along their way they give off branches, Volkmann canals, which join 
adjacent haversian canals. The most commonly suggested arrangement of 
collagen fibres in lamellae of an osteon is that they lie in parallel in each lamella to 
the next as a twisted helicoidally structure. Between the individual lamellae are 
small spaces called lacunae and each contains a cell called an osteocyte. Each 
central canal, with its surrounding lamellae, lacunae, osteocyte and a canaliculi, 
forms a Haversian system (Giraud-Guille, 1988) (figure 1-4). 
1.5.1.2 Trabecular bone 
In contrast to cortical bone, trabecular bone (also known as cancellous bone) does 
not contain osteons, although like cortical bone it is lamellar in structure. The 
microstructure of the trabecular bone is made of a series of interconnecting rods or 
occasionally plates of bone called trabeculae. As in cortical bone, the trabeculae 
contain osteocytes that lie in lacunae and again radiating from the lacunae are 
canaliculi containing osteocyte processes. Unlike osteocytes in the cortical bone, 
those in trabeculae normally receive their nourishment directly from the blood 
circulating through the marrow cavity. Haversian canals occur in very thick 
trabeculae (Fratzl, 2007).  
1.5.2 Bone Matrix 
Bone matrix is composed of organic (collagens and non-collagenous proteins) and 
inorganic (mineral crystals). The primary organic component of the bone matrix is 
type 1 collagen, although minor amounts of other collagen types such as types III 
and V have been reported as well (Niyibizi and Eyre, 1989, 1994). Type 1 collagen 
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comprises approximately 95% of the entire collagen content of bone and about 
80% of the total proteins present in bone (Niyibizi and Eyre, 1994). The inorganic 
component of bone matrix is known to consist largely of hydroxyapatite [Ca10 
(PO4)6 (OH)2] and small but significant amounts of substitution ions such as HPO2
-
, 
Na+, Mg2+, citrate, carbonate, K+ and others whose positions and configurations 
are not completely known yet (Ziv and Weiner, 1994). 
 
 
 
 
 
Figure1-5    Bone structure 
(A) Mouse tibia bone showing cortical shaft and trabecular part towards the 
periphery. (B) Trabecular part of the bone composed of rods and plates. (C) 
Transverse section of a typical long bone’s cortex. Modified and adopted Gray’s 
anatomy 20th Edition. 
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1.5.3 Bone Cells 
Bone cells are responsible for producing, modifying and maintaining a continuous 
cellular layer that covers all available extracellular matrix surfaces. The majority of 
these cells are in turn, connected in a network of cells which is dispersed thought 
out the matrix (figure1-5). Four types of cells are commonly recognised, three 
(osteoblast, osteoclast and bone lining cells) of which cover the surfaces of bone 
tissue while the fourth type of cells (osteocyte) are encased within the mineralised 
extracellular matrix (Miller and Jee, 1987; Burger and Klein-Nulend, 1999; 
Hadjidakis and Androulakis, 2006). 
The processes of cellular differentiation that gives rise to the skeleton are 
regulated by genes, which first establish the pattern of skeletal structure in the 
form of cartilage and mesochyme and then replace them with bone through the 
differentiation of osteoblasts (Wellik and Capecchi, 2003). 
1.5.4 Osteoblast and Osteocyte 
Osteoblasts are a cuboidal, polar, basophilic cells covering (Lian and Stein, 1995) 
the bone matrix at sites of active matrix formation. Undifferentiated mesenchymal 
stem cells that have the potential to become osteoblasts usually reside in bone 
canals, endosteurm, periosteum and marrow. Osteoblasts remain in their 
undifferentiated form until they are stimulated to proliferate and differentiate into 
mature osteoblasts. Osteoblasts produce extracellular matrix proteins and are 
regulators of matrix mineralization during initial phase of bone formation and later 
bone remodelling. In addition to bone formation, osteoblasts regulate osteoclast 
differentiation and resorption activity by the secretion of cytokines or by direct cell 
contact (Lian and Stein, 1995). 
Osteoblast derives from pluripotent mesenchymal stem cells (Caplan, 1991; 
Pittenger et al., 1999). Several specific transcription factors are responsible for the 
commitment of pluripotent mesenchymal cells into the osteoblast cell lineage. One 
of the most important of these is Cbfa1 (core-binding factor α1), a transcription 
factor belonging to the runt-domain gene family, which plays a critical role in 
osteoblast differentiation (Hoshi et al., 1999). Cbfa1-deficient mice are completely 
lacking in bone formation (Hoshi et al., 1999). Another runt-related gene that plays 
an important role in the commitment of multipotent mesenchymal cells to the 
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osteoblastic lineage and for osteoblast differentiation at an early stage is Runx-2. 
Runx-2 is involved in the production of bone matrix proteins (Otto et al., 1997), as 
it is able to up-regulate the expression of major bone matrix protein genes, such 
as type 1 collagen, osteopontin, bone sialoprotein and osteocalcin (Miyoshi et al., 
1991; Ogawa et al., 1993). Runx-2 deficient mice are completely lacking in bone 
formation, because of an absence of osteoblasts.  
The progressive development of the osteoblast phenotype from an immature cell 
to a mature osteoblastic cell synthesizing specific bone proteins is characterized 
by a definite sequential expression of tissue specific genes that identifies three 
periods of osteoblast development: proliferation, maturation and extra-cellular 
matrix synthesis, and matrix mineralization. 
During active proliferation phase, pre-osteoblasts express genes that support 
proliferation and several genes encoding for extracellular matrix proteins such as 
type 1 collagen and fibronectin. During this phase bone morphogenic proteins 
(BMP), BMP-2 and BMP-5 play a significant role in increasing alkaline phosphatise 
activity, osteocalcin synthesis (Takuwa et al., 1991; Yamaguchi et al., 2000) and 
parathyroid hormone (PTH) responsiveness (Kodama et al., 1982; Takuwa et al., 
1991). 
During the post proliferative phase, which is characterized by the high synthesis of 
alkaline phosphatise, the extracellular matrix progresses into the mineralization 
phase in which osteoblasts synthesize several proteins that are associated with 
the mineralized matrix in vivo (Hauschka et al., 1989), including sialoprotein, 
osteocalcin and osteopontin (Gerstenfeld et al., 1987; Owen et al., 1990). 
Osteopontin is expressed during the active proliferation phase (Lian and Stein, 
1995), and highest level of expression is achieved during mineralization. 
Osteopontin might be involved in the control of the relationship between the cells 
and extra-cellular matrix (Oldberg et al., 1986). Osteocalcin is maximally 
expressed during the phase of mineralization in (Hauschka et al., 1989) and it is 
involved in the regulation of mineral deposition and that it acts as a bone matrix 
signal that promotes osteoblast differentiation and activation (DeFranco et al., 
1991; Chenu et al., 1994). Osteocalcin synthesis is regulated by various 
hormones, 1, 25 OH Vitamin D, and growth factors e.g (Tissue growth factor -β.) 
TGF-β.  
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Figure1-6  Bone cells and contributing factors 
Representative diagram showing different factors affecting bone cell’s 
differentiation and regulation. Osteoblast derives from pluripotent mesenchymal 
stem cells. Osteoblasts express receptors for various hormones including PTH, 1, 
25(OH) 2D3, oestrogens, and glucocorticoids which are involved in the regulation 
of osteoblast differentiation and activity. Vitamin D affects the metabolic activity of 
osteoblasts through a series of Vitamin-D-responsive genes that reflect a more 
mature osteoblast phenotype. Osteocytes are metabolically quiescent osteoblasts 
embedded in bone matrix; they communicate with other bone cells through cell 
processes and function as strain and stress sensors. Osteoclasts cells are 
terminally differentiated multinucleated cells that are the principal, resorptive cells. 
These multinucleated cells derived from hematopoietic stem cells. Factors 
including vitamin D, PTH, oestrogen, calcitonin, thyroxin, and vitamin A are 
involved in the regulation of Osteoclast differentiation and activity. 
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At the end of the synthesis and mineralization of the extracellular matrix, 50%-70% 
of mature osteoblasts undergo apoptosis, whereas the remainder can differentiate 
into lining cells or osteocytes or into the cells that deposit chondroid bone (Franz-
Odendaal et al., 2006). Osteocytes are metabolically quiescent osteoblasts 
embedded in bone matrix; they communicate with other bone cells through cell 
processes and function as strain and stress sensors (Lozupone et al., 1996) 
(figure 1-6). 
Osteoblast also synthesizes IGF-1, interleukin-1 (IL-1) and IL-6. IL-1 can affect 
proliferation, collagen and osteocalcin synthesis and alkaline phosphatise 
production (Kim et al., 2002). 
Osteoblasts express receptors for various hormones including PTH (Demiralp et 
al., 2002), 1,25(OH)2D3 (Lian et al., 1999), oestrogens (Boyce et al., 1999) and 
glucocorticoids (Ishida and Heersche, 1998) which are involved in the regulation of 
osteoblast differentiation and activity. Vitamin D affects the metabolic activity of 
osteoblasts through a series of Vitamin-D-responsive genes that reflect a more 
mature osteoblast phenotype (figure 1-6). 
Activation and regulation of bone resorption requires an interaction between 
osteoblasts and osteoclasts (Grano et al., 1990). In order to obtain mature 
osteoclasts, the presence of osteoblasts was necessary and this phenomenon 
was explained with the identification of RANK (receptor activator of nuclear factor 
κB)/RANKL (RANK ligand)/OPG (osteoprotegerin) system (Yasuda et al., 1998). 
RANKL is an essential factor for the recruitment, differentiation, activation and 
survival of osteoclastic cells through binding to its specific receptor RANK, on the 
surface of osteoclast. OPG is a soluble receptor of RANK and is synthesized by 
osteoblasts. OPG inhibit osteoclast differentiation and activity (Lacey et al., 1998). 
OPG-deficient mice exhibit an osteoporotic phenotype and presents an increased 
number of osteoclasts (Bucay et al., 1998). Through the modulation of RANKL and 
OPG, osteoblasts can control osteoclast differentiation and activity and 
consequently bone remodelling. 
Osteocytes are terminally differentiated cells of the osteogenic lineage that are 
derived from mesenchymal precursor cells. Important markers of osteocytes 
includes matrix extracellular phophoglycoprotein (Gowen et al., 2003), sclerostin 
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(Balemans et al., 2001), dentin matrix protein and phex protein (Feng et al., 2006). 
The osteocytes are the most abundant cells in adult bone and are constantly 
spaced throughout the mineralized matrix. 
Mature osteocytes have a characteristic dendritic cell shape with processes 
radiating from the cell body through the canaliculi in different directions. These 
processes of osteocytes form an intercellular network through gap and adherent 
junctions with surrounding osteocytes, the cells lining the bone surface and bone 
marrow (figure 1-6). Osteocytes through this unique 3D network, are anatomically 
placed in a prime position not only to sense deformations driven by stresses place 
upon bone, but also to respond with passage of signal to the neighbouring 
osteocytes (Vatsa et al., 2007). 
Although it has not been determined which of the osteocyte cell parts are most 
important for the function of the osteocyte as mechanosenor, it has been 
suggested that fluid flow over dendritic processes in the lacunar canalicular 
porosity can induce strains in the actin filament bundles of the cytoskeleton that 
are more than an order of magnitude larger than tissue level strains (Han et al., 
2004). In single osteocytes mechanical stimulation of both cell body and cell 
process resulted in up-regulation of intracellular NO production (Vatsa et al., 
2006). These results indicate that both cell body and cell process might play a role 
in mechanosensing and Mechanotransduction in bone (Vatsa et al., 2006). 
Furthermore it was shown that a mechanically stimulated single osteocyte can 
pass on the information of local mechanical stimulus to the neighbouring cells in 
the vicinity independent of intercellular connections, suggesting that this 
communication happens through extracellular soluble factors (Vatsa et al., 2007). 
Other studies have suggested an alternative mechanosensing structure i.e., 
osteocytes project a single cilia from their cell surface (Xiao et al., 2006). 
Osteocyte cilia can translate fluid flow stimuli into a cellular response, indicating 
that primary cilia might act as a mechanosensitive structure within the osteocytes 
(Malone et al., 2007). 
Osteocytes also play a pivotal role in bone remodeling. The final step of the 
mechanical signal transduction pathway towards bone remodeling is the 
transmission of molecules produced by osteocytes to the effector cells i.e., 
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osteoblasts and osteoclasts. Due to the close physical proximity of osteocytes to 
local osteoblasts and periosteal fibroblasts, it is highly plausible that soluble 
factors produced by osteocytes act in a paracrine manner to affect these cells. 
Soluble mediators released by osteocytes may regulate the properties of 
neighbouring bone cell populations including their proliferation and differentiation. 
Studies have supported the hypothesis that the osteocyte is an orchestrator of 
different cell populations in bone in response to mechanical loading (Vezeridis et 
al., 2006). 
1.5.5 Osteoclast 
Osteoclasts are terminally differentiated multinucleated cells that are the principal, 
resorptive cells of bone, and play a critical role in the development of the skeleton 
and regulation of its mass. These multinucleated cells derived from hematopoietic 
stem cells (Suda et al., 1999; Teitelbaum, 2000; Nakamura et al., 2003) (figure 1-
6). Thus a premyeloid precursor can differentiate into either an osteoclast a 
macrophage or a dendritic cell, depending on whether it is exposed to receptor 
activator of NF-kBB ligand (RANKL; also called tumor necorsis factor-related 
activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL) or 
osteoclast differentiation factor (ODF) macrophage colony-stimulating factor (M-
CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), 
respectively (Kong et al., 1999; Nutt et al., 1999; Suda et al., 1999). Osteoclast 
lack many of the antigens that are characteristic of macrophages and inflammatory 
polykaryons, in particular Fc and C3 receptors and express very high levels of 
Tartrate-resistant acid phosphatase (TRAP) and vitronectin receptor (VNR). They 
also express calcitonin receptors (CTRs) that are absent from macrophages. Most 
uniquely osteoclasts ex vivo excavate bone within hours, but macrophages show 
no excavation whatsoever, even on extended incubation on bone surfaces. 
Many of Osteoclast responses are dependent on cells of the osteoblastic lineage; 
osteoblastic cells, after diverse stimuli express osteoclast-resorption-stimulating 
activity (ORSA) as the common pathway for osteoclast stimulation. Although 
ORSA has been detected in culture supernatants from hormone stimulated 
osteoblastic cells it has also frequently been detectable only when osteoblasts are 
in contact with osteoclasts (Chambers, 1982; Chambers et al., 1984; Thomson et 
al., 1986; Wesolowski et al., 1995). Studies have shown that osteoclasts formed in 
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vitro similarly depend on osteoblastic cells for activation of bone resorption 
(Wesolowski et al., 1995; Jimi et al., 1996) 
Several cytokines and hormones, including macrophage colony-stimulating factor 
(M-CSF)(Yoshida et al., 1990; Fuller et al., 1993), interleukin 1 (IL-1)(Jimi et al., 
1995), RANKL (Lacey et al., 1998; Yasuda et al., 1998) and tumour necrosis factor 
(TNF-a)(Kobayashi et al., 2000), regulate the differentiation, activation and survival 
of osteoclast. They are essentially responsible for the mineralized matrix 
degradation during physiological and pathological bone turnover. 
Osteoclast resorption consists of several complicated processes: (1) the 
proliferation of osteoclast progenitors; (2) differentiation of the progenitors into 
mononuclear perfusion osteoclast (pOCs); (3) fusion of pOCs into multinucleated 
osteoclasts; (4) adherement of osteoclasts to calcified tissue; (5) polarization; that 
is, the development of a ruffled border and clear zone (actin ring), followed by the 
secretion of acids and lysosomal enzymes into the space beneath the ruffled 
border ; (6) finally apoptosis (Grano et al., 1990). 
Presence or absence of mechanical stimulation is known to affect formation, 
absorption, and maintenance of the bone, especially in association with multiplier 
effects such as the systemic or hormonal disorders (Bourrin et al., 1995; Xie et al., 
1997). Animal studies have shown that the bone resorption is observed in the 
palate of rats after experimental loading device and that the osteoclast resorption 
is potentially a pressure threshold-regulated phenomenon (Mori et al., 1997; Sato 
et al., 1998).  
Bone resorption under compressive strain is attributed to the accumulation of 
micro-damage that exceeds the bone’s capacity for repair and certain thresholds 
of strains induced in bone govern its response (Nicolella et al., 2005). Interestingly 
one of the recent studies has suggested that the osteoclastic resorption is 
location-dependent and is sensitive to the local strain intensity (Fujiki et al., 2013). 
Bone histomorphometric analysis from this study showed that osteoclasts were 
localized in the bone subsurface adjacent to the loading site and the in the 
periphery of the bone marrow space of the intracortical region. More than 90% of 
the osteoclasts were observed in the areas with strain intensity higher than 85.0 μ 
strain for the high stimulation group. 
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1.6 Bone homeostasis, remodelling and mechanobiology 
Bone accumulates damage throughout life and is continuously removed and 
replaced. The ongoing replacement of old bone tissue by new bone tissue is called 
remodelling. The regulation of bone resorption serves two important functions 
firstly the maintenance of the skeleton as a structural support system which is 
constantly being remodelled and secondly a metabolic role in mineral homeostasis 
as bone provides a reservoir of calcium and phosphate for the body. Remodelling 
helps in removal of damaged and injured bone, replacing it with new tissue and 
freeing up reservoirs of calcium required by other tissues. The premise of 
mechanobiology, which includes the interaction of mechanical stimuli and 
biological responses, is that biological processes, including bone remodelling, are 
regulated by signals to cells generated by mechanical loading. Exactly how 
external and muscle loads are transferred to the tissue, how the cells sense these 
loads, via either through stress or strain levels, and how the signals are translated 
into the cascade of biochemical reactions to produce cell expression are still 
unknown. 
Bone replacement is started with orthoclastic bone resorption followed soon after 
by osteoblastic bone formation. These are usually regarded as independent 
processes, but, in reality, resorption and formation are closely linked within 
discrete temporary anatomic structures (Rho et al., 1998). These structures were 
first named by Frost (Frost, 1969), who gave them the term ‘basic muticellular 
units’ usually abbreviated to BMU. A fully developed BMU consists of a team of 
osteoclasts in front forming the cutting cone, a team of osteoblasts behind forming 
the close cone, some form of blood supply and associated connective tissue 
(Parfitt, 1994). The lifespan of a single BMU is about 6-9 months during which 
several generations of osteoclasts (average life of about 2 weeks) and osteoblasts 
(average life of about 3 months) are formed. 
The BMU basically moves in three directions, excavating and refilling a tunnel 
through cortical bone or trench across the surface of trabecular bone. A cortical 
bone BMU travels at about 20μm per day (Parfitt, 1994) while the cancellous BMU 
travels about half this distance at about half the speed, thus functioning similar 
timings as compact bone (Parfitt et al., 1996). 
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Two types of bone remodelling have been suggested: One that is not site 
dependent and second that is targeted towards the specific sites (Parfitt et al., 
1996). The re-establishment of mineral content does not require that bone is 
removed or replaced in a specific area. However, the repair of both fractures and 
microfractures or any damage in bone by fatigue loading requires site dependent 
remodelling. Whether this remodelling occurs, and if indeed it does how much of 
bone turnover is targeted and how much is non-targeted is still unknown (Burr, 
2002). 
In adulthood the activities of osteoblasts and osteoclasts are balanced in adults 
and remodelling has no overall effect on the amount of bone. However during 
childhood there is more modelling than remodelling. Modelling helps in the 
maintenance of the normal shape of bones during growth and is responsible for 
the increase in bone circumference during growth. In late adulthood, bone loss 
occurs as in menopausal osteoporosis, when the amount of bone resorption is 
higher than the amount of bone formation. Trabecular bone is more active in 
remodelling than the cortical bone. Bone modelling and remodelling are influenced 
by parathyroid hormone (PTH), oestrogen, calcitonin, serotonin and leptin growth 
factors which primarily act on osteoblasts modifying RANKL and OPG expression 
but minimally affecting RANK expression. Other factors like cytokines, and 
prostaglandins, hereditary and nutritional factors and physical activity also affects 
bone remodelling (Seeman and Delmas, 2006; Shapiro, 2008). 
Both PTH and 1,25 (OH)2D3 increase RANKL mRNA expression and decrease 
OPG mRNA expression but these changes vary with maturation of osteoblast cells 
(Thomas et al., 2001). Oestrogen acting directly on osteoblasts, has a dual effect; 
it increase bone formation and reduce bone resorption by enhancing osteoblast 
proliferation (Majeska et al., 1994), and further reduce osteoclast activity by 
increasing OPG production in osteoblasts (Hofbauer et al., 1999). Calcitonin, a 
known inhibitor of bone resorption, can act directly on osteoblasts by enhancing 
proliferation, increasing OPG mRNA expression and inhibiting RANKL mRNA 
(Tian et al., 2007). Leptin has also been reported to be expressed by osteoblasts 
(Reseland et al., 2001). Leptin is a cytokine like hormone also secreted by 
adiposities and controls food and energy expenditure. Leptin is a potent inhibitor of 
bone formation and possibly act through a central relay (Elefteriou, 2008). 
Destruction of Leptin receptors leads to an increased cancellous bone mass. This 
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finding confirms that leptin can control bone formation through the central nervous 
system (Takeda et al., 2002). Following these observations, a number of central 
nervous mediators which are able to modulate bone remodelling have been 
identified in animal studies. Among these researches, the Neuropeptide Y system 
(Baldock et al., 2002) supports the idea that the central nervous system is involved 
in the control of bone remodelling. 
1.6.1 Mechanotransduction in bone tissue 
Several researches with different loading mechanisms showed that mechanical 
stimuli have an influence at the cellular level of bone tissue. Prerequisite for this 
influence is the transduction of mechanical signals into the cell; this phenomenon 
is termed as Mechanotransduction. The mechanotransduction process is essential 
for the maintenance of skeletal homeostasis in adults. This phenomenon is 
considered to be regulated by hormones, osteoblastic cells and mechanical 
stimuli. Mechanotransduction involves mechanoreceptors, such as integrins, 
cadherins and stretch-activated Ca2+ channels, together with various signal 
transduction pathways and ultimately regulates gene expression in the nucleus.  
1.6.1.1  Cellular mechanism of Mechanotransduction 
Initially transfer mechanism of the mechanical signal, deformation of the cell 
membrane by stretch as well as shear stress mediated by the fluid flow in the 
canaliculi is detected by the osteoblasts and osteocytes respectively (Duncan and 
Turner, 1995; Pavalko et al., 2003). Osteoblasts are directly activated by loading, 
which leads to matrix synthesis and proliferation, as well as being indirectly 
activated by growth factors, and by the release of prostaglandins and NO by the 
osteocytes (Mikuni-Takagaki, 1999). 
Glycocalix is a primary sensor of mechanical loading signals that can transmit 
force to plasma membrane or the submembrane cortex (actin cortical skeleton) 
(Tarbell et al., 2005). Mechanotransduction sites within the plasma membrane 
include lipid rafts, calveolae or at more remote regions of the membrane including 
intercellular junctions (adherens junctions) and cell matrix contacts (Pavalko et al., 
2003).  Mechanical strain also enhanced expression of cadherins, proteins of the 
adherens junctions which interlink the cytoskeleton between neighbouring cells 
(Rezzonico et al., 2003). Adhesion kinase interacts with the large conductance 
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calcium-activated hSlo K+ channel in the focal adhesion complexes of human 
osteoblasts (Rezzonico et al., 2003). Previous research has shown GTPases, 
such as RAS are activated by mechanical strain in osteoblast-like cells. Stretch-
activated Cation channels (SA-CAT) are also thought to be responsible for 
Mechanotransduction in osteoblasts. It has also been studied that expression of 
connexion (Cx) 43, a major component of gap junctions, is increased by 
mechanical strain and regulated by prostaglandin E2 (PGE2) in an autocrine 
manner (Cherian et al., 2005). 
Signal transduction of mechanical stimuli is dependent on the structural integrity of 
the microfilament component of the cytoskeleton. Research has shown that cyclic 
forces induce an enhanced cytoskeleton anchorage of tyrosine-phosphorylated 
proteins and an increased activation of FAK and mitogen-activated protein (MAP) 
kinase. Attractive candidates for integrating mechanical signals includes, nuclear 
matrix proteins including nuclear matrix protein (NMP) 4/cas interacting zinc finger 
protein (CIZ). These transcription factors localize at adhesion plaques, transfer 
into the nucleus, bind to consensus DNA sequences, and can activate promoters 
of mechanosensitive genes. Mechanical stimulation leads to upregulation of 
growth factors, such as insulin-like growth factor (IGF) I and II, vascular 
endothelial growth factor (VEGF), transforming growth factor (TGF) β1 and bone 
morphogenetic protein (BMP) 2 and 4, which act via autocrine and paracrine 
mechanisms, through their tyrosine and serine/threonin receptors (Mikuni-
Takagaki, 1999; Hughes-Fulford, 2004). Furthermore BMP-2 induced signalling 
pathway, leads to the expression of the three osteogenic master transcription 
factors including Osterix, Runx2, and Dlx5 (Lee et al., 2003). Previous studies 
have provided evidence of signal pathways interacting, such as for IGF-I with the 
estrogen receptor (ER) signaling pathway in the proliferative response to 
mechanical strain (Lau et al., 2006). A crosstalk among anabolic, intercellular 
pathways may enhance the upregulation of these pathways, eventually leading to 
the cellular response on mechanical loading. 
Osteoblast differentiation is triggered by mechanical stimulation, which induces the 
secretion of hormones and growth factors, thus affecting the differentiation and 
proliferation potential of osteoblasts. Osteocytes are the mechanotransducer cells 
of bone. It is osteocytes that combine actions of hormones and growth factors and 
promote osteoblastogenic events in response to a range of mechanical stimuli, 
53 
 
including (oscillating) fluid flow, substrate strain membrane deformation, vibration, 
altered gravity and compressive loading. 
Nitric oxide (NO) secretion is another key load-sensing event. Research has 
demonstrated secretion of NO by cyclically stretched primary osteoblasts. NO 
binds to a regulatory site on Ras and potentially stimulates proliferation and ECM 
production through the Ras-Raf-mitogen-activated protein kinase (MEK)-
extracellular signal-regulated kinase (ERK) cascade. Cyclo-oxygenase (Cox) 1,2 
activation downstream of NO and ERK1,2 activation is also necessary for 
induction of anabolic functional changes in osteoblast (Kapur et al., 2003). 
Studies have shown that osteocytes are very sensitive to stress applied to intact 
bone tissue. Imaging research involving computer simulation models have shown 
that mechanosensors lying at the surface of bone, as osteoblasts and bone lining 
cells do, would be less sensitive to changes in the loading pattern than the 
osteocytes, lying within the calcified matrix (Skerry et al., 1989; el Haj et al., 1990; 
Dallas et al., 1993; Lean et al., 1995; Terai et al., 1999; Tatsumi et al., 2007). 
Furthermore targeted ablation of osteocytes in mice disturbs the adaptation of 
bone to mechanical loading (Tatsumi et al., 2007).  
When bones are loaded, the resulting deformation will cause a thin layer of 
interstitial fluid surrounding the network of osteocytes to flow from regions under 
high pressure to regions under low pressure (fluid flow hypothesis). This flow of 
fluid is sensed by the osteocytes which in turn produce signalling molecules that 
can regulate bone resorption through the osteoclasts, and bone formation through 
osteoblasts leading to adequate bone remodeling (Cowin et al., 1995; You et al., 
2000). Previous study has shown that the cell shape and distribution of actin and 
paxillin staining in osteocytes of mouse tibiae and calvariae were orientated 
accordingly to the respective mechanical loading patterns applied in these bones, 
suggesting that osteocytes might be able to directly sense matrix strains in bone 
(Vatsa et al., 2008).  
The conversion of physical force into biochemical information is essential to overall 
development and physiology and goes beyond the skeletal system. Bone is 
naturally designed to respond to and adapt to changes in mechanical loads. The 
mechanisms by which overloading or underuse in mechanical stimuli cause bone 
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formation or resorption are the same, although the direction of changes is 
different. There are no absolute levels of activity that constitute overuse or 
underuse for example it is worth noting that overloading and underuse should be 
defined as the increase and decrease respectively, in activity relative to that in 
which skeleton is currently habituated (Skerry, 2008). One of important 
manifestations of aberrant mecahncotransduction “cross talk” between osteoblasts 
and osteoclasts is osteoporosis, in which an increased rate of bone resorption and 
reduced bone formation per se is observed. RTT bone phenotype has been 
frequently linked with osteoporosis. Osteoporosis can originate from disease, 
hormonal or dietary deficiency and show a clinical spectrum of loss of bone 
density, thinning of bone tissue and increased vulnerability to fractures. Similar 
bone loss can also result from decreases in mechanical loading owing to inactivity/ 
extended bed rest or exposure to microgravity (Bucaro et al., 2004). 
1.7 Bone development and growth 
Bone development (ossification) involves two types of processes; 
intramembranous ossification (flat bones) and endochondral ossification (long 
bones). The main difference between the two types of development is the 
presence of the cartilaginous phase in endochondral ossification (figue 1-7). 
 
 
 
Figure1-7  The ossification process in long bone 
Progression of ossification from the cartilage model of the embryo to young adult. 
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Figure 1-8   Microscopic view of an epiphyseal disc showing 
cartilage production and bone replacement 
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1.7.1 Intramembranous ossification 
A group of mesenchymal cells, under the influence of the local growth factors, 
forms a condensation within the highly vascularised area of the embryonic 
connective tissue by proliferating and differentiating directly into pre-osteoblasts 
and then on osteoblasts(Shapiro, 2008). The osteoblasts then join together to form 
an ossification centre. Subsequent mineralisation of the osteoid matrix begins 
working outward from the ossification centre (figure 1-7). This leads to the early 
trabeculae formation and the periosteum develop resulting in the formation of 
woven bone. 
1.7.2 Endochondral ossification 
Most bones of the skeleton, including those of the limbs, vertebral column, pelvis 
and base of skull, develop by endochondral ossification. In this process of 
ossification the primitive mesenchymal cells differentiate into chondrocytes and 
produce crude cartilage models of the adult bone destined to form at that site. An 
avascular fibrous layer, the perichondrium, surrounds each cartilage model. 
Chondrocytes near the centre becomes hypertrophic and matrix undergoes 
mineralization (Boyce et al., 1999). Perichondrium then converts into periosteum 
by invasion of capillaries and osteoclast, which later on establish a vascular 
network. Pro osteoblasts also enter with the invading capillaries and differentiate 
into osteoblasts, which deposit osteoid on remnants of the mineralized cartilage, 
creating a primary ossification centre. Secondary ossification centres appear at 
one or both ends and expand by endochondral ossification to form the epiphyses 
of long bones (figure 1-7). As the epiphyses expand, they remain separated from 
the primary ossification centre, now occupying the diaphysis and metaphysic of 
the developing bone, by the physis or growth plate. Very limited growth in size of 
epiphysis continues by endochondral ossification beneath the articular cartilage at 
the articular-epiphyseal cartilage complex (Boyce et al., 1999). The epiphyseal 
side ofthe growth plate soon becomes capped by a layer of trabecular bone, which 
prevents further growth from that side but proliferation of chondrocytes in the 
growth plate and endochondral ossification on the metaphyseal side continues till 
maturity (Jubb, 1993) (figure 1-8). 
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1.8 Animal models of Rett Syndrome 
Rett syndrome being a monogenic disorder has raised an interest in the scientific 
community to investigate further the pathogenesis, causative factors and 
therapeutic interventions (Neul and Zoghbi, 2004). Since Rett syndrome is caused 
by MECP2 mutations, RTT can be modelled using Mecp2 knockout mice. Several 
models of RTT have been created and many of them have shown RTT phenotype 
similar to the one found in Rett syndrome patients. Summary of animal models 
that have been used is as below: 
1. One of the early mouse models was created by Chen et al by the deletion 
of exon 3. In this Mecp2-/y (null) male mice model Mecp2 was knocked out 
either globally or specifically in central nervous system (CNS)(Chen et al., 
2001). The mouse model showed nervousness, pila erection, body 
trembling, and occasional hard respiration around age of 5 weeks but 
showed a normal growth before that period. The heterozygous females, 
Mecp2-/+ with mosaic network of cells expressing WT Mecp2 allele and cells 
expressing mutant Mecp2 allele (absent Mecp2) displayed many of the 
cardinal features that characterise RTT in humans, with initial period of 
approximately 4 months of normal growth followed by weight gain, reduced 
activity, ataxia and gait abnormalities during the later stage (Chen et al., 
2001). The same group of researchers created another mouse model by 
knocking out Mecp2 specifically in postnatal neurons and the mouse model 
displayed the similar milder phenotype as compared to the germ line Mecp2 
deletion. Both of these models showed that RTT phenotype is caused 
primarily by lack of functional copy of Mecp2. 
2. Guy and colleagues (Guy et al., 2001) also have developed mouse models 
mimicking the human RTT phenotype. In 2001 they created a Mecp2-/y 
(null) mouse model in which Mecp2-exon3 and exon4 were deleted. This 
mouse, unlike the mice created by Chen et al (Chen et al., 2001), did 
display an apparent normal development in first 3-4 weeks after birth 
corresponding to the characteristic normal growth in first 6-18 months in 
RTT patients. After 4 weeks, the henizygous KO male mice developed gait 
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abnormalities, hypoactivity, and respiratory problems followed by premature 
death around 12-14 weeks. Heterozygous female mice, Mecp2-/+ show 
normal developmental period of 3 months followed by inertia development 
and hind limb clasping. Some of the females remain symptomless as long 
as one year while majority developed RTT like phenotype between 6-9 
months which grew more severe but then stabilised.  
3. More mouse models have been developed as well  including Mecp2308 
mouse model (Shahbazian et al., 2002a). This mouse model was created 
with a truncated version of Mecp2 and recapitulated many features of RTT 
phenotype but display an extended survival of up to one year as compared 
to early morbidity and mortality shown in Stop mouse model.  
4. In 2006, another group of researchers have generated a mouse line by 
insertion of missense mutation in Mecp2 to replace amino-acid threonin 
T158 with methionine to mimic one of the most common missense mutation 
in human (Bienvenu and Chelly, 2006). This mouse model displayed a 
milder RTT phenotype in comparison to Null mouse models and a slightly 
extended survival (Goffin et al., 2012). The analysis of this mouse model 
suggested that a single MECP2 mutation could be almost as lethal as the 
absolute absence of the protein. 
5. Guy et al in 2007 created a functional knockout mouse model through 
silencing the endogenous Mecp2 gene by the insertion of a lox-stop 
cassette (Dragatsis and Zeitlin, 2001) into intron 2 of Mecp2 gene (Guy et 
al., 2007). Mecp2Stop/y male mice displayed tremor, hypoactivity, breathing 
problems, gait problems, and general deterioration with death around 11 
weeks of age. The same group of researchers used a modified approach of 
this model to create a mouse model in which Cre recombinase and 
modified oestrogen receptor (Cre-ER) were combined with the Mecp2lox/stop 
allele. This combination allowed conditional activation (un-silencing) of 
endogenous Mecp2 under its own promoter and regulator elements (Guy et 
al., 2007). This Stop mouse model (Guy et al., 2007) mirrors the human 
disease in that the inactivation is lethal in males and leads to delayed but 
enduring phenotypes in females, making them a good model to test efficacy 
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of new therapeutic interventions. I have used this mouse model in my 
current project and will be described in more detail in next chapter. 
6. Another mouse model was created by Samaco et al (Samaco et al., 
2008)by silencing Mecp2 in tyrosine hydroxylase containing neurons. These 
mice displayed motor abnormalities and respiratory problems with an 
increased rate of apnoea. The observations obtained from this mouse 
model points towards the possible link between dysfunction in aminergic 
systems may be responsible for the breathing problems of RTT. 
7. More recently a subtle RTT phenotype including autistic like repetitive 
behaviours was observed in a mouse model created by Chao et al. In this 
mouse model a Mecp2 was silenced specifically in inhibitory GABAergic 
cells (Chao et al., 2010). 
1.9 Reversibility of RTT-like phenotype 
It is generally accepted that the abnormalities in brain development lead to 
permanent neurological and psychiatric features due to the limited ability of brain 
to generate new neurons or radically repair itself. However during the past decade 
a number of animal models of such diseases including  Down syndrome, fragile X 
syndrome and Angelman syndrome (Dolen et al., 2007; Fernandez et al., 2007) 
have started showing that some disease phenotypes can be rescued even in adult 
mice (Ehninger D, 2008). The similar trend has been reported in RTT (Guy et al., 
2007; Derecki, 2012; Derecki NC, 2012). 
Rett syndrome has been found to result from failure of neurons to mature or failure 
to maintain a mature phenotype (Kishi and Macklis, 2004; Palmer et al., 2008). 
Although MeCP2 is also present in astrocytes (Schmid et al., 2008) a deletion and 
neuron specific expression of Mecp2 studies in mice showed a dominant mutant 
phenotype is principally due to absence of MeCP2 in neurons (Chen et al., 2001; 
Guy et al., 2001; Luikenhuis et al., 2004). 
Whether RTT phenotype is reversible or even preventable needs much 
consideration. Since neurons seems to require MeCP2 throughout their lives, 
there is possibility that the introduction of normal MeCP2 or treatment strategies 
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targeting MeCP2-related signalling might restore function and thereby reverse 
RTT phenotype. Another possibility is based on the assumption that may be 
MeCP2 is essential for neuronal development during a specific time frame and 
after which damage caused by its absence is permanent and are thus insensitive 
to simple restoration of MeCP2 or other intervention beyond a critical period. 
1.9.1 Rescue of RTT like phenotype in Mecp2 knockout animal 
models 
Several mouse model studies have been conducted in order to test the reversibility 
of RTT-like phenotype.  
1.9.1.1 Global reintroduction of Mecp2 in mouse model studies 
In one study it was shown that modest over expression of Mecp2 transgene under 
a generic neuron-specific (tau) promoter in the Mecp2-null mice could prevent RTT 
like phenotype on the other hand the severe overexpression of Mecp2 transgene 
(2-4 fold of the WT level) in the same mouse model showed a profound motor 
dysfunction (Luikenhuis et al., 2004). This study highlighted the importance of 
maintain MeCP2 protein expression at an appropriate level. This is especially 
important when considering potential gene therapies. 
Similarly another study using an early brain-specific activation of Mecp2 under 
either nestin (drive Mecp2 expression on pre-mitotic cells) or tau (drive Mecp2 
expression on post mitotic neurons) promoter, suggested that the introduction of 
Mecp2 to the nervous system under artificial promoter is sufficient to enable a 
modest amelioration of RTT- like phenotype (Giacometti et al., 2007). 
Guy and colleagues (Guy et al., 2007) have created a mouse model in which 
endogenous Mecp2 gene is silenced by insertion of a lox-stop cassette but can be 
conditionally activated. These mouse models showed robust symptom reversal 
and dramatically enhanced survival if treated once symptoms had developed. 
Another study by the same authors has shown an improvement in wide range of 
respiratory and locomotors phenotypes along with the structural remodelling in the 
brain following Mecp2 activation (Robinson et al., 2012a). 
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Another interesting study (McGraw et al., 2011) in which an adult mouse model of 
RTT was created (tamoxifen-induced excision of a floxed Mecp2) suggested that 
MeCP2 is critical for maintenance of neurological function in the adult nervous 
system. Studies conducted by Robinson & colleagues and McGraw & colleagues 
suggested, that potential therapies for RTT are likely to be required throughout life. 
1.9.1.2 Restricted re expression of Mecp2 in mouse model studies 
Studies, on more restricted expression of Mecp2, in which promoters other than 
the endogenous Mecp2 promoter have been used, have shown a more modest 
effect. Study conducted by Alvarez Saavedra et al in which they have used 
Ca2/calmodulin dependent protein kinases II (CamKII) or enolase promoter in the 
forebrain and cerebellum/striatum respectively, didn’t rescue the RTT like 
phenotype in Mecp2-/y  male mice (Alvarez-Saavedra et al., 2007). However 
Mecp2-/+ female mice shown improvement in mobility and locomotors activity to 
WT levels (Jugloff et al., 2008). The sustained deficits found in these mouse 
models could be due to dysfunction of region or cell types in the brain still devoid 
of Mecp2 or enhanced expression of exogenous promoters or other unknown 
mechanism. 
1.10 Therapeutic interventions for RTT 
Currently several treatment strategies are employed in order to combat the 
underlying pathology of Rett syndrome. MECP2 target approaches broadly 
includes, activating a silent copy of MECP2, gene therapy, and pharmacological 
approaches. 
Guy et al (Guy et al., 2007) demonstrated reversibility of the Mecp2 knockout 
phenotype, as described in previous section and raised interest in exploring 
therapeutic approaches designed to reverse existing pathogenesis of  RTT and to 
prevent its onset. 
1.10.1 Reactivation of the normal allele 
As described earlier, MECP2 is located on the X chromosome and is subject to X 
chromosome inactivation (XCI). Each cell in a heterozygous female RTT patient 
expresses either the normal or mutant MECP2 allele, never both. The process of X 
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chromosome inactivation is random and results in an approximately 50:50 mixture 
of cells, although there might be variations between individuals. Studies have 
shown a mosaic pattern of brain cells expressing normal and mutant Mecp2 alleles 
(Guy et al., 2007). The likely strategy will involve re activation of the inactive X to 
allow expression of the normal allele in the same cells (Mohandas et al., 1981). 
However this approach is unlikely applicable, as the re activation of entire inactive 
X can lead to pathological levels of gene expression at many loci. Re-activation 
needs to be targeted only at the MECP2 locus but currently no obvious resources 
are there to target re-activation. 
1.10.2 Pharmacological approaches 
Identifying factors that are downstream of MeCP2 function and tackle those 
pharmacologically seems to be a sensible approach to develop therapeutic 
interventions in RTT. Nevertheless it is unlikely for drug molecules to replace the 
yet unknown, function of MeCP2. For example brain biopsies from RTT patients 
have reported decrease in monoamines (noradrenalin, serotonin and dopamine) 
levels (Lekman et al., 1989). This reduction was also observed in Mecp2-null mice 
(Roux et al., 2010). The in vitro application of noradrenalin to the brainstem in 
Mecp2 null mice, which displayed irregular rhythms, stabilized the respiratory 
network rhythmogenesis (Van Esch et al., 2005) suggesting a potential role of 
monoamine in RTT therapy.  
Similarly loss of MeCP2 is associated with other neurotransmitters like glutamate 
(Maezawa and Jin, 2010), GABA (Chao et al., 2010) and various pharmacological 
approaches have been employed for therapeutic benefits in RTT patients. 
Another pharmacological approach would be to target immediate consequences of 
the specific mutation responsible for the MeCP2 abnormal functions in the 
particular patient. Many patients carry nonsense mutations in MECP2 (e.g 
p.R168X, p.R255X, p.R270X) which are associated with premature stop codons 
(PSCs). Antibiotics like aminoglycoside, which permit ribosomal read-through of 
PSCs during translation, would enable production of full length functional protein 
(Martin et al., 1989). Forty percent of typical Rett syndrome patients with MECP2 
mutations have one of the nonsense mutations (Philippe et al., 2006), 
aminoglycosides seem a promising avenue to achieve a full length functional 
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MeCP2. However the low read through efficiency together with the known toxicity 
of these drugs indicates that currently available aminoglycoside drugs are unlikely 
to represent a new therapeutic approach at present. 
1.10.3 Gene therapy 
Gene therapy is a promising approach for treating multiple disorders including 
neurological, genetic and cancers (Blömer et al., 1996). Overall the gene therapy 
involves delivering of new genetic instructions into target tissues to compensate 
for missing or aberrant genes or to convey a new function. Gene therapy for 
genetic disorders provides treatment at the molecular level to fix the primary 
underlying cause of the disorder instead of tackling variable secondary effects. 
As previously explained Rett syndrome is caused mainly by the MECP2 gene 
mutations whose encoding sequences, isoforms and resultant protein products are 
well studied. The lack of effective conventional therapeutic approaches and a lack 
of understanding of the downstream effects of MeCP2 highlight the importance of 
tackling RTT at the genetic level. Also the reported phenotype reversibility of RTT-
like phenotypes in Mecp2 knockout mice models makes it a very important 
candidate for gene therapy. In RTT the major objective of this therapy will be to 
deliver a working copy of MECP2 to as many affected brain cells as possible to 
raise function (at both the molecular and cellular level) above a threshold required 
for improvement of the clinical picture. One study has demonstrated the potential 
for lentiviral transgene delivery to improve the phenotype of Mecp2 null neurons 
derived from neuronal stem cells in culture (Rastegar et al., 2009). 
Recently an improvement in survival and severity profile was reported in a Mecp2 
null male mice (Gadalla et al., 2013). The researchers have used a neonatal 
intracranial delivery approach of a single-stranded (ss) AAV9/chicken β-actin 
(CBA)-MECP2 vector resulting into a significant improvement in the phenotype 
severity score, in locomotor function and in exploratory activity. In another recent 
study using a female mouse models it was shown that self-complementary AAV9, 
bearing MeCP2 cDNA under control of a fragment of its own promoter 
(scAAV9/MeCP2), is capable of reversing and stabilising RTT phenotype (Garg et 
al., 2013). However encouraging these results may be, there are many challenges 
to overcome for this approach to be successful. Some of these challenges include 
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finding an appropriate vector, transducing sufficient cells, avoidance of transgene 
repression and over expression of exogenous MeCP2 in the mosaic female brain. 
It will be important to assess how such novel therapies impact on non-CNS 
aspects of RTT and thus it is important to characterised and investigate inherent 
reversibility of bone phenotypes in animal models of Rett syndrome. 
1.11 Summary and Aims 
Rett syndrome (RTT), traditionally considered a neurodevelopmental disorder, 
mainly affects girls and is due principally to mutations in the X-linked gene methyl-
CpG-binding protein 2 (MECP2). Whilst it is well established that the majority 
(>95%) of classical RTT cases are due to mutations in the MECP2 gene, the 
underlying function and regulation of MeCP2 protein remains unclear. MeCP2 is a 
nuclear protein and is especially abundant in the brain. However, it is also 
expressed throughout the body and in addition to the neurological phenotypes, a 
number of overt peripheral phenotypes are also common in RTT. For instance, 
spinal deformity (principally scoliosis) is a very common feature with ~50-90% of 
patients developing severe scoliosis, many of whom require corrective surgery.  
Other prominent skeletal anomalies include early osteoporosis, osteopenia, bone 
fractures and hip deformities. Previous studies have found that Rett syndrome 
patients have reduced bone mass. As a result, RTT patients have an increased 
risk of fractures and commonly sustain low-energy fractures. Whilst MeCP2 is 
known to be expressed in bone tissues and studies have suggested a role of the 
protein in osteoclastogenesis, the role of MeCP2 in bone homeostasis is poorly 
defined.  
The exact mechanism by which disrupted MeCP2 function affects bone tissue is 
not yet defined. Therefore the main aim of my PhD was to assess skeletal 
phenotypes in a mouse model of Rett syndrome and to explore whether aspects of 
bone-related pathologies were amenable to genetic recue of the Mecp2 gene. 
Specific goals were as follow: 
 To establish whether silencing of the Mecp2 gene results in biomechanical 
bone phenotypes in a Mecp2stop/y  mouse model of Rett syndrome. 
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 To establish if postnatal reactivation (genetic rescue) of MeCP2 gene  
results in any reversal or prevention of RTT-related biomechanical bone 
phenotypes. 
 Explore the effects of MECP2 protein mutation on bone structure, bone 
mineral, bone collagen or bone cells. 
The overall objective of my thesis research is thus to analyse the biomechanical 
and anatomical properties of bone tissue in a mouse model of Rett syndrome and 
explore whether such features are potentially reversible using gene-based 
therapeutic approaches.  
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Chapter 2 
General materials and methods 
 
2.1 Experimental Animals Models 
The Mecp2-stop mouse model [Mecp2stop/y (male) and Mecp2+/stop (female)] and 
Mecp2 genetic rescue mice [Mecp2stop/y, CreER (male) and Mecp2+/stop, CreER 
(female)] were created and supplied by Prof Adrian Bird’s laboratory at the 
University of Edinburgh, Edinburgh, United Kingdom (UK) (Guy et al., 2007, 
Robinson et al., 2012). These mice together with wild-type littermates were used 
as part of a larger study to assess various neurological and brain morphological 
phenotypes (Robinson et al., 2012). After the completion of such behavioural 
phenotyping studies, adult male and female mice were killed by cervical 
dislocation and were transcardially perfused with 4% paraformaldehyde (0.1M 
phosphate buffered saline, pH 7.4) prior to shipping to the University of Glasgow, 
Glasgow, UK for use in my PhD studies. Another subset of mice was used to 
establish the expression of Mecp2 in bone cells (see section 2.5 for details) 
 
2.2  Design of Mecp2 stop and rescue mouse mode 
Guy and colleagues (Guy et al., 2007) created a mouse model in which the 
endogenous Mecp2 gene was silenced by insertion of a lox-stop cassette flanked 
by loxP sites. By crossing this line with mice expressing an inducible Cre 
recombinase fused to a modified oestrogen receptor (CreER) (Hayashi and 
McMahon, 2002), an additional cohort of mice enabled the conditional reactivation 
of MeCP2 under the control of its endogenous promoter and regulatory elements 
by Stop cassette deletion (figure 2-2) (Guy et at., 2007; Robinson et al., 2012). 
2.2.1 lox- stop cassette and Mecp2 stop models 
A strategy has been adopted in studies (Nagy, 2000)  aiming to characterise the 
function of gene products by rescuing lineage or developmental stage specific 
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knockout phenotypes by conditional gene repair. This approach is based on the 
targeted insertion of a positive selection gene cassette (typically the neomycin 
phosphotransferase gene, neo) flanked by loxP sites into an intron. Positive 
selection cassettes have been known to have the potential to interfere with normal 
expression of the targeted allele by promoter interference, disruption of normal 
splicing patterns or by premature transcript termination (Meyers et al., 
1998).Insertion of neo (neomycin phosphotransferase) within an intron has its 
potential drawbacks on the expression level of the target gene, including unaltered 
expression, a reduction in targeted gene expression (generating a hypomorphic 
allele), or complete inactivation (Meyers et al., 1998; Nagy et al., 1998; Dietrich et 
al., 2000; Wolpowitz et al., 2000). 
Usually conditional gene inactivation employs the Cre/loxP site-specific 
recombination system, which provides a means to control the development and 
tissue specific gene disruption, thus circumventing the early lethality found in 
knockouts of developmentally critical genes (Sauer, 1998). The Cre/loxP system 
has also been employed to activate conditionally transgene expression by 
employing a floxed synthetic transcriptional/translational ‘stop’ cassette (STOP) 
(Lakso et al., 1992). The STOP cassette consists of the 3’ portion of yeast His3 
gene, an SV40 polyadenylation sequence and a false translation initiation codon 
followed by a 5’ splice donor site. The floxed STOP cassette is inserted between 
the promoters and coding sequences of a transgene, ensuring that few, if any, 
transcripts containing the coding region are generated. In presence of Cre, 
recombination at the loxP sites, Tamoxifen excises the STOP cassette, and there 
by activating expression of the transgene (Lakso et al., 1992; Wakita et al., 1998) 
(figure 2-1). 
In summary, the one powerful use of Cre/loxP technology is in the conditional 
removal or activation of gene function. In the former, Cre mediated recombination 
leads to the precise excision of an essential region within a gene so that a 
functional product is not produce and in the latter, Cre-mediated recombination 
removes a functional barrier to the production of an active gene product, thereby 
switching on gene activity. 
Mecp2-stop mice [Mecp2stop/y (male) and Mecp2+/stop (female)] (Guy et al., 2007) 
were created using a lox-stop cassette (Dragatsis and Zeitlin, 2001) which was 
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inserted into intron 2 of Mecp2  to generate an incomplete Mecp2 mRNA that 
precludes translation of Mecp2 protein. Guy and colleagues performed the 
western blots and in situ immunofluorescence to confirm the absence of 
detectable MeCP2 protein in Mecp2lox-Stop/y (Stop/y) animals. 
 
2.2.2 Rescue of Mecp2 stop models 
Guy and colleagues (Guy et al., 2007) controlled the activation of Mecp2 by 
combining a transgene expressing a fusion between Cre recombinase and a 
modified oestrogen receptor (cre-ER) with the Mecp2lox/Stop allele (Hayashi and 
McMahon, 2002). 
2.2.2.1 Cre recombinase and modified oestrogen receptors 
 
As described previously in section 2.3.1, Cre integrase from bacteriophage P1 to 
catalyze recombination between its loxP target sites has gained popularity as an 
essential tool for conditional gene activation or inactivation in mouse models 
(Rossant and Nagy, 1995; Rossant and McMahon, 1999; Nagy, 2000). 
Scientific community thought about the way in which the utility of Cre/loxP system 
approach can be enhanced is by developing ways in which Cre activity can be 
controlled and a number of groups has described various approaches to control 
the spatial and temporal expression of the enzyme (Rossant and McMahon, 1999; 
Nagy, 2000).  
A fusion gene is created between Cre and mutant form of the ligand-binding 
domain of the oestrogen receptor (ERTM). This mutation prevents binding of its 
natural ligand (17b-estradiol) at normal physiological concentrations, but renders 
the ERTM domain responsive to 4 hydroxyl (OH)-TM (Fawell et al., 1990; 
Littlewood et al., 1995). Fusion of Cre with ERTM leads to the ERTM dependent 
cytoplasmic sequestration of Cre by Hsp90 (Picard, 1994) and thus preventing 
Cre-mediated recombination, a nuclear event. 
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Figure2-1 Representative diagram showing, the Cre ER/loxP 
system. 
CreER is tamoxifen inducible Cre recombinase. The Cre-ER protein in rescue 
models remained in the cytoplasm unless exposed to the oestrogen analog 
tamoxifen (TM), which causes it to translocate to the nucleus. Cre-mediated 
recombination removes a functional barrier (loxP-Stop cassette) to the production 
of an active gene product, thereby switching on gene activity. 
 
Guy and colleagues rescue model was created by adopting the techniques used 
by Hayashi et al in which they had created a more broadly useful strain of mouse 
to generate a line in which Cre-ERTM is ubiquitously expressed. Crossing these 
mice to an appropriate target strain permitted TM-dependent recombination in all 
tissues, with precise temporal control, at embryonic and adult stages (Hayashi and 
McMahon,2002).
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2.2.2.2 Tamoxifen treatment 
The Cre-ER protein in rescue models remained in the cytoplasm unless exposed 
to the oestrogen analog tamoxifen (TM), which causes it to translocate to the 
nucleus (figure 2-1). Guy and Colleagues verified this in their Stop mouse models 
by southern blotting that the Cre-ER molecule did not spuriously enter the nucleus 
in the absence of TM and cause unscheduled deletion of the lox-Stop cassette in 
Mecp2lox-Stop/+, cre-ER (Stop/+, cre) females. Even after 10 months in the presence 
of cytoplasmic Cre-ER, there was no sign of deleted allele found (Guy et al., 
2007).  
The absence of spontaneous deletion of the lox-Stop cassette was evaluated 
independently confirmed by the finding that Stop/y males showed identical survival 
profiles in the presence or absence of Cre-ER. Therefore it was evaluated that in 
the absence of TM, the Cre-ER molecule does not cause detectable deletion of 
the lox-Stop cassette. The ability of Tamoxifen (TM) to delete the lox-Stop 
cassette in Mecp2lox-Stop/y, cre-ER (Stop/y, cre) male mice rescue was also tested 
and showed high levels of recombination efficiency (Guy et al., 2007).  
 
2.2.2.3 Tamoxifen injection regime 
The unsilencing of the mice (removal of Stop cassette) was achieved by tamoxifen 
(100mg/kg; Sigma, UK) treatment, administered via intrapertoneal injection at an 
injection volume of 5ml/kg (dissolved in corn oil) body weight. A treatment regime 
of one injection of tamoxifen per week for 3 weeks followed by four daily injections 
on consecutive days in the fourth week was employed (Guy et al., 2007; Robinson 
et al., 2012a) (figure 2-3). 
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Figure2-2  Experimental design of Tamoxifen regime (rescuing) of 
Mecp2stop/y mice 
Experimental design of the current study showing treatment (A) and sampling 
phases (B) in male mouse comparison cohorts. Wild-type (Wt) , Mecp2stop/y ( non-
rescue) and Mecp2stop/y,CreER (rescue) were given one injection of tamoxifen 
(100mg/Kg) per week for 3 weeks (age 6-8 weeks) then  followed by 4 daily 
injections in consecutive days in the 4th week (age 9 weeks). Mice were then 
culled at 14 weeks and bones were sampled for imaging, histology and 
biomechanical tests. 
 
2.2.2.4 Behavioural testing after tamoxifen treatment 
After the tamoxifen treatment, Guy and colleague (Guy et al., 2007) performed 
observational test to monitor the specific features of the RTT-like mouse 
phenotype. These tests include inertia, gait, hind-limb clasping, tremor, irregular 
breathing, and poor general condition. Each symptom was later on scored weekly 
as absent, present or severe (scores 0, 1, and 2 respectively). Wild type mice 
always showed the zero score, whereas Stop/y animals typically showed 
aggregated symptoms and hence the higher scores (3-10) during the last 4 weeks 
of life. On the other hand majority of symptomatic Stop/y, cre were rescued by TM 
treatment.  
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These mice did showed milder symptoms and score (1-2) and were thought to 
survive for up to 4 weeks from the date of first injection, instead they survived well 
beyond the maximum recorded life span of Mecp2lox-Stop/y (17 weeks). 
Heterozygous females may be the most accurate model for human RTT 
(Kriaucionis and Bird, 2003) because both knockout Mecp2+/- and silenced 
Mecp2Stop/+ females develop RTT like symptoms, including inertia, irregular 
breathing, abnormal gait, and hind-limb clasping at 4-12 months of age. Similar to 
the RTT patients, the phenotype stabilizes, and the mice have an apparently 
normal life span. The mice do become obese with time which is not seen in RTT 
patients. 
Similar to the Stop/y, cre male mice, Guy et al, TM-treated Stop/+ females with 
clear neurological symptoms were also used for behavioural testing. These mice 
progressively reverted to a phenotype that scored at or very close to wild type. The 
report from this study (Guy et al., 2007) demonstrated that the late onset 
neurological symptoms in mature adult Stop/+,cre heterozygotes are reversible by 
de novo expression of MeCP2. 
Behavioural studies performed by Robinson and colleagues on these Stop/y, cre 
and Stop/+, cre showed an improvement in structural deficits in cortical neurons, 
rescue of respiratory phenotype and improvement in sensory motor tasks 
(Robinson et al., 2012a). In my PhD project I have used these cohorts of these 
mice to explore putative RTT-related bone phenotypes (see next chapters 3, 4 and 
5). 
 
2.3 Breeding strategy of Mecp2- Stop mice 
Local Mecp2-Stop colonies at University of Aberdeen were established by 
breeding heterozygous Mecp2Stop/+ mice in which the endogenous Mecp2 allele is 
silenced by a targeted stop cassette (Mecp2tm2Bird, Jackson Laboratories Stock No. 
006849) were crossed with hemizygous Cre ESR transgenic mice (CAG-
Cre/ESR1*, Jackson Laboratories Stock No. 004453) to create experimental 
cohorts (Guy et al., 2007) ( table 2-1)  
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A breeding strategy of crossing C57BL6/J/CBA F1 animals and using the F2 
offspring (Robinson et al., 2012a) was used. The genotype of the mice was 
determined by polymerase chain reaction (Guy et al., 2007). Mice were housed in 
groups with littermates, maintained on a 12-h light/dark cycle and provided with 
food and water ad libitum. Experiments were carried out in accordance with the 
European Communities Council Directive (86/609/EEC) and a project licence with 
local ethical approval under the UK Animals (Scientific Procedures0 Act (1986). 
2.4 Age of experimental animals 
Age matched male mice cohort (Wild-type, Stop/y, Stop/y,cre) of mean age14 
weeks ± 4 days and female mice cohort (Wild-type, Stop/+, Stop/+,cre) of mean 
age of 20 months ±  5days were used in my PhD project experiments.  
All mice were treated were treated by a single injection of tamoxifen (see section 
2.3.2.3) at 6 week postnatal age followed by 2 further weekly does at 7 week age  
and 8 week age with subsequent  4 consecutive daily doses in 9 week (figure 2-1) 
. The mice were culled after 4 weeks of tamoxifen treatment. 
Female (Stop/+, cre) mouse models were rescued with injection of tamoxifen at 18 
months of age followed by 3 weekly injection and 4 consecutive daily doses. The 
mice were culled 2 months after the tamoxifen treatment. Wild type control mice 
were treated with tamoxifen in parallel with their Mecp2stop/y and Mecp2stop/y, Cre ER 
littermates. 
2.5 Establishment of expression of MeCP2 on bone cells 
To establish MeCP2 expression in bone tissues, we have used an MeCP2-GFP 
reporter line (McLeod et al., 2013). The heterozygous female mice aged 10-13 
weeks were engineered to express a Mecp2-EGFP fusion by a targeted gene 
knock-in in mouse ES cells (generated in Adrian Bird’s laboratory at the University 
of Edinburgh; Mecp2tm3.1Bird, Jackson Laboratories stock no. 014610). Mecp2 
status was detected in cells by the presence or absence of fluorescence in living 
or fixed cells. Further on the experimental cohort was produced by breeding 
Mecp2+/- females with Mecp2 GFP/Y males (supplied by Adrian Bird’s laboratory) on 
a C57BL6/j background). 
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2.5.1 Methodology 
In these mice, MeCP2 has a GFP tag cloned into the 3’ end of exon 4 to create a 
C terminal GFP fusion product which enables the straightforward localisation of 
endogenous MeCP2 protein via epifluorescence or laser scanning confocal 
microscopy (figure 2-3).  
 
Figure 2-3  MECP2-GFP mouse model GENOTYPE CONSTRUCT 
Schematic diagram showing GFP tagged MECP2 mouse model design. A GFP 
tag is cloned into the 3’end of exon 4 to create a C terminal GFP fusion product. 
NTD, N-terminal domain; MBD, methyl binding domain; ID, inter domain; TRD, 
transcription repression domain; CTD, C-terminal domain; NLS; nuclear 
localisation signals (red line). 
Femur bone from male and female mice were dissected out and decalcified in 
10% EDTA Solution (7.4 pH) (280g EDTA, 1.5 L of distilled water, 180ml of 
ammonium hydroxide), for two weeks in a refrigerator at 4°C. The fresh 10% 
EDTA solution was changed every other day, until the bones are properly 
decalcified. Midshaft transverse section of 20μm thickness were carefully cut by 
using a Leica VT1000 microtome (Leica Milton Keynes, UK) which is maintained 
by Robert Kerr, West Medical Building, University of Glasgow, Glasgow, UK.  
Images were taken by using laser scanning confocal microscopy (Zeiss LSM710, 
Bio-Rad Radiance 2100, UK) using 20x and 40x objectives. Laser scanning 
confocal microscopy is maintained by Andrew Todd, west medical building, 
University of Glasgow, Glasgow, UK. 
After the laser scanning confocal microscopy, we observed that all bone cells 
express nuclear GFP fluorescence in wild type male (figure 2-4 Ai-iV) and female 
mice. In contrast, GFP fluorescence is found absent in hemizygous Stop 
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(Mecp2stop/y) mice (figure 2-4 Bi-iv), in which Mecp2 is silenced by a stop cassette, 
and is observed only in ~50% of bone cells nuclei in female heterozygous Stop 
(Mecp2+/stop) mice in which one Mecp2 allele is silenced to mimic the mosaic 
expression pattern seen in human Rett syndrome (Guy et al., 2007; Robinson et 
al., 2012a).  
 
   Figure 2-4 MeCP2 is expressed widely in bone tissues 
          
(Ai) Low power and (ii-iv) high power micrographs of transverse sections taken 
from mid shaft mouse femur showing GFP expression in all DAPI-labelled nuclei in 
a male wild type (Mecp2+/y) mouse in which the native MeCP2 is tagged with a C-
terminal GFP. Note that MeCP2 is restricted to the nucleus of osteocytes as 
indicated by the complete overlap with DAPI staining but present in all nuclei. (B) 
GFP expression is not observed in stop mice in which MeCP2 expression is 
functionally silenced by a neo-stop cassette. (C) Low power (i) and (ii-iv) high 
power micrographs showing mosaic expression of GFP-tagged MeCP2 protein in 
~ 50% of DAPI positive nuclei in a female heterozygous stop (Mecp2+/stop)  mouse 
in which one Mecp2 allele is functionally silenced. All scale bars: 100μm.  
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2.6 General solutions 
All chemicals below without specified origins were supplied from Merck Ltd. (BDH 
Laboratories, UK) or Sigma-Aldrich Company Ltd, (Sigma, UK). 
 
2.6.1 0.2 M PB 
 
Materials 
 Solution A: 37.44 g of NaH2PO (2H2O) in 1200 ml ultrapure H2O 
 Solution B: 84.90 g of NaH2PO4 in 3000 ml ultrapure H2O  
Methods 
 
Add 1120 ml of solution A to 2880 ml of Solution B and mix well. Adjust PH to 7.4 
with either HCL or NaOH. Add 3000 ml distilled water to the final solution. 
 
 
2.6.2 0.1 M PB 
0.1 PB was made by 50/50 (v/v) dilution with distilled water. 
 
2.7 Dissection 
2.7.1 Material 
Dissection of mice was carried out to obtain, right and left femur, tibia, humerus 
and lumbar 5 vertebrae from each mouse (n=6 per genotype). 
 
 50 mL Falcon tube containing 70% ethanol ( EtOH ) for sterilizing surgical 
equipment. 
 Dissection board 
 Pins 
 Scissors 
 Plain and tooth forceps 
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2.7.2 Method  
 
2.7.2.1 Tibia and Femur dissection 
Each Mouse was pinned to the dissection board, lying on the dorsal back with 
ventral surface of the body facing up. Hind limbs were sprayed down with 70% 
ethanol / 30% H20.  For each right and left leg, first nails were trimmed off with 
small dissecting scissors. Then a cut is made in the skin around the full 
circumference of the ankle. A second cut down the inside of the leg is made, 
starting at the ankle cut and ending at the tip of the 3rd metatarsal. With the help of 
small teethed forceps skin was peeled from the ankle towards the phalanges. 
Another cut is made inside the leg, starting at the original ankle cut and continuing 
along the tibia and femur. Skin was peeled off to the level of the hip. The medial 
thigh muscles are dissected 2mm proximal to and along the course of the deep 
femoral branch.  
Dissection is continued laterally in 2 mm distance to and along the bundle of the 
femoral nerve, artery and vein. The tendinous insertion sites of the medial thigh 
muscles are clipped and the entire medial thigh muscle package excised. Excision 
of calf muscle composed of gastrocnemicus, soleus and plantaris from the fascia. 
To keep the bones in natural environment freshly dissected bones were 
transferred in labelled tubes filled with 0.1 M Phosphate buffer solution (figure 2-5).  
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Figure2-5  Dissection of femur and tibia 
Images showing stepwise dissection of lower limb long bones (femur and tibia). 
(A-D) dissection of mouse femur and tibia. (A); white arrow point towards the start 
of incision area for dissection on left lower limb. (B); Skin and subcutaneous tissue 
removed around femur and tibia (C); Skin, subcutaneous fat and muscle removed 
around femur and tibia to expose the underlying bones; white arrow points toward 
the skin, subcutaneous fat and medial thigh muscles (D); Image showing 
dissected femur (blue arrow) and tibia (red arrow). 
2.7.2.2 Lumbar vertebrae 5 dissection 
Each Mouse was pinned to dissection board, with ventral surface of the body 
facing up. Ventral body surface was sprayed down with 70% ethanol / 30% H20. 
After the fur, skin and soft tissue removal, vertebrae were identified. With the help 
of forceps, scissors and scalpel, Lumbar 5 vertebrae were carefully dissected out 
from the rest of vertebrae. Excision of vertebral surrounding structure consists of 
Para spinal ligaments and muscles (figure 2-6). 
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Figure2-6  Dissection of 5th Lumbar vertebrae 
Images showing stepwise dissection of 5th lumbar vertebrae (A-C). (A) image 
taken after the dissection and removal of skin, subcutaneous tissue and organs. 
(B);Image taken after removal of muscles and ligaments around the vertebral 
column. (C); Image showing lumbar vertebrae. White arrow points towards the hip 
bone as the identifying anatomical point for the lumbar vertebral dissection. 
 
 
2.8 Morphometric measurements  
After the dissection both right and left femur and tibia along with the 5th lumbar 
vertebrae from each experimental genotype group were subjected to 
morphometric measurement (see below) before further biomechanical, radiological 
and histological analysis.  
2.8.1 Whole body weights 
Whole body weight measurements were taken using analytical balance (APX60, 
Denver Instruments, UK) and accuracy was taken to be 0.0001g. These 
measurements were required for the normalisation of individual bone weight 
measurement. For results, see chapter 3 result section. 
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2.8.2 Individual bone weights 
Femur, tibia and lumbar vertebrae wet weight measurements were obtained using 
analytical balance (APX60, Denver Instruments, and UK) and accuracy was taken 
to be 0.0001g. These measurements were taken to analyse if there are any gross 
differences in individual weights of the bones of three comparison genotypes. For 
results see chapter 3 and 4 result section. 
2.8.3 Individual bone lengths 
In order to obtain the individual bone lengths, femur and tibia were imaged in an 
anteroposterior position and posteoranterior position, using a WolfVision VZ9.4F 
(WolfVision Ltd, Maidenhead, UK). 
Images were analysed for subsequent measurements using Axiovision 4.8 
Software (Carl Zeiss Ltd, Cambridge, UK). Femur gross length measurement was 
taken from the proximal anatomical point of the greater trochanter to the distal 
anatomical point of  medial condyle (Di Masso et al., 1998). Tibial gross length 
measurements were taken from proximal anatomical point of centre of the 
condyles to the distal anatomical point of medial malleolus (Di Masso et al., 2004) 
(figure 2-7). 
Right femurs were used for mechanical testing (the proximal part for the femoral 
neck test and the midshaft part of femur bone was used for microindentation), see 
details in chapter 3.  
Left femurs were used for the bone histology (the proximal femur for Sirius red and 
TRAP staining, the distal femur for scanning electron microscopy), see details in 
chapter 4 and 5.  
Right tibias were used for μCT, see chapter 4 and three-point bending tests, see 
details in chapter 3 and left tibias used for the ash weight density measures, see 
full text in chapter 3.  
The 5th lumbar vertebrae were used for trabecular bone structure measures, see 
chapter 4 for full detail. 
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Figure2-7  Morphometric length measurements of femur and tibia 
(A) Image of femur and tibia obtained using a WolfVision VZ9.4F Visualizer to 
obtained length measurements (WolfVision Ltd, Maidenhead, UK). (B) Images 
were analysed for subsequent length measurements using Axiovision 4.8 Software 
(Carl Zeiss Ltd, Cambridge, UK). Femur gross length measurement was taken 
from the proximal anatomical point of the greater trochanter to the distal 
anatomical point of medial condyle. Tibial gross length measurements were taken 
from proximal anatomical point of centre of the condyles to the distal anatomical 
point of medial malleolus. 
 
2.9 Data handling and analysis 
For each biomechanical, structural and histological analysis data results have 
been summarized using descriptive statistics. These were presented as mean ± 
standard deviation (SD) values and compared by using one way ANOVA followed 
by Tukey’s post hoc test.  All statistical analyses were performed with the aid of 
Prism 5.0 (Graph pad) software.  
I have performed a series of biomechanical, morphological and histological on the 
above mentioned dissected bones which will be described in detail in the next 
three result chapters.
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Chapter 3 
Biomechanical tests revealed genotype differences 
in bone properties 
  
3.1 Introduction  
The majority of females with Rett syndrome are growth retarded (Schultz et al., 
1993; Neul et al., 2010; Roende et al., 2011b) and this postnatal pattern of altered 
growth is one of RTT’s earliest clinical expressions. Head growth typically 
decelerates during the first year of age and this further followed by a decline in 
somatic (height and weight) growth (Armstrong et al., 1999; Neul et al., 2010). 
Although not included in the clinical scales for diagnosis of Rett syndrome, 
patients nevertheless do suffer from bone related symptoms such as increased 
risk of fractures, spinal deformity (eg. scoliosis) (Roberts and Conner, 1988; 
Guidera et al., 1991a; Cepollaro et al., 2001; Neul et al., 2010) and bone mass 
anomalies (Leonard et al., 1999c; Budden and Gunness, 2001, 2003; Bebbington 
et al., 2008; Shapiro et al., 2010; Jefferson et al., 2011; Roende et al., 2011a). The 
effects of this high fracture incidence on the quality of life, care needs, and 
outcome for RTT patients, are likely to be of importance. Children having fracture 
episodes was reported to be one of the most strongly negative associations with 
mother’s mental health status (Laurvick et al., 2006).  
In my current study, I have looked at the bone biomechanical properties in an 
accurate genetic mouse model of Rett Syndrome in order to establish the possible 
impact of MeCP2 insufficiency on bone strength and propensity of fractures. 
3.1.1 Fracture risk epidemiology in RTT patients 
As described in the introductory chapter, multiple clinical studies suggest that 
patients with Rett syndrome suffer from an increased risk of fracture (Leonard et 
al., 1999c; Bebbington et al., 2008; Downs et al., 2008a).  
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It was found in one study that nearly one third of RTT patients had sustained a 
fracture by the age of 15 years(Leonard et al., 1999c), compared with only 15% of 
girls and women in the general population by the age of 20 year (Cooley and 
Jones, 2002). Similar finding were found by Downs and Colleagues, who reported 
38% of RTT patients in their study suffered from fracture episodes.  
The incidence of any facture episode was 43.3 episodes per 1000 patient per 
years and thus the fracture rate was found to be around 4 times higher in RTT 
patients as compared to the girls of similar age (Downs et al., 2008a). Recently in 
a case control study of a Danish RTT patient cohort, the investigators reported an 
approximately 36% fracture events occurrence among cases as compared to the 
27% in controls of same age. The first fracture event typically occurred (77.3% of 
cases) below 15 years of age (Roende et al., 2011b).  
Studies have been conducted in past to establish the site, cause (Leonard et al., 
1999c; Jones et al., 2002; Cooper et al., 2004; Downs et al., 2008a) and 
mechanism (Roende et al., 2011b) of fractures within Rett syndrome patients but 
exactly how and why RTT patients suffer from bone symptoms remains poorly 
defined. 
3.1.2 Fracture site in RTT patients 
Greater frequency of fractures was found in lower limb long bones (Leonard et al., 
1999c; Jones et al., 2002; Cooper et al., 2004; Downs et al., 2008a; Roende et al., 
2011b) within RTT patients as compared to the controls, although fractures have 
been reported in all regions (spine, ribs, sternum, clavicle, humerus, radius, ulna, 
wrist bones, fingers, femur, tibia, fibula, patella, ankle bones, foot), including face. 
The bone found most commonly to be fractured was femur followed by tibia, 
humerus, ankle and wrist bones respectively (Downs et al., 2008a). Vertebral 
fractures were not found to be common in Rett syndrome young population and 
mostly found in elderly patients aged ~60 years (Roende et al., 2011b). 
3.1.3 Determinants of Fracture risk in RTT patients 
Genetic predispositions as the cause of RTT bone symptoms have been observed 
by Downs and colleagues. In their study they categorized the cases according to 
mutation types, including p.R106W, p.R133C, p.T158, p.R168X, p.R255X, 
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p.R270X, p.R294X, p.R306C, C-terminal deletion, early truncating and large 
deletion mutations. The study found a threefold increased risk of fracture in 
patients with p.R270X mutation and nearly twofold increase in patients with 
p.R168X mutations. Individuals with p.R270X were found to be particularly 
susceptible (Downs et al., 2008a). Interestingly this mutation in the nuclear 
localization signal region of the transcription repression domain is the one that was 
found to be most severe in a number of studies (Huppke et al., 2003; Colvin et al., 
2004). However no association between the mutation types and fracture 
distribution was found by Roende and colleagues and they attributed this due to 
the lack of actual number of different MECP2 mutations in their study cohort 
(Roende et al., 2011b) as compared to Downs and colleagues. The issue 
regarding genotype and fracture occurrence within RTT are in dire need of further 
studies.  
Low bone mass is seen in RTT (Haas et al., 1997; Leonard et al., 1999c; 
Cepollaro et al., 2001; Motil et al., 2006; Zysman et al., 2006; Gonnelli et al., 2008; 
Shapiro et al., 2010) and an association between low bone mass and fractures in 
RTT has been found. 
In Rett syndrome 80% of patients suffer from seizures (Jian et al., 2006), 
prompting widespread use of antiepileptic drugs (AEDs). In a recent study it was 
observed that 64% of the Rett syndrome patients are taking anti-epileptic drugs 
(Anderson et al., 2014). Interestingly it has been observed that the risk of fracture 
increases with antiepileptic drugs and was found elevated for valporate (anti-
epileptic drug) in particular, prescribed on its own or in combination with other 
AEDs after one or more years (Leonard et al., 2010). In another case control study 
RTT subjects with a diagnosis of epilepsy were found to have nearly 3 times the 
risk of fracture and those receiving more than two AEDs had nearly twice the risk 
of those who were receiving no medication (Downs et al., 2008a). 
Risk of epilepsy in itself and development of scoliosis(Ager et al., 2006), in RTT 
patients is also thought to be genotype related (Jian et al., 2006), pointing towards 
the potential relationship between genotypes and bone strength acquisition.  
Physical activity is often limited in RTT with patients have difficulty in standing and 
walking, which declines further with age (Downs et al., 2008b). Association of risk 
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of fracture with mobility is less clear in RTT population (Leonard et al., 1999c; 
Downs et al., 2008a). It was also found that years without anticonvulsant 
medication and learning to walk were both separately protective against fractures, 
but when both variables were combined, only the absence of medication remained 
significant (Leonard et al., 1999c). Maintaining mobility, particularly in those RTT 
patients with high-risk mutations, has potential as an environmental modification to 
optimize bone health(Roende et al., 2011b). 
Reduced serum 25 hydroxyvitamin D levels [25-(OH) D] <50nmol/L, have been 
found in Rett syndrome patients. This reduction in vitamin D levels could be, 
associated with less exposure to sunlight, inherently dark skin, an indoor life style, 
the latitude at which they live. Among all these above stated factors, only race and 
ethnicity influenced 25-(OH)D levels in the RTT. Ambulatory status of girls and 
women with RTT did not show an association with 25-(OH)D concentration (Motil 
et al., 2011). On the other hand biochemical analysis of serum calcium, 
phosphate, alkaline phosphate, and Parathyroid hormone levels in RTT were not 
shown to differ from controls (Jefferson et al., 2011). The normal biochemical 
findings suggest that vitamin D deficiency, if present is not severe and other 
factors responsible for decrease in bone strength and fractures should be taken 
into consideration. 
Individual with severe physical and intellectual morbidities like RTT patients often 
live in protected environments and usually are not subject to fractures by falls, 
trauma, childhood games and other sports activities (Cass et al., 2003). Hence the 
high fracture rate in young Rett syndrome population may represent the effects of 
other risk factors, such as genotype and the presence of epilepsy. 
3.1.4 Low energy fractures in RTT patients 
Recently Roende and colleagues (Roende et al., 2011b) found in their study that 
“low energy fractures” (Spontaneous fractures of bones that occur without any 
external trauma or falls) to be the common characteristic of fractures in Rett 
syndrome patients.  
In their case control study, the majority of Rett cases suffered from low-energy 
fractures as compared to the controls that experienced significantly high-energy 
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fractures (fractures due to falls from one level to another or because of activities 
involving speed). Cases tended to fracture mostly the lower limb by low energy 
mechanisms, whereas controls tended to fracture mostly the upper limb by high 
energy mechanisms.  
In order to understand the mechanisms underlying the bone fractures an 
enhanced knowledge of biomechanical properties is required. In the next section 
of this chapter I am going to discuss a brief review of bone biomechanics. 
3.2 Biomechanical properties of bone 
As described in chapter 1, the organic and inorganic constituents together give 
bone its unique properties. In general the mineral phase provides the “stiffness”. 
The viscoelastic properties and resistance to fracture are attributed to the collagen 
phase (Currey, 1979). 
There is clinical and laboratory evidence that, in addition to bone mineral density, 
the mechanical properties of bone tissue may play a critical role in bone strength 
(Currey, 1979; Chavassieux et al., 2007). Alterations in these mechanical 
properties would be expected to play a significant factor in bone fracture risk, even 
though it has not been clear what mechanical properties are most important 
(Currey, 2004). 
Bone is a composite hierarchical material, therefore investigation of the 
relationship between the materials properties and the geometry and mechanical 
behaviour of whole bone is challenging and very complicated.  
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A thorough understanding of this relationship is of importance as it helps to 
understand the normal behaviour of whole bones during physiological loading as 
well as identifying areas of peak stresses which are more likely to fracture during 
intense activity, and allows the prediction of effects of various pathological 
processes and drug treatments (Sharir et al., 2008). 
The hierarchical structure of bone material changes at different length scales. It is 
also a graded material, as its composition, structure and mechanical properties 
may vary continuously or in discrete steps from one location to another (Suresh, 
2001).The mechanical behaviour of bone is determined by its geometry and the 
properties of the material of which it is made. 
There are a number of biomechanical parameters that can be used to characterize 
the integrity of bone. One of the key relationships is between applied load to bone 
and displacement in response to the load-displacement curve (figure 3-1). The 
extrinsic stiffness or rigidity of the bone (S) is represented by slope of the elastic 
region of the load-displacement curve. Other biomechanical properties of the bone 
can be derived from the same graph including ultimate force (Fu ), work to failure 
(area under the load-displacement curve , U) and ultimate displacement (du). Each 
of these biomechanical parameters reflects a different property of bone. Ultimate 
force also called ultimate load reflects the general integrity of the bone structure; 
stiffness measure is closely related to the mineralization of the bone (figure 3-1). 
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Figure3-1  Load-displacement curve for bone  
The Load displacement curve displaying stiffness (S) or rigidity (slope of the 
curve); Ultimate force (Fu) (the height of the curve); area under the curve is work to 
failure (U); and Ultimate displacement (du) (total displacement to fracture). Red 
Cross represents the fracture (breaking point). Figure modified and adopted from 
(Turner, 2006). 
 
Work to failure is the amount of energy necessary to break the bone; and ultimate 
displacement is inversely related to the brittleness of the bone. Biomechanical 
status of bone cannot be described by just one of these properties; in order to 
understand the biomechanical status of a bone fully, the range of these properties 
need to be considered. For example in young children bone tends to be poorly 
mineralized and weak, but very ductile (increased ultimate distance), resulting in 
increased work to failure. On the other hand bones can be very stiff as in 
osteopetrotic patient but also very brittle, resulting in increased risk of fracture and 
reduced work to failure (Turner, 2006)(figure 3-2). 
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Figure3-2 Load displacement curve showing various bone 
pathologies 
Brittle bones displayed a reduced work to failure and inversely proportion to the 
displacement. Young children bones are usually ductile, showing increased work 
to failure and large ultimate displacement. Red Cross represents the fracture event 
(breaking point). Figure modified and adopted from (Turner, 2006). 
 
When load is converted into stress and deformation converts into strain, by the 
relationship between stress and strain in bone follows a curve called the stress-
strain curve. The slope of the stress-strain curve within the elastic region is called 
the elastic or Young’s modulus (E). Young’s modulus is a measure of the intrinsic 
stiffness of the material (Turner, 2006)(figure 3-3). 
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Strength and stiffness are commonly used to define the bone health. Strength and 
stiffness are not directly proportional to risk of fracture but the amount of energy 
required to cause fracture is directly related to risk of fracture (Currey, 1979). 
 As described earlier, the bone tissue is a two-phase porous composite material 
composed primarily of collagen and mineral, with mechanical properties 
determined primarily by the amounts, arrangement, and molecular structure of 
both of these constituents. The mineral part provides strength and stiffness to the 
tissue (Turner, 2006). The collagen phase is tough and improves bone’s work to 
failure or toughness. The ratio of mineral to collagen in bone does affect bone’s 
strength and brittleness (Wang et al., 2002) (figure 3-3). 
 
                                             
Figure3-3  Summary of contributing factors towards the bone 
strength  
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Bone hardness is represented by the resistance of the material to the load as the 
structure is deformed. This response occurs in many material including bone, 
tendons and ligaments (Choi and Goldstein, 1992). A hard material will respond 
with a minimum deformation to the load increase. When the material fails in the 
end of the elastic phase, it is considered a fragile material. The higher the load 
imposed to the bone, the higher the deformation. In addition, if the load exceeds 
the elastic limits of the material, there will be a permanent deformation and failure 
of material (Choi and Goldstein, 1992) (figure 3-4). 
 
Figure3-4  The Stress-strain curve for bone  
The slope of the curve is called Young’s modulus (E). The yield point represents a 
transition, above which strains begin to cause permanent damage to the bone 
structure. Red Cross represents the fracture event (breaking point). Figure 
modified and adopted from (Turner, 2006). 
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3.3 Animals models and bone biomechanics 
Animal models, in particular mice, offer the possibility of naturally achieving or 
genetically engineering a skeletal phenotype and determining the resulting change 
in bone’s mechanical properties. In contrary to traditional strength tests on small 
animal bones, fracture mechanics tests display smaller variation and therefore 
offer the possibility of reducing sample size (Vashishth, 2008). 
 Many types of mechanical tests have been proposed for mouse bones. As mouse 
bones have the well-defined organizational hierarchy, mechanical tests scale the 
natural length scale from mineral and protein levels to whole bone tests. Nano and 
microindentation tests have been conducted on inbred or genetic knockout mouse 
bones to determine the local elastic and viscoelastic properties associated with 
bone protein and bone mineral modifications (Akhter et al., 2004a; Kavukcuoglu et 
al., 2007; Ng et al., 2007; Tang et al., 2007).  
At the whole bone level, three and four-point bending tests have been popular due 
to the inherent simplicity of such tests in determining the mechanical properties 
associated with changes in the structure and material due to exercise (Maloul et 
al., 2006; Wergedal et al., 2006; Wallace et al., 2007), variations among different 
inbred mouse strains (Wergedal et al., 2006) accelerated senescence and 
ovariectomy and growth factor (Maloul et al., 2006). Less common biomechanics 
tests for mouse bone includes femoral neck test which have been used in past to 
determine genetic influence on bone and whole bone fracture studies (Hessle et 
al., 2013). 
In Three-point bending test, the tested bone is positioned onto two supports, and a 
single-prolonged loading device is applied to the opposite surface at a point 
precisely in the middle between the two supports. The alternative 4-point bending 
method is similar except for the fact that the load is applied by two loading, located 
equi-distance from the midpoint (Brodt et al., 1999)The main advantage of this test 
is that the whole section of bone between two load-applying prongs is subjected to 
a uniform moment. Nevertheless, bones are mostly tested in 3-point bending, 
since their irregular surface geometry creates difficulty in having both prongs 
contact the bone simultaneously. 
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Along with bending tests, indention technique has been used in order to determine 
the mechanical properties in mouse bones (Hessle et al., 2013). The indentation 
technique allows determining the hardness of a material. The hardness is the 
resistance to the penetration of a hard indenter.  
 
 
Figure 3-5  Load Types (Compression, Tension, Torsion, Shear, Bending) 
 
 
Bone as a structure may be loaded in tension, compression, bending, shear, 
torsion, or a combination of these modes (figure 3-5). If the magnitude of applied 
load does not exceed the bone’ elastic limits, fracture does not occur and the 
bone, elastically deformed, returns to its prestrained state. The failure mode of 
bone under circumstances of catastrophic overload is directly related to the 
loading mode of the bone. That is, from an evaluation of the fracture 
characteristics, it is possible to speculate what loading modes produced the 
fracture. 
3.3.1 Load Types 
The skeletal system is subjected to a variety of different types of forces on such a 
way that the bone receives loads in different directions. There are loads produced 
by the weight sustentation, by the gravity, by muscle forces and by external forces. 
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The loads are applied in different directions producing forces that may vary from 
five different types: compression, tension, shear, curvature or torsion. 
TENSION 
Because bone as a structural component of the musculoskeletal system must 
withstand large axial loads (both compressive and tensile) to sustain weight 
bearing and locomotion, it by adaptation, exhibits greater strength when subjected 
to tension directed longitudinally versus tension directed transversely. This 
observation is essentially a restatement of Wolff’s law and helps to explain bone’s 
anisotropic mechanical behaviour (i.e., varying strength as a function of load 
direction) (figure 3-5). 
COMPRESSION 
Compressive forces on a structure tend to shorten and widen it. As in pure 
tension, maximal stresses occur on a plane perpendicular to the applied load; 
however, the stress distribution and resultant fracture mechanics in compressive 
failure are often very complicated. Unlike failure in tension, compressive failure in 
bone does not always proceed along the theoretic perpendicular plane of 
maximum stress, but rather once a crack is initiated it may propagate obliquely 
across the osteons following the line of maximum shear stress. 
SHEAR 
Tensile and compressive forces act perpendicular or normal to a structure’s 
surface. In contrast, shear forces act parallel to the surface and tend to deform a 
structure in an angular manner. 
BENDING 
Bending is a loading mode that results in the generation of maximum tensile forces 
on the convex surface of the bent member and maximum compressive forces on 
the concave side. Between the two surfaces, that is, through the cross section of 
the member, there is a continuous gradient of stress distribution from tension to 
compression. Because mature healthy bone is stronger in compression than in 
tension, failures usually begins on the tension surface. In very young animals or 
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severely osteoporotic bone, however folding or buckle fractures are sometimes 
noted on the concave or compression side of the bone, indicating in a 
compressive mode subsequent to bending. 
TORSION 
Torsion loading is a geometric variation of shear and acts to twist a structure about 
an axis (the neutral axis). The amount of deformation is measured in terms of 
shear angle, alpha. As in bending, in which maximum tensile and compressive 
stresses occur on the surface and distant from the neutral axis, torsional loading 
produces maximum shear stresses over the entire surface, and these stresses are 
proportional to the distance from the neutral axis. 
The skeletal system injury can be produced by applying a high-magnitude single 
strength of one these types of load or by repeated application of low-magnitude 
single strength of one these types of load or by repeated application of low-
magnitude loads over a long period. The second type of injury in the bone is called 
stress fracture; fatigue fracture or bone distension. These fractures occur because 
of cumulative microtrauma imposed on the skeletal system, when the placement of 
loads on the system is so frequent that the process of bone repair cannot be equal 
to the breakdown of the bone tissue(Egan, 1987). 
 
3.3.2 Aim of the study 
Given that Rett syndrome patients have a demonstrated increased risk of fracture 
and reduced bone strength, the aim of this study was to analyse the 
biomechanical properties of bones in  Mecp2-Stop mice modelling Rett Syndrome 
compared to wild-type and genetically rescued mice. We aimed to explore 
potential genotype-related deficiencies in mechanical properties of bone and 
hypothesize reduced bone strength in Mecp2-Stop mice with improved functional 
integrity following genetic rescue. 
3.4 Material and Methods 
Right tibial and femoral shafts from each comparison genotypes of male and 
female cohorts were subjected to mechanical testing (three point bending and 
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microindentation tests) after they are scanned by Sky scan 1172/A X-ray 
computed microtomgraphy (μCT). The mechanical tests were selected to test the 
cortical and cancellous parts of the bone. The tests were performed using a 
Zwick/Roell z2.0 testing machine (Leominster, UK) with a 100N load cell. 
3.4.1 Three-point bending test 
For three-point bending test (Hessle et al., 2013), tibias were placed on the lower 
supports, at 8 mm separation, with the posterior surface of the tibia facing down. 
Load was applied on the shaft of the tibia using the Zwick/Roell testing machine 
until the fracture occurred (figure 3-5) 
 
Figure3-6  Three point bending test on right tibias  
(A)Tibia was placed on the lower supports, with posterior surface facing down. 
Load was applied until the fracture occurred. Supports were separated 8mm. (B) 
Test was performed using the Zwick/Roell testing machine with a 100N load cell 
until fracture occurred. These tests were performed in Mechanical Engineering 
Lab, Rankine Building, Department of Engineering University of Glasgow. 
 
From each bone tested, a load-displacement graph was obtained using the 
testXpert® II software installed in computer linked to the Zwick/Roell z2.0 testing 
machine. The stiffness was calculated by measuring the slope in the graph of 
force-displacement and the ultimate load by measuring the maximum force that 
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the bone was able to resist. The second moment of area was calculated using the 
equation that considers the bone as a hollow cylinder: 
                                                 
 
  
         )        (eq.1) 
Where I is the second moment of area, the    is outside diameter and the    is the 
internal diameter; both of these measurements were taken from the μCT 
Young’s modulus measure was also estimated from the geometry of the loading 
device and the measured stiffness of the bone. Such an estimate is based on 
beam theory and the approximation of the shaft of the tested bone as a uniform 
hollow tube.  
For Young’s modulus following equation was used: 
                                          
          
    
      ................................... (eq.2) 
Where          is the stiffness, determine from the load-displacement curve.     is 
the separation of the supports and   is the second moment of area of the tibias. 
This is a commonly used method to estimate the mechanical properties of the 
material bone within the whole bone (Sharir et al., 2008). 
3.4.2 Micro indentation hardness test 
Right femur diaphysis from male and female mice cohort were cut transversely at 
midpoint of each bone shaft, using a diamond saw (IsoMet Plus Precision Saw; 
Buehler Ltd.). The midpoint of each bone was measured using venire calliper. 
Distal mid-shaft sections were used for the micro indentation test in each mouse 
bone. Proximal part of each right femur per mouse per genotype was used in 
femur neck test (see below). 
Bone sections were air dried and embedded in metallurgical mounting resin 
prepared by using, VARI-SET Acrylic powder/liquid system (VARI-SET 10/20 
liquid, Meta Prep, UK). The moulds were then allowed to solidify at room 
temperature for 24 hours. The bone cross-section surface was subsequently hand 
polished using silicon carbide papers with decreasing grain size (240, 400, 600, 
98 
 
800, and 1200) impregnated with diamond pastes (15, 6 and 1µm) to produce a 
smooth polished surface. 
Vickers test method (Dall’Ara et al., 2007; Hessle et al., 2013) was employed while 
using the microindentation hardness test. Seven indentations with an applied load 
of 25gf were done, along the transverse section of each specimen, using a Wilson 
Wolport Micro-Vickers 401MVA machine UK (figure 3-6). The indenter of the 
machine is held in place for each indentation for 10 or 15 seconds according to the 
average value found in the literature. Furthermore, to avoid overlapping of 
deformation from one indentation to another a minimum distance of 2 diagonals 
between indentations was established (ASTM E384).The Vickers pyramid number 
(HV) was calculated with an equation where the load (L) is in grams force and the 
average of the two diagonals (d) is in millimetres:                                        
HV=1.854 
 
  
        ...................................................... (eq.3) (figure 3-7) 
3.4.3 Femoral neck fracture test 
The femoral neck fracture test was used to test the mechanical properties 
(stiffness and ultimate load) at the proximal part of femur. The shaft of the femur 
was fixed in a mechanical chuck and placed in the Zwick/Roell z2.0 mechanical 
testing machine (Akhter et al., 2004b). The bone sample was clamped at a 9˚ 
angle lateral to the vertical axis of the bone (Hessle et al., 2013). Load was applied 
to the femoral head until fracture occurred. After each bone being tested the load-
displacement graph is obtained by using the testXpert® II software installed in 
computer linked to the Zwick/Roell z2.0 testing machine Stiffness and ultimate 
load measurement were calculated in a similar method as described earlier (see 
section3.4.2 above) (figure 3-7). 
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Figure3-7  Microindentation Test for hardness 
(A) Image showing Wilson Wolport Micro-Vickers 401MVA machine used for the 
micro indentation test. (B) Resin mould, with embedded bone tissue, white arrow 
pointing towards the bone sample held in clippers. (Ci) mouse femur, dotted line 
black line showed the midpoint of femur, distal half was used for the 
microindentation test. (Cii) transverse section of the bone sample showing the 
diamond shape indentation marks on the bone samples (arrows). (Ciii) Insert 
shows higher power image of region indicated by box in Cii. Scales bars as 
shown.  
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Figure3-8  Femur neck test 
(A) Image showing proximal femur mounted at 9° to the horizontal plane in the 
mechanical chuck. Load was applied on the head of the femur until the fracture is 
produced. (B) Image showing Zwick Roell testing machine used for the femur neck 
test.Results 
 
3.5 RESULTS 
In order to determine any gross skeletal abnormalities caused by MeCP2 
deficiency, the tibia and femur of male Mecp2stop/y mice together with wild-type 
littermates were examined for gross morphometric analyses; measurements are 
summarized below (table 3-1).  
Morphometric measurements revealed no significant difference in average body 
weights of male and female genotypes. Weight measures of femur and tibia 
showed a significant reduction in Stop mice and Rescue mice showed a significant 
treatment effect and improvement in weight of femur bone. No difference in femur 
length was observed. All data given as mean ± SD for each group of samples (n=5 
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per genotype). Significance was assessed by one way ANOVA with Tukey’s post 
hoc test. Abbreviations: * p<0.05, ** p<0.01. Symbol¶ (a comparison is made 
between Wild-type control and Stop).Symbol ɸ (a comparison is made between 
Stop and Rescue). Symbol ψ (a comparison is made between Wild-type control 
and Rescue). For ease of understanding, the male mice comparison genotypes 
will be addressed as Wt (control); Stop (Mecp2stop/y); and Rescue (Mecp2stop/y, 
CreER) mice and female genotypes cohort as Wt (control); Stop (Mecp2+/stop); and 
Rescue (Mecp2+/stop, CreER) mice in subsequent chapters. 
3.5.1 No difference in whole body weights of male and female 
cohorts 
No difference in whole body weights was observed genotypes in male mice (figure 
3-9). 
 
Figure3-9  Bodyweight measurements in male and female mice 
cohort. 
Bar graphs showing, male (A) and female (B) mice cohort analysis results for 
whole body weight measurements (A) In male mice whole body weight 
comparison among genotypes showed no significant difference (WT= 30.73 ± 3.75 
g; Stop = 28.50 ± 3.75g; Rescue= 28.21 ± 2.37g; n=6 per genotype; p<0.05, 
ANOVA with Tukey’s post hoc test) (p<0.05). (B) Similar trend was seen in female 
mice cohort (p<0.05) (WT= 32.72 ± 5.59g; Stop= 41.70± 7.15g; Rescue= 39.47 ± 
9.77g; n=6 per genotype; p<0.05, ANOVA with Tukey’s post hoc test). 
Abbreviation: ns = not significant, Plots show mean ± SD. 
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3.5.2 Reduced weight of femur and tibia in Mecp2-Stop male mice 
Mecp2stop/y mouse femurs showed a significantly (p<0.05) reduced weight in 
comparison with wild-type (Wt) littermate controls and Mecp2stop/y, CreER. A 
similar trend of reduction in whole bone weight was observed in Mecp2 Stop mice 
tibias, weight measures (table 3-1). 
Table 3-1  Morphometric measurements of stop male and female 
mice 
 
 
 
3.5.3 No significant difference in long bone (femur and tibia) 
weights in Mecp2-Stop female mice 
In contrast of the measurements made in male tissues, the female comparison 
cohort did not show any significant p>0.05 difference in femur weight measures 
between genotypes and similarly no reduction in female tibia weight was found 
(table 3-1). 
3.5.4 Significant reduction in tibial length of Stop male mice 
There was an accompanying reduction p<0.05 in tibial length in male Mecp2 Stop 
mice but no significant difference in femoral length between comparison groups 
(table 3-1). 
3.5.5 No significant difference in long bone (femur and tibia) 
length measures in Mecp2-Stop female mice 
Female Mecp2 Stop mice showed no significant difference in tibial and femur 
length among the comparing genotypes (table 3-1). 
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3.5.6 Significant reduction in biomechanical properties in Stop 
male mice and improvement in bone integrity of Rescue 
male mice. 
Following the morphometric analysis, mechanical tests were applied in order to 
explore possible differences in the biomechanical properties of MeCP2-deficient 
mice bones. Results from this test revealed a reduced structural stiffness (p<0.01), 
ultimate load (p<0.01) and Young’s modulus (p<0.05) measures in male 
Mecp2stop/y mice.  Samples from Rescue mice revealed that stiffness, ultimate load 
and Young’s modulus measures were not different from wild-type values (figure 3-
10).  
Figure3-10  Three point bending test results in male mice cohort                
Male mice measures of (A) cortical bone stiffness (WT= 106.8 ± 17.88 N/mm; Stop 
= 64.7 ± 10.50 N/mm; Rescue= 90.7 ± 14.83 N/mm , n=5 per genotype; p<0.01, 
ANOVA with Tukey’s post hoc test) (B) Ultimate load (WT= 17.50 ± 2.45 N; Stop= 
12.09 ± 1.94 N; Rescue=15.7 ± 0.08 N; n=5 per genotype; p<0.01, ANOVA with 
Tukey’s post hoc test) and (C) Young’s modulus (WT= 12.1 ± 2.37 kN/mm²; Stop= 
7.6 ± 1.60 kN/mm²; Rescue = 12.4 ± 3.49 kN/mm2;  n=5 per genotype; p<0.05, 
one way ANOVA with Tukey’s post hoc test) were significantly reduced in 
Mecp2stop/y (Stop) mice as compared to wild-type (WT), and genetically rescued 
Mecp2stop/y; CreER (rescue) mice. Abbreviation: ns = not significant; * p<0.05, ** 
p<0.01. Plots show mean ± SD. 
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3.5.7 Female mice tibia showed no difference in biomechanical 
properties of bones  
The same tests when conducted on tibia from female Mecp2 Stop mice showed no 
significant difference in stiffness, ultimate load and Young’s modulus (measure of 
stress-strain relationship) measures (figure3-11). 
 
 
 
 
Figure3-11  Three point bending test measures in female cohorts 
Bar plot showing measures of (A) cortical bone stiffness, (WT= 98.62 ± 7.24 
N/mm; Stop = 84.48 ± 10.07 N/mm; Rescue= 85.17 ± 13.00 N/mm , n=5 per 
genotype;, ANOVA with Tukey’s post hoc test) (B) ultimate load (WT= 16.60 ± 
3.77 N; Stop= 12.68 ± 1.86 N; Rescue=12.63 ± 3.25 N; n≤5 per genotype; 
p0>0.05, ANOVA with Tukey’s post hoc test)  and (C) Young’s modulus (WT= 
12.29 ± 4.33 kN/mm²; Stop= 13.94 ± 2.50 kN/mm²; Rescue = 14.67 ± 0.70 
kN/mm2;  n=3-5 per genotype; p0>0.05, one way ANOVA with Tukey’s post hoc 
test)  in female wild-type (Wt), Mecp2Stop/+ (Stop) and Mecp2stop/+ (Rescue) mice. 
Abbreviation: ns = not significant; Plots show mean ± SD. 
3.5.8  Male and Female Rescue mice showed a significant 
improvement in bone hardness 
Results from male mice showed significantly reduced bone hardness in male Stop 
mice as compared to wild-type littermates. Moreover, tamoxifen-treated Rescue 
mice did not differ significantly from wild-type and showed a significant treatment 
effect when compared with the Mecp2Stop/y cohort (WT= 73.7 ± 1.3 HV, Stop = 65.4 
± 1.2 HV, Rescue = 72.1 ± 4.7 HV, n = 5 per genotype, p<0.01, ANOVA with 
Tukey’s post hoc test). A significant deficit in bone hardness was also observed in 
female Mecp2 Stop mice femurs (WT= 72.8 ± 6.3 HV, Stop = 63.2 ± 3.0 HV, 
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Rescue = 75.7 ± 2.2 HV, n=3-5 per genotype; p<0.01, ANOVA with Tukey’s post 
hoc test). Again, rescue mice showed a significant treatment effect and measures 
were not found significantly different, from wild-type (figure 3.12). 
 
Figure3-12   Microindentation results in male and female cohorts  
(A) Bar chart showing a significant reduced cortical bone hardness in Mecp2stop/y 
(Stop) mice when compared with the wild-type (Wt) controls  (p<0.05, one way 
ANOVA with Tukey’s post hoc test, n = 5 femurs per genotype). In contrast, micro 
hardness measures in rescued Mecp2stop/y, CreER (rescue) mice were not different 
from controls (p>0.05; n=5 femurs). (B) Microindentation hardness test results in 
female mice showed a similar pattern with reduced cortical bone hardness in 
Mecp2+/stop (Stop) mice when compared with wild-type(Wt) controls and rescued 
mice (n= 3-5 femurs per genotype, one way ANOVA with Tukey’s post hoc test). 
Abbreviations: ns = not significant, * = p<0.05, **= p<0.01, ***=p<0.001). Plots 
show mean ± SD.  
3.5.9  Male and Female Stop mice showed no significant 
difference in femur biomechanical properties 
This test was conducted to assess possible group differences in the mechanical 
properties of the femoral neck. Femurs were mounted and force applied as shown 
in figure 3-7. In male mice, no significant differences were observed in stiffness 
and ultimate load measures of biomechanical properties. 
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Similar findings were obtained in the female mice cohorts (Figure 3-13). 
 
 
Figure3-13  Fracture neck test results of male and female cohort 
Bar Plot of male stop (A-B) mice femur neck test results, showing; (A) stiffness, 
(WT = 130 ± 35.1 N/mm; Stop= 119 ± 28.2 N/mm; Rescue = 131 ± 13.9 N/mm, 
n=5 per genotype; p>0.05, ANOVA with Tukey’s post hoc test) (B) ultimate load 
(WT = 15.9 ± 3.9 N; Stop = 12.6 ± 2.4 N; Stop = 13.4 ± 2.2 N, n = 5 per genotype, 
p>0.05, ANOVA with Tukey’s post hoc test) (C-D) Female mice femur displayed 
the similar pattern; (C) cortical bone stiffness WT = 157± 43.23 N/mm; Stop= 118 
± 41.73 N/mm; Rescue = 137± 42.33 N/mm, n=5 per genotype; p>0.05, ANOVA 
with Tukey’s post hoc test) (D) ultimate load (WT = 13.77 ± 5.77 N; Stop = 12.05 ± 
3.93 N; Stop = 12.6 ± 3.90 N, n=3-5 per genotype, p>0.05, ANOVA with Tukey’s 
post hoc test). Abbreviation: ns = not significant; Plots show mean ± SD. 
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3.6 Discussion 
As describe earlier, MeCP2 is a nuclear protein, abundant in post mitotic cells of 
the brain but also widely expressed throughout the body (Shahbazian et al., 
2002b; Braunschweig et al., 2004; Zhou et al., 2006). The results of my 
fluorescence confocal microscope images confirmed this nuclear expression of 
Mecp2 in all bone cells nuclei stained with DAPI (4’,6-Diamindino-2 Phenylindole 
Dilactate, a blue fluorescent nucleic acid stain) of male wild type GFP tagged 
mice( figure 2-4Ai-iv)  . 
Further on, confocal images from hemizygous stop male mice (figure 2-4 Bi-iv) in 
which Mecp2 is silenced by a stop cassette, GFP tagged Mecp2 nuclear 
expression was found absent in all bone cells. On the other hand heterozygous 
Mecp2+/stop (Stop) female (figure 2-4 Ci-iv) showed only ~50% of nuclear bone 
cells expression of Mecp2 in mice in which one Mecp2 allele is silenced to mimic 
the mosaic expression pattern seen in human Rett syndrome (Guy et al., 2007; 
Robinson et al., 2012a). 
For the morphometric and biomechanical analysis I have used the lower limb long 
bones (femur and tibia) as these were found to be the most commonly effected 
bones in RTT patients in terms of  increase rate of fracture was found in these 
bones (Downs et al., 2008a; Roende et al., 2011b). 
The results of  morphometric analysis of long bones revealed that Mecp2 stop 
male have an abnormal skeletal phenotype that shares components of the clinical 
skeletal features of RTT patients (Neul et al., 2010). Long bone morphometric 
analysis showed that Mecp2 stop male mice have lighter (a significant reduction of 
14% in femur weight and 13% in tibial weight) and shorter bones (a significant 
reduction of 10% in tibial lengths) as compared to age matched wild type controls 
(table 3-1).  These findings were consistent with the growth retardation found in 
RTT patients (Schultz et al., 1993; Neul et al., 2010).  
Although there was no significant difference found in whole body weight measures 
of three comparison groups in male stop mice cohorts. The basis for this apparent 
discrepancy was the observation that male stop mouse model often had more 
subcutaneous fat than their wild type matched littermates detected during the 
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dissection. These findings of my study were also found consistent with the findings 
of O’Connor and colleagues study on RTT bone phenotype using the Mecp2 null 
mouse model. 
In Robinson and colleagues study  of  morphological and phenotype reversal  in 
Mecp2 stop male mice, an observation of reduced skeletal size along with the 
presence of a kyphotic curvature of the spine had been made (Robinson et al., 
2012a). In my project I have used the same stop mice. Kyphotic posturing 
frequently observed in the stop mice is comparable to the ‘S’ type scoliotic 
curvature of the spine that is more common among RTT patients (Koop, 2011; 
Riise et al., 2011). These skeletal dysmorphic findings in stop mouse model were 
also found consistent with the bone phenotype of Mecp2 null mouse model by 
O’Connor et al. One of the unique features of my study was the use of Rescue 
mice. Morphometric analysis of rescue mice in which Mecp2 gene has been 
reactivated showed a significant improvement in femur bone weight (15%) as 
compared to stop mice. A similar trend of increase in tibial weight (10%) as 
compared to wild type was also observed but it does not reach statistical 
significance owing to the power of my study. Tibial and femur length 
measurements remained reduced. 
 In contrast to male stop mice, adult female heterozygous Mecp2+/stop mice did not 
showed any significant differences in gross tibia and femur length/weight 
measures. However an interesting similar trend as found in male stop was also 
noted in female stop mice cohort displaying lighter bones (7% reduction in femur 
weight and 5% reduction in tibial weight) and in case of tibia shorter bones (5%) as 
compared to age match wild type but the values did not reached the statistical 
significance (table 3-1).  
My study is the first study in which female mice have been used to explore the 
bone phenotype of RTT. Female Mecp2+/stop are a gender appropriate and 
accurate genetic model of RTT yet display a more subtle and delayed onset (4-12 
months) of neurological features (Guy et al., 2007) compared to hemizygous male 
mice who become symptomatic by the age of 6-8 weeks. 
A major finding of the current study was the demonstrated robust deficits in 
mechanical properties and micro-hardness of bone seen in the male Mecp2 Stop 
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mice. This is the first time that biomechanical tests have been performed on stop 
mice modelling RTT bone phenotype. Such deficiencies in mechanical and 
material properties were profound (39.5% reduction in stiffness in the three point 
bending test; 37% decrease in Young’s modulus, 31% in load and 12.3% 
reduction in micro hardness) (figure 3-10) and could explain the occurrence of low 
energy fractures reported in Rett syndrome patient (Leonard et al. 1999; Zysman 
et al. 2006; Downs et al. 2008; Leonard et al. 2010). Whilst I have not observed 
overt signs of spontaneous fractures in experimental colonies of mice, such a 
magnitude of reduced bone stiffness and load properties could mirror the 4 times 
increased risk of fracture in Rett patients compared to the population rate (Downs 
et al. 2008). Given that the mice are housed under standard laboratory conditions 
and there is not opportunity for traumatic bone insult, it is perhaps not surprising 
that spontaneous fractures are not apparent.  
Male rescue mice interestingly showed a significant improvement in bone stiffness 
(40%), ultimate load (10%),Young’s modulus (61%) and microindentation (12%) 
when the gene is reactivated as compared to male stop mice. These findings were 
quite encouraging and potentiated our hypothesis of genetic basis of RTT bone 
phenotype (figure 3-10). 
Mechanical properties and micro hardness test was also performed in female 
heterozygous cohort. This is the first time that female mice modelling RTT bone 
phenotype has been used.  
Biomechanical analysis of heterozygous stop female showed similar trend (15% 
reduction in stiffness and 24% reduction in ultimate load as compared to age 
matched wild-type control) as the results of their morphometric analysis results but 
like morphometric findings, these values does not reach the statistical significance 
(figure 3-11). 
The finding that a similar significant reduction as male stop mice values, in micro 
hardness (14%) measure was seen in female mice that are heterozygous and 
mosaic for the mutant allele is important and demonstrates that the bone deficits 
are not restricted to the more severe male RTT-like phenotype but are seen in a 
gender and MeCP2 expression pattern appropriate model of RTT.  
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A very interesting finding in female heterozygous rescue mice was found to be a 
significant improvement in microhardness (19%) when the gene is reactivated as 
compared to the stop female. These findings were quite encouraging and 
displayed that the bone deficits rescue is not restricted to the more severe male 
RTT-like phenotype but rescue effects can be seen in a gender and MeCP2 
expression pattern appropriate model of RTT (figure 3-12). 
 Analysis of femoral neck fracture showed no difference between genotypes. Male 
stop mice showed a decrease of 9% in stiffness and 21% decrease in load 
measures but the values did not reach the statistical significance. Male rescue 
mice displayed a 10% improvement in stiffness and 6% improvement in ultimate 
load measures but these values were also not found statistically different (figure 3-
13).  
Female stop mice showed a similar trend of decrease in stiffness values of 15% 
and load value of 13% as compared to age matched wild type control, while 
female rescue mice showed a 16% improvement in stiffness as compared to stop 
mice and no improvement are seen in ultimate load values. Similar to male stop 
and rescue mice measures of femur neck test all these measures did not reached 
the statistical significance (figure 3-14).  
It is possible that the complex microstructure of bone in the femoral neck (cf. the 
simple cortical shaft geometry) is a confounding factor and limits the sensitivity of 
this test. Indeed, we also noted greater variance in this test than in the other 
biomechanical tests which may limit our ability to resolve subtle changes in this 
parameter. Nevertheless, this test has been used in other rodent models to show 
deficits in femoral neck integrity (Hessle et al., 2013). 
An important finding of the current study and one with therapeutic implications is 
that the observed deficits in cortical bone material and biomechanical properties 
were rescued by delayed postnatal activation of the Mecp2 gene. This finding 
mirrors the improvements seen in multiple non-bone phenotypes seen in the 
Mecp2Stop/y  mice after delayed activation of the Mecp2 gene including survival, 
normalized bodyweight, locomotor and behavioural activities and well as 
morphological features within the brain (Guy et al., 2007; Robinson et al., 2012a). 
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 These results suggest that the bone abnormalities present in RTT patients may 
be at least partially reversible using gene-based therapies that are currently being 
developed (Gadalla et al., 2013; Garg et al., 2013) should the animal studies 
translate to clinical studies. However, it is also possible that significant 
amelioration of bone phenotypes may also be achieved using pharmacological 
strategies. Pharmacological approaches are being investigated in RTT, both in 
pre-clinical studies as well as clinical trials (Gadalla et al., 2011; Gadalla et al., 
2013; Garg et al., 2013). Of particular importance for this approach with respect to 
bone phenotypes is to identify the mechanisms by which MeCP2 deficiency results 
in altered bone properties. Whilst we show that MeCP2 is expressed in osteocytes 
(figure 3.8), the protein is widely expressed throughout the body and it is possible 
that metabolic and endocrine perturbations elsewhere in the body (Motil et al., 
2006; Motil et al., 2011; Roende et al., 2014) may also impact on bone 
homeostasis.  
However the results obtained from our biomechanical tests study were quite 
encouraging, the decrease in bone strength in Mecp2 deficient mouse and the 
subsequent improvement of bone integrity when the gene is switch back lead us to 
explore further into the mechanism by which Mecp2 is causing this deficiency in 
bone strength. The experiments performed in this regard will be discussed in detail 
in the next chapters. 
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Chapter 4 
Radiology based structural studies to assess 
trabecular and cortical bone parameters in a 
mouse model of Rett Syndrome  
  
4.1 Introduction 
Radiographic and ultrasound studies have been conducted in Rett syndrome 
patients to better understand the underlying pathology that may account for the 
reduced bone strength and increased risk of fractures in RTT patients (Leonard et 
al., 1995; Leonard et al., 1999b; Cepollaro et al., 2001). The majority of these 
imaging studies have been conducted to investigate the bone mineral density and 
bone mineral content in RTT patients. However there remains to be a detailed 
study exploring the effect of MECP2 mutations on bone structural geometry in 
humans. One reason for this may be the lack of appreciation of bone phenotypes 
in what is considered a largely neurological disorder. Another difficulty might be 
the application of radiological test in patients with many other confounding 
impairments. For instance, patients with scoliosis who require spinal rod 
placements have implanted metal, which interferes with the ability of Dual-energy 
X-ray absorptiometry (DXA) in provision of accurate assessment of bone 
parameters. 
Bone mass has been investigated in detail in RTT patients (Haas et al., 1997; 
Leonard et al., 1999c; Cepollaro et al., 2001; Motil et al., 2006; Zysman et al., 
2006; Gonnelli et al., 2008; Shapiro et al., 2010) as it is  shown to be a strong 
predictor of fracture risk in adults (Hui et al., 1988) and children (Hui et al., 1988; 
Flynn et al., 2007). Although prospective measures of BMD in the lumbar spine of 
children with cerebral palsy did not predict subsequent fracture risk (Henderson, 
1997).  
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Neurological disabilities found in RTT patients evolves over several years with 
potential co-morbidities such as poor nutrition due to problems with swallowing 
(Oddy et al., 2007), surgical procedures (Kerr et al., 2003) for the correction of 
bone deformities (scoliosis) and certain anticonvulsant medications usage 
(Leonard et al., 2010), that together may limit the development of normal bone 
mass. The availability of murine RTT models now permits an assessment of the 
effects of MECP2 mutation on bone mass independent of theses contributing 
factors. The ultra structure and density of bone in mice with and without the Mecp2 
protein have been investigated in a study by O’Connor and colleagues (O'Connor 
et al., 2009b). This study showed, growth retardation, abnormal growth plates 
(irregular shape chondrocytes) and decreased cortical and trabecular bone 
parameters. Another study conducted on the same Mecp2 null mouse model by 
Shapiro and colleagues found differences in cortical thickness, mineralization of 
the medullary cavity in long bones and spinal bone density (Shapiro et al., 2010). 
O’Connor and colleague in their Mecp2 knockout mouse model also found 
modestly lower values of bone mineral density (BMD) and bone mineral content 
(BMC) but this decrease did not achieve statistical significance and hence bone 
mineral density changes as a cause of bone anomalies seen in RTT murine model 
is still not fully understood. 
Rett syndrome bone phenotypes have been frequently compared to osteoporosis 
which has been defined as ‘a systemic skeletal disease characterized by low bone 
mass and micro-architectural deterioration of bone tissue with a resulting increase 
in fragility and risk of fractures’ (Zysman et al., 2006). Hence, a comprehensive 
approach to investigate bone material and structural properties is required to 
better understand the bone phenotype in RTT. 
Previous studies investigating various osteoporotic processes in murine model 
have used femur, tibia and lumbar 5 and 6 vertebrae (Sheng et al., 2002; Rubin et 
al., 2004) as sample biopsies to better understand underlying structural 
pathologies in a range of conditions. The work presented in the current chapter 
was an analysis of long bones and vertebrae in order to explore aspects of cortical 
and trabecular bone structure of Mecp2 stop mice. 
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4.1.1 Bone structure and Bone strength 
Predicting fracture propensity for fracture requires a proper understanding of the 
relationship between bone structure and the mechanical properties of bone. The 
material composition and structural design of bone determines its strength. 
In recent years the concept of bone strength has moved beyond density alone and 
has expanded to include an amalgamation of all the factors that determine how 
well the skeleton can resist fracturing, such as micro architecture, accumulated 
microscopic damage, the quality of collagen, the size of mineral crystals and the 
rate of bone turn over (Chavassieux et al., 2007). 
In particularly, the supremacy of bone structure has been found over tissue-level 
material properties. The net response of osteoblasts for bone formation and 
osteoclasts for bone resorption are reflected by changes in the trabecular structure 
and bone volume fraction (Nazarian et al., 2008). 
Studies in the past have concluded that a unified consideration of the relationship 
of bone tissue mineralization and trabecular structure can predict the mechanical 
properties of normal and pathologic bones (Cody et al., 1991; Kim et al., 2007).  
 
4.1.2 µCT use in skeletal phenotypes  
Histological and radiological studies are usually employed to understand the bone 
micro architecture. Micro computerised tomography (µCT) has now become the 
gold standard for the evaluation of bone morphology and micro architecture in 
mice and other small animals (Martín-Badosa et al., 2003). The accuracy of µCT 
morphology measurements has been evaluated both in animals (Waarsing et al., 
2004; Bonnet et al., 2009) and in humans (Kuhn et al., 1990; Müller et al., 1998) 
specimens. These studies have shown that 2D and 3D morphologic 
measurements by µCT generally are correlated highly than these from 2D 
histomorphometry. 
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4.1.3 Aim of the study 
The results obtained from the analyses of biomechanical properties described in 
the previous chapter were encouraging in that they demonstrated a reduction in 
bone strength in Mecp2 mice and also an amelioration of this phenotype in stop 
mice genetic rescue. This suggested that at the functional level in stop mice, bone 
deficits were overt but reversible. The aim of the experiments described in the 
current chapter was to explore further the potential structural alterations in bone of 
Mecp2 deficient mice that might account for some of the observed biomechanical 
deficits. I hypothesised that the reduction in bone strength, seen in  Mecp2 stop 
mice is due to alternations in bone structure and bone mineral density (BMD) 
levels. In order to analyse these features I have used the µCT scanning 
technology to analyse the ultra structure of bones from wild-type, Mecp2 stop and 
genetically rescued mice of male and female cohorts. 
4.2 Material and Methods 
The structural properties of bone samples from wild-type, Mecp2-stop and 
genetically recued mice were assessed using scanning electron microscopy and 
were also visualised using a µCT scanner (see below). The result analysis 
obtained were then used to investigate cortical and trabecular bone structure.  
4.2.1 Micro-computed tomography (µCT) 
After the gross morphometric measurements (chapter 3) a subset of bone samples 
was scanned using µCT. The samples were scanned prior to any biomechanical 
tests being performed. All scans were conducted using the micro computed 
tomography facility at the Orthopaedic Research group, University of Edinburgh, 
Edinburgh, UK. We have used the Sky Scan 1172/A X-ray Computed 
Microtomgraphy system (µCT) maintained by Robert Wallace, Chancellors 
Building, Orthopaedic Research Group, Edinburgh, UK. 
The micro CT scanner is composed of a sealed micro focus X-ray tube, air cooled 
with a spot size lens and a camera. The maximum length of object that is capable 
of fitting into this device is 40mm. Bone specimens were scanned in wet form by 
placing them first in a vial containing water to maintain hydration (figure 4.1). 
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The sample vial was subsequently fixed to the machine stub (mounting plate) with 
masking tape, which in turn was securely fastened to the holder in the µCT x-ray 
chamber. This must be secured correctly as any movement of the sample could 
render the scan unusable. 
Multiple projection images were obtained with a rotation of 0.45°- 0.1° between 
each image. Given a series of projection images a stack of 2D sections was 
reconstructed for each specimen. CT-Analyser v1.8.1.3 (Skyscan, Kontich, 
Belgium) and NRecon v1.6.6.0 (Skyscan, Kontich, Belgium) were used for the task 
of reconstruction and whole data processing as described in user’s manual and 
according to protocols followed by local technical faculty. Image slices obtained 
and stored in the .bmp format with indexed grey levels ranging from 0 (black) to 
255 (white). Understandably, this is a resource intensive computer task and as 
such a dedicated computer was used for this process (2x 3GHz Quad core CPUs, 
8Gb Ram, NVIDIA Quadro FX 570). 
 
Figure4-1  Micro CT scanning of Tibia 
(A) Mouse tibia in the test tube filled with water to maintain hydration during the CT 
scanning (B) Scanned image of tibia placed in test tube taken during the µCT 
scan. Images were scanned at a voxel resolution of 34μm for male and female 
stop tibia, using a sky scan micro CT machine. The X-ray tube was operated at 
54KV and 185μA. The Sky scan 1172 micro CT scanner at Chancellor’s building, 
Orthopaedic Research Group facility at the  University of Edinburgh, Edinburgh UK 
was used for the trabecular and cortical bone parameters analysis. 
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4.2.2 Micro-computed tomography (µCT) for cortical bone 
measures 
In order to obtain accurate internal and external diameter measures for calculating 
second moment of area and for cortical bone structural parameter evaluation, right 
tibias from male (n=5) and female cohorts (n3-5) were scanned at a voxel 
resolution of  34μm using a sky scan micro CT machine. The X-ray tube was 
operated at 54KV and 185μA. For cortical bone parameter analyses, 2mm 
midshaft region of interest (ROIs) were selected from tibial diaphysis, starting from 
the anatomical point of tibiofibular junction in each bone specimen.  
 
 
Figure4-2 Screen shot of image analysis while using the CT 
analyser software, displaying region of interest at mid diaphysis 
of tibia 
Representative screen shot showing mouse tibia with a region of interest at the 
mid-diaphysis, while CT scan images of tibia were analysed using the CT analyser 
software v 1.8.1.3. A region of interest (2mm) was selected from tibial shaft per 
bone specimen per genotype. A lower grey threshold value of 113 and upper grey 
threshold value of 255 was used as thresholding values. Care was taken that all 
the reconstruction parameters selected were applied identically to all bone scans. 
  
A 
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Images obtained were reconstructed and analysed using the NRecon software v 
1.6.6.0 and CT analyser software v 1.8.1.3. The data from each scan was then 
split by region of interest. A lower grey threshold value of 113 and upper grey 
threshold value of 255 was used as thresholding values in each cortical bone 
sample. All the reconstruction parameters selected were applied identically to all 
bone scans (figure 4-2). 
 Individual two dimensional object analyses were performed on six sections per 
bone specimen within each comparison genotype group to calculate the inner and 
outer perimeters of bone. An average of six values per specimen then used as the 
final measure for the inner and outer perimeter and subsequently cortical 
thickness measurement was derived from these values. Three dimensional 
analyses further used to calculate marrow area, cortical area, total area and bone 
volume. 
4.2.3 Scanning Electron Microscopy (SEM)  
The Undecalcified, left distal femur metaphyseal region from both male mice (n=5) 
and female (n=3-5) mice were selected to observe any trabecular structural 
differences using scanning electron microscope (SEM) Stereoscan 250 MK3, 
Cambridge, UK) at the Anatomy Department, University of Glasgow, Glasgow, UK. 
4.2.3.1 Sample preparation for SEM 
Distal parts of left femur per bone per genotype from both male and female mice 
were cut with diamond saw (IsoMet plus Precision Saw; Buehler Ltd.) transversely, 
3mm above the condyles. The 3mm distance from the medial condyle was 
measured with vernier calliper before cutting. Bones were then stored in 2.5% 
paraformaldehyde in 0.1M sodium phosphate buffer (water, pH7.4) at 4°C for 48h. 
Adherent soft tissue was removed by immersion in 3% hydrogen peroxide solution 
for 48h. After rinsing with distilled water, specimens were defatted in 50:50 
methanol/chloroform for 24h at room temperature and transferred to a 5% trypsin 
solution (0.1M PB, pH 7.4) at room temperature for 48h. After cleaning with 
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distilled water, specimens were desiccated. Samples were gold coated by using a 
sputter coater (Polaron E5000, East Sussex, UK). An extra coating with silver 
paint was done to have the proper imaging. Images were obtained using a 
scanning electron microscope (Stereoscan 250 MK3, Cambridge, UK).  
4.2.4  5th Lumbar vertebrae, µCT scan for trabecular parameters  
5th Lumbar vertebrae from the mice from each genotype were scanned at a 
resolution of 5µm.  
 
 
 
Figure4-3  Micro CT scan of 5th Lumbar vertebrae 
The L5 vertebrae (n=6) from each genotype of male mice cohort (WT, Stop, and 
Rescue) were dissected out. The micro CT scans of each vertebra were taken 
using the sky scanner µCT facility. (A) Lateral view of L5 vertebrae scanned at 
5um resolution. A cylindrical shape region of interest (ROI), comprising of 150 
slices was taken from the body of the vertebrae. The shell properties of cortical 
bone were not included. (B) Reconstructed image of 5th Lumbar vertebrae, 
showing the selection region of interest (ROI) within the body of vertebrae. A lower 
grey threshold value of 81 and upper grey threshold value of 252 was used as 
thresholding values in each trabecular bone sample. Scale bar=200μm. 
  
120 
 
A higher resolution was needed to scan the trabecular bone and hence 5 μm 
selected for the mouse trabecular bone parameters as compared to the cortical 
bone parameters(Ito, 2005). The X-ray tube was operated at 41kV and 240μA. 
Table 4-1: Trabecular bone parameters 
Abbreviation Description Definition Standard 
Unit 
TV Total volume Volume of the entire region of 
interest 
mm-3 
BV Bone volume Volume of the region segmented as 
bone 
mm-3 
BS Bone surface Surface of the region segmented as 
bone 
mm-3 
BV/TV Bone volume 
fraction 
Ratio of the segmented bone 
volume to the total volume of the 
region of interest. 
% 
BS/TV Bone surface 
density 
Ratio of the segmented bone 
surface to the volume of the region 
of interest. 
mm-2/ mm-
3 
BS/BV Specific bone 
surface 
Ratio of the segmented bone 
surface to the segmented bone 
volume. 
mm-2/ mm-
3 
Conn.D Connectivity 
density 
A measure of the degree of 
connectivity of the trabeculae 
normalised by TV. 
1/ mm-3 
SMI Structure model 
index 
An indicator of the structure of 
trabeculae, 0=parallel plates, 3= 
cylindrical rods 
 
Tb.N Trabecular 
number 
Average number of trabeculae per 
unit length 
1/mm 
Tb.Th Trabecular 
thickness 
Mean thickness of trabeculae 
assessed using Direct 3D methods. 
mm 
Tb.Sp Trabecular 
separation 
Mean distance between trabeculae mm 
DA Degree of 
anisotropy 
Length of longest divided by 
shortest mean Intercept length 
vector. 
a 
Note: Modified and adopted from (Bouxsein et al. 2010). 
 
 
A lower grey threshold value of 81 and upper grey threshold value of 252 was 
used as thresholding values in each trabecular bone sample. A cylindrical region 
of interest (150 slices or 0.774mm) was selected from the centre of each vertebral 
body excluding the cortical shell area, in order to analyse only the trabecular 
parameter specifically (figure 4.3). Images reconstructed and analysed using the 
NRecon 1.6.6.0 and CT-Analyser 1.8.1.3 software. Vertebral body lengths were 
determined by measuring a line drawn at a 90° angle from the proximal part of the 
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vertebral body to the distal part. Three dimensional analysis was performed for the 
following parameters: trabecular thickness, trabecular separation, trabecular bone 
volume, trabecular porosity, as well as degree of anisotropy (DA) and structure 
model index (SMI); for details of these parameter see (table 4-1 
 
4.2.4.1 Density calibration of 5th lumbar vertebrae in µCT scanner 
 
Bone mineral density (BMD) was standardized to the volumetric density of calcium 
hydroxyapatite (CaHA) in terms of g.cm-3.  For bone mineral density (BMD) 
calibration, the Skyscan CT- analyser, was calibrated by means of phantom rods, 
with known BMD values of 0.25 and 0.75 g.cm-3 CaHA respectively.  
Trabecular (medullary) density can refer to the density of a defined volume of bone 
plus soft tissue. 
Hounsfield units (HU) are a standard unit of x-ray CT density, in which air and 
water are ascribed values of -1000 and 0 respectively. The Skyscan CT-analyser 
software provides for an integrated calibration of datasets into these two density 
scales (HU and BMD). Both require the appropriate calibration phantom scans and 
measurements. 
For density calibration, a scan of free standing tibia, within a tube of water was 
performed. Then the two BMD rods (under the same conditions as the bone scan) 
with BMD values of values of 0.25 and 0.75 g.cm-3  CaHA were scanned as well. 
Reconstruction of the scan of the bone in the water tube was done by using the 
NRecon 1.6.6.0 and CT-Analyser 1.8.1.3 softwares. Reconstruction parameter 
were selected and same parameter were applied throughout the scans of each 
sample bone per genotype. Also care was taken with the selection of the lower 
and upper contrast limits. 
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With the scans and reconstruction of the bones and the calibrating phantoms 
complete, the HU and BMD calibration was implemented in CT-analyser.Following 
density range calibration was selected (Table 3-2). 
Table 4-2: Density range calibration 
Calibration unit Min Value Max Value 
Index 0 255 
HU -1000 7292 
 
4.3 Results 
µCT analysis was used to examine the three dimensional structure of wild-type 
and Mecp2 stop male and female tibias. Micro CT analysis of male Mecp2-Stop 
mice tibia revealed considerable differences in cortical bone parameters while 
several trends were noteworthy in the trabecular bone. 
4.3.1 Micro CT revealed male Mecp2-Stop mice to display altered 
cortical bone properties. 
One of the major structural findings of my current study was the reduction found in 
cortical bone parameters results obtained from the µCT analysis of male Mecp2 
mice cortical bone. These results were consistent with the reduced biomechanical 
strength findings and also correlate with the reduced cortical bone parameters 
seen in RTT patients.  
A significant difference in male stop mice cortical bone parameters was found in 
cortical bone thickness (54%), outer perimeter (20%), inner perimeter (12%), 
marrow area (38%), total area (20%) and bone volume (30%) values as compared 
to wild type control mice However no significant difference was seen in cortical 
area values of Mecp2 stop mice (figure 4-4 i-vii). Rescue mice didn’t show any 
improvement in bone cortical parameters and values obtained, remain reduced 
when a comparison is made with WT control values. 
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Figure4-4 Cortical bone parameter in Mecp2 Stop and Rescue 
male mice 
Bar graphs (i-vii) showing a significant decrease in cortical thickness, (WT= 0.41±0.17mm, Stop= 
0.19±0.07mm, Rescue= 0.21±0.08mm; n=5 per genotype; p<0.05, ANOVA with Tukey’s post hoc 
test outer perimeter (WT= 1.65±0.22mm, Stop= 1.32±0.07mm, Rescue= 1.38±0.05mm; n=5 per 
genotype; p<0.05, ANOVA with Tukey’s post hoc test), inner perimeter (WT= 1.26±0.24mm, Stop= 
1.12±0.07mm, Rescue= 1.08±0.05mm; n=5 per genotype; p<0.05, ANOVA with Tukey’s post hoc 
test), marrow area (WT=0.48±0.14mm², Stop=0.30±0.02mm², Rescue=0.29±0.03mm²; n=5 per 
genotype; p<0.05, ANOVA with Tukey’s post hoc test),total area (WT=1.26±0.17mm², 
Stop=1.05±0.11mm², Rescue=0.98±0.05mm²; n=5 per genotype; p<0.05, ANOVA with Tukey’s 
post hoc test), and bone volume (WT= 1.75±0.21 mm³, Stop=1.39±0.19 mm³, Rescue= 1.39±0.11 
mm³; n=5 per genotype; p<0.05, ANOVA with Tukey’s post hoc test). No significant difference was 
seen in cortical area (WT=0.81±0.08 mm², Stop=0.75±0.13 mm², Rescue= 0.69±0.045 mm²; n=5 
per genotype; p>0.05, ANOVA with Tukey’s post hoc test) values of Mecp2 stop mice as compared 
to wild-type controls. Abbreviation: ns = not significant; * p<0.05, ** p<0.01. Plots show mean ± SD.
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4.3.2 Micro CT scans of heterozygous female Mecp2-Stop and 
Rescue mice showed no significant differences in cortical 
structure parameters 
 
 
Figure4-5 Cortical bone parameters in Mecp2 Stop and Rescue 
Female mice.  
Bar graphs (A-G) showing no significant difference (p>0.05) in results of outer perimeter (WT= 
1.44±0.05mm, Stop= 1.42±0.17mm, Rescue= 1.35±0.05mm; n=3-5 per genotype; p0>.05, ANOVA 
with Tukey’s post hoc test), inner perimeter (WT= 1.21±0.09mm, Stop= 1.18±0.12mm, Rescue= 
1.12±0.12mm; n=3-5 per genotype; p>0.05, ANOVA with Tukey’s post hoc test)  cortical thickness 
(WT= 0.22±0.08mm, Stop= 0.21±0.07mm, Rescue= 0.22±0.06mm; n=3-5 per genotype; p>0.05, 
ANOVA with Tukey’s post hoc test), cortical area (WT=0.82±0.09 mm², Stop=0.71±0.08 mm², 
Rescue= 0.76±0.14 mm²; n=3-5 per genotype; p>0.05, ANOVA with Tukey’s post hoc test), marrow 
area (WT=0.39±0.09mm², Stop=0.40±0.10mm², Rescue=0.29±0.07mm²; n=3-5 per genotype; 
p>0.05, ANOVA with Tukey’s post hoc test), total area (WT=1.21±0.14mm², Stop=1.11±0.17mm², 
Rescue=1.06±0.18mm²; n=3-5 per genotype; p>0.05, ANOVA with Tukey’s post hoc test), and 
bone volume (WT= 1.73±0.22 mm³, Stop=1.51±0.21mm³, Rescue= 1.54±0.31 mm³; n=3-5 per 
genotype; p>0.05, ANOVA with Tukey’s post hoc test) as compared to wild-type controls 
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4.3.3 Scanning electron microscopy revealed altered trabecular 
structure in Stop male mice 
Qualitative analysis using scanning electron microscopy (SEM) of the distal femur 
(n=5 per genotype) revealed porous structure in cortical bone (3 of 5 mice) as well 
as alterations in the architecture of trabecular bone in Mecp2stop/y mice (figure 4-6). 
The central metaphyseal region in Mecp2stop/y mice showed a sparse trabecular 
mass consisting of short, thin trabecular rod and plate structures. In contrast, a 
more robust trabecular structure, with a network of shorter and thicker rods and 
plates was found in wild-type control tissue (figure 4-6). The porosity and altered 
trabecular structure was less evident in rescued Mecp2stop/y, CreER mice. 
 
 
 
Figure 4-6 Scanning electron microscopy reveals pitted cortical 
bone and altered trabecular structure in distal femur of male 
MeCP2-deficient mice. 
Scanning electron micrographs of distal femur in (Ai) wild-type (Wt) and (Bi) 
Mecp2stop/y (stop).Higher powered images of cortical (ii) and metaphyseal (iii) 
regions (areas indicated in A) reveal a more porous structure in cortical bone 
(arrows in Bi indicate pores) and a sparse trabecular structure in Mecp2stop/y mice 
when compared with representative with Wt controls. (Ci-iii) Representative 
micrograph from a Mecp2stop/y, CreER (rescue) mouse.  
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4.3.4 Micro CT scans showed improvement in trabecular bone 
thickness in Rescue male mice 
Three dimensional μCT scan analyses were performed to obtain a quantitative 
measure of trabecular architecture in wild-type, Stop and Rescue mouse 5th 
lumbar vertebrae. A significant reduction of 5th lumbar, trabecular thickness 
(~30%) was observed in Stop male mouse tissues compared to the wild-type 
controls. Interestingly rescue male mice 5th lumbar μCT scan results, showed a 
significant increase (+80%, p<0.01) in trabecular rod and plates thickness 
compared to Mecp2stop/y mice   (Wt=0.073 ± 0.01mm; Stop = 0.051 ± 0.02mm; 
Rescue= 0.09 ± 0.02 mm; n=6 per genotype; p<0.01, ANOVA with Tukey’s post 
hoc test) suggesting a significant treatment effect (figure 4.6). 
 
 
 
 
 
 
 
 
Figure4-7 MicroCT scans of L5 vertebrae revealed thinner 
trabecular mass in MeCP2-deficient mice 
(A) Bar plot showing quantitative analysis of trabecular thickness (arrows in B-D). 
Note the reduced thickness in Mecp2stop/y samples (p<0.05; n=6 per genotype). (B-
D) Micrographs showing representative trabecular samples from wild-type (Wt), 
Mecp2stop/y (Stop) and Mecp2stop/y, CreER (rescue) mice. (E) Scale bar: B-D, 
50µm. Abbreviations: ns = not significant, * = p<0.05, ** = p<0.01; one way 
ANOVA with Tukey’s post hoc test). Plots show mean ± SD.  
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Length of the vertebral bodies revealed a significant difference (WT= 4.157 ± 
0.52mm, Stop= 3.48 ± 0.39mm, Rescue= 3.14 ± 0.37mm; n=6 per genotype; 
p<0.05, ANOVA with Tukey’s post hoc test) in Mecp2 stop and rescue mice 
vertebral body length measurements as compared to age matched wild-
typecontrol. No significant difference was observed in trabecular separation, 
trabecular bone volume, trabecular porosity, bone mineral density (BMD), degree 
of anisotropy (DA) and structure model index (SMI) between comparison 
genotypes of male mice cohort. All findings are summarized in figure 4.6 and table 
4.3. 
 
 
Table 4-3    Lumbar vertebrae trabecular bone parameters 
Body of 5th Lumbar vertebrae was selected as region of interest (ROI) and was 
analysed to assess the trabecular part of the bone. All data given as mean ± SD 
for each group of samples (n=6 per genotype). Significance was assessed by one 
way ANOVA with Tukey’s post hoc test. Abbreviations: * p<0.05, ** p<0.01. 
Symbol¶ (a comparison is made between Wild-type control and Stop male mice). 
Symbol ɸ (a comparison is made between Stop and Rescue male mice).  
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Figure4-8 Trabecular bone parameters bar graphs of Mecp2 stop 
mice 
Bar graphs (A-E); displaying trabecular bone parameters, showed an apparent 
trend of decrease in bone volume fraction (%), connectivity density (1/mm3), 
trabecular separation and structure model index measurements but these values 
does not reach any statistical significant (p>0.05) difference; n=6; Abbreviations: 
ns = not significant ; one way ANOVA with Tukey’s post hoc test). Plots show 
mean ± SD. 
 
4.3.5 Bone density measurements from μCT did not revealed any 
significant difference in Mecp2 stop mice. 
 
In order to analyse bone density measurements, 5th Lumbar vertebrae were 
scanned, and no significant difference was not observed in male stop mice 
genotypes (WT= 0.96±0.06; Stop= 0.92±0.07; Rescue=0.94±0.06 n≤7 per 
genotype; p>0.05, ANOVA with Tukey’s post hoc test). All data given as, mean ± 
SD (figure 4-9). To further confirm these finding we have performed and 
experiment to calculate the ash content. See chapter 5 for full details. 
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Figure4-9  Micro CT derived bone mineral density in Mecp2 stop 
mice 5th lumbar vertebrae 
Bone mineral density (BMD) values in Stop and rescue mice cohorts. (A) BMD 
values derived from the CT scan after density calibration showed no significant 
difference p>0.05 among the comparison genotypes; n=6, one way ANOVA with 
Tukey’s post hoc test. Abbreviations: ns = not significant; one way ANOVA with 
Tukey’s post hoc test). Plots show mean ± SD. 
4.4 Discussion 
The main finding of the current chapter was the demonstration that MeCP2 
deficient in bone results in significant changes in bone both at macro and 
microstructure levels. The alternation in cortical and trabecular bone parameters in 
the structure found could account for the biomechanical defects reported in the 
previous results. Radiological study using µCT revealed some interesting finding in 
Mecp2 stop and rescue hemizygous male and heterozygous female mice.  
The cortical bone parameters analysis of male Mecp2 stop mice revealed a 54% 
decrease in cortical thickness, 20% reduction in total area and outer perimeter 
values, 12% reduction in inner perimeter along with the 38% reduction in marrow 
and 30% reduction in bone volume measures in a bone (tibia) that is 90% the 
length of the age-matched wild-type group (figure 4-4). This cortical bone thinning 
found in Mecp2 stop mice was consistent with what is expected in an osteoporotic 
model and it is known that reductions in bone strength and increases in cortical 
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micro damage affect the fragility of bone (Seeman, 2008a). Interestingly, RTT 
bone phenotype has been frequently related to osteoporosis because of the 
reduced level of bone strength, increase in fracture risk and reduced bone mineral 
density reported in RTT patients (Zysman et al., 2006; Roende et al., 2011b). My 
findings of cortical bone parameters were also found consistent with the one 
reported in RTT patients by Leonard and colleagues. They reported a decrease in  
total area of 20%, medullary area of 47%, cortical thickness of 30% and cortical 
area of 20% in patients suffering from Rett syndrome  (Leonard et al., 1999b). 
However in my study Mecp2 stop showed a modest reduction of only 8% in 
cortical area which did not reached statistical significance owing to the high 
variance found in stop mice. 
These values of reduction in cortical bone parameters were also consistent with 
my earlier biomechanical test results analysis and pointed towards the potential 
underlying alternation in ultra-structural arrangement as the possible mechanism 
of reduced bone strength values seen in Mecp2 stop mice. My findings of cortical 
bone parameters were also found consistent with the O’Conner’s micro CT 
analysis of cortical bone of Mecp2 null mouse model, in which they showed a 
similar reduction of 20% in total area and a similar significant but modest reduction 
of 17% reduction in cortical thickness, 7% reduction in outer perimeter and 14% 
reduction in marrow area (O'Connor et al., 2009b) as compared to Mecp2 male 
stop mouse model. The slight variations in results of my study and O’Conner’s 
RTT bone analysis could be because of the high variance found in Mecp2 stop 
mice statistical analysis, or difference of age, strain or type of mutation among the 
mouse models (O'Connor et al., 2009b). There was a difference of age between 
the two mouse models, Mecp2 null mouse model was much younger 8 weeks as 
compared to stop mouse model which was of 14 weeks. Hence the enhanced 
reduction of cortical bone parameter in my stop mouse models could be the result 
of worsening of bone phenotype with age. This point is also further supported by 
the fact that bone phenotype (reduction in cortical thickness, cortical area of bone, 
total area and bone mineral density values) in RTT patients have also been 
reported to deteriorates with age (Leonard et al., 1999c; Motil et al., 2008).  
Finding of 30% reduction in bone volume by μCT in current study in particular is 
very interesting as it is consistent with the bone histomorphometric analysis of iliac 
crest biopsies of 5 RTT children. This histological analysis in RTT patients showed 
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decreased bone volume, decreased osteoclast surface and number, and a 
reduced rate of bone formation suggesting decreased osteoblast function in RTT 
patients (Budden and Gunness, 2003).  
One of the unique features of the current study was the use of rescue male mice 
for the structural analysis of bone. Rescue mice did showed a significant 
improvement in biomechanical properties but failed to show improvement in 
cortical bone structural parameters (figure 4-4). These findings surfaced the need 
to explore further the possible causes of improvement in bone strength identified in 
rescue male mice, outside the realms of structural entity of bones and hence we 
carried out the extracellular matrix analysis (see chapter 5). 
In this study we also explored the cortical parameters in heterozygous stop female 
mice. This is the first time that female mouse model has been used to explore the 
structural properties of Mecp2 deficient mice. Unlike male mouse, female mouse 
displayed a modest decrease in cortical thickness (5%), total area (7%), cortical 
area (13%) and bone volume (14%). This decrease in values didn’t reach 
statistical significance because of the high variance and with the number of 
animals that I had available for this study. This subtle decrease in cortical bone 
parameters was found consistent with my biomechanical tests results of stop 
female mice. Female stop rescue mice similar to the male stop mice did not 
showed any significant improvement in cortical structural parameter. 
After the cortical bone analyses, I also wanted to explore the trabecular structure 
of the bone. For this reason distal femoral metaphyseal region was scanned and 
imaged using the scanning electron microscopy. Qualitative analysis by scanning 
electron microscopy did reveal altered trabecular architecture (thin trabeculae) in 
Mecp2 stop mice, consistent with the overall osteoporotic picture and suggesting 
clear structural differences between genotypes which would be consistent with 
reduce bone integrity results obtained after the biomechanical analysis. The 
cortical area surrounding the central rod and plate mass showed characteristic pits 
in Mecp2stop/y which were much less numerous in wild-type controls. These could 
result from increased nutrient foramina or poorly laden osteoporotic bone due to 
osteoblast dysfunction. This is further supported by the known fact that the 
increasing porosity of cortical bone effectively trabecularizes the cortex and hence 
leads to osteoporotic bone phenotype (Brown et al., 1987; Foldes et al., 1991). 
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The quantitative μCT on the trabecular portion of L5 vertebrae were carried out 
and the results were found consistent with the SEM osteoporotic findings in that 
the trabecular thickness was significantly reduced in Mecp2 stop mice (figure 4-6). 
The trabeculae in vertebral bodies of Mecp2 stop mouse were found significantly 
thinner and but displayed a trend of increase in number and hence reduced 
trabecular separation, although the enhance in trabecular number and trabecular 
separation was not found statistically significant due to the high statistical variance 
shown in Mecp2 stop mice. This discrepancy could also be because of the overall, 
decrease in length of vertebral body in Mecp2 stop mice as compared to the age 
matched wild type group and hence the apparent increase in number and reduced 
trabecular separation. Nonetheless, the significant thinner trabecular finding in 
vertebral bodies and thinning of cortical thickness along with decrease in total area 
and bone volume found in cortical bone supported the overall osteoporotic picture 
seen commonly in RTT patients (Zysman et al., 2006; Roende et al., 2011a; 
Roende et al., 2011b). 
An interesting finding consistent with the functional tests results on long bones 
was seen, and trabecular thickness was normalized to wild type levels upon 
unsilencing Mecp2 in the Rescue cohort. This is indicative of a pronounced 
phenotypic rescue and evidence of structural remodelling upon activation of 
MeCP2 analogous to structural rescuing demonstrated in the brain by Robinson 
and colleagues (Robinson et al., 2012b).   
Other parameters of the trabecular bone showed loss of bone volume fraction 
percentage (10%), connectivity density (17%) and structural model index (30% 
reduction, indicating more plate like trabecular structure rather than rod like) 
(Hildebrand and Rüegsegger, 1997) in male stop mice but these values didn’t 
reached the statistical significance owing to the high variance among the 
comparison groups (figure 4-7). The number, thickness, spacing, distribution and 
connectivity (i.e., connection) of trabeculae reflect the trabecular network and 
determine bone strength (Chavassieux et al., 2007). It is also known that for the 
same defect in trabecular density, loss of connectivity has more deleterious effects 
on bone strength than thinned but well-connected trabeculae (Weinstein and 
Hutson, 1987; van der Linden et al., 2001). In my trabecular bone analysis I found 
significant reduction in trabecular thickness and loss of connectivity in Mecp2 stop 
5th lumbar vertebrae, though the latter does not reach statistical significance. As 
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stated earlier, overall the decrease in trabecular thickness, bone volume fraction % 
in vertebral bodies points towards an osteopenic phenotype frequently reported in 
RTT patients and seen in RTT bone phenotype animal models as these results 
were also found consistent with µCT and histomorphometric analysis reported by 
O’Connor and colleague using the Mecp2 null mouse model (O'Connor et al., 
2009b).  
Surprisingly, bone mineral density (µCT) values didn’t show any difference in 
comparison genotypes in male stop mice 5th lumbar vertebrae (figure 4-8). 
Reduced bone mass is commonly associated with osteoporotic phenotypes (Hui et 
al., 1988; Leonard et al., 1999c; Cummings et al., 2002; Ager et al., 2006; Flynn et 
al., 2007) and bone mineral density, differences have been reported in Mecp2-null 
mice (Shapiro et al., 2010). The lack of observed differences (density) in the 
current study could be due to differences between mouse models (strain, mutation 
type, age). However my findings of bone mineral density were consistent with the 
ones reported in Mecp2 null of bone mineral density and bone mineral content. 
They did found a modest difference in BMD and BMC, but this decrease did not 
reach statistical significance due to the small number of animal they used in the 
study (O'Connor et al., 2009a).  
Interestingly among the indicators of cortical bone loss, the percentage cortical 
area is considered to be the most directly related to bone mass (Leonard et al., 
1999c). In my current study no significant difference was observed both in cortical 
area and bone mineral density suggesting that the primary cause of reduced bone 
strength might be the result of cellular, osteoblast decrease activity as seen by 
reduction in bone volume or because of the increase osteoclast number/activity or 
probable defect in organic part of the bone. Based on these findings I had 
performed histological experiments. See Chapter 5 for further details. 
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Chapter 5 
An analysis of the material composition of bone in 
an mouse model of Rett Syndrome 
  
5.1 Introduction 
A number of clinical studies have investigated potential properties of bones that 
might underlie reduced bone strength seen in RTT patients. Such studies have 
adopted both static and dynamic histomorphometric approaches (Budden and 
Gunness, 2001, 2003; Zysman et al., 2006; Motil et al., 2008). Overall, these 
studies have so far revealed consistent decreases in bone volume, accompanied 
by reduction in bone formation rates (Budden and Gunness, 2003; O'Connor et al., 
2009b).However significant changes in osteoid thickness and number per bone 
surface as well as absolute osteoclast number has remained inconclusive (Budden 
and Gunness, 2003; O'Connor et al., 2009b; Rastegar et al., 2009). And hence the 
exact cellular mechanism leading to bone phenotypes in RTT remains poorly 
defined.  
5.1.1 The material composition of bone: collagen and mineral 
Bone is a specialized connective tissue and is composed of an organic matrix of 
type 1 collagen. The unique feature of collagen component is its mineralization 
with an inorganic phase comprising of calcium hydroxyapatite-like crystals. The 
organic matrix of bone tissue provides flexibility, whereas increasing amount of 
mineral contributes towards material stiffness (Cooper et al., 2004). 
Collagen molecules are structural macromolecules present in the extracellular 
matrix. They include as a part of their structure one or several domains that have a 
characteristic triple helical conformation. Most common types includes I II, III,V, 
and XI with less common subtypes including types IV and VIII (van der Rest and 
Garrone, 1991). Type 1 collagen is the most ubiquitously distributed and most 
abundant of the collagen family of protein.  
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Structure wise, collagen is a heterotrimer which is composed of two alpha1 chains 
and one alpha 2 chain (Dalgleish, 1997). The type 1 collagen is encoded by 
COL1A1 and COL1A2 respectively. Collagen abnormalities can result from 
mutations in these genes with over 200 of such mutations having been reported 
(Chavassieux et al., 2007). Mutations at these loci can lead to pathologies such as 
osteogenesis imperfect (OI) and Ehlers-Danlos syndrome. Mutations at these loci 
have also been reported to be linked with osteoporosis and Marfan’s syndrome 
(Dalgleish, 1997; Chavassieux et al., 2007). Bone phenotype in OI, has been 
particularly linked with RTT bone phenotype. 
As described in the introductory chapter, the basic structural units (BSUs) in bone 
matrix are not uniformly mineralized. More recently completed BSUs are less 
densely mineralized than older BSUs that have had more time to undergo 
secondary mineralization (crystal enlargement) (Boskey, 2003). Even within a 
BSU, the organisation is formed as a composite. The higher and lower density 
lamellae with collagen fibers oriented in different directions creates a structure that 
serves to prevent the occurrence of cracks and limits crack progression in skeletal 
tissue. Loss of the lamellar organization as seen in woven bone in Paget’s disease 
and loss of heterogeneity in tissue mineral density as frequently seen in prolong 
use of bisphosphonate may affect bone’s ability to prevent crack occurrence and 
progression (Boivin and Meunier, 2002). Keeping this in mind, the mechanism of 
low energy fractures seen in RTT patients can be explained however research in 
terms of collagen component of bone pathologies seen in RTT patients is still 
poorly define. 
Recently a case control study (Roende et al., 2014) has been conducted by 
Roende and colleagues, which revealed a decrease in the bone formation marker  
N-terminal propeptides of collagen type 1 (PINP), pointing towards the potential 
role of collagen along with mineral component as the contributing factors to altered 
bone integrity seen in Rett Syndrome. However, analogous and controlled studies 
assessing collagen content and composition have so far not been conducted in 
animal mouse models of RTT. 
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5.1.2 The Cellular Machinery for bone homeostasis and turnover 
As mentioned earlier the cellular activities of bone modelling and remodelling 
determine the material composition and structure of bone. Bone modelling 
represents the formation of new bone phase whereas bone remodelling 
encompasses both a resorptive phase and a bone formation phase. The whole 
process of bone modelling and remodelling contributes to the bone strength 
(Chavassieux et al., 2007). Bone cells (see section 1.5.3) plays a vitol role in this 
regards, osteoclast in particular starts the remodelling by first differentiation under 
the stimulation by osteoblast cells (Nakashima, 2014).  
Receptor activator of nuclear factor-kB (RANK) LIGAND (RANKL) is expressed  
and secreted by osteoblast precursor cell and binds RANK expressed by 
osteoclasts, thus promoting the differentiation and activity of osteoclasts. 
Osteoblasts secrete osteoprotegerin (OPG), which binds to RANKL and inhibit the 
RANK-RANKL interaction (Nakashima, 2014). RANKL knockout mice have display 
severe osteoporosis and an analysis of cell types reveal that they lack osteoclasts 
despite the presence of osteoprogenitors (OPG). In contrast to the consequences 
of reduced RANKL expression, increased expression of RANKL may explain 
disorders associated with increased / excessive resorption such as multiple 
myeloma. Interestingly OPG-deficient mice showed a sever osteoporosis as well 
resulting from increase in osteoclastic activity and formation (Horowitz et al., 2001; 
Kon et al., 2001; Chavassieux et al., 2007). 
5.1.3 Aim of the study 
Results from the previous chapters showing altered biomechanical as well as 
material (microhardess) properties of MeCP2-deficient bone suggest that there are 
likely to be alteration in bone composition.  In the current set of experiments I 
hypothesised that alterations in the protein or mineralisation of MeCP2 deficient 
bone may explain the earlier biomechanical and material bone phenotypes 
observed in the mouse model of Rett Syndrome. Thus, the specific aim of the 
experiments in this chapter was to determine whether deletion and restoration of 
MeCP2 is accompanied by detectable changes in bone mineralisation, collagen 
content and osteoclast number / activity.  
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5.2 Methods and Material 
5.2.1 Preparation of histological sections of bone 
Whilst the distal parts of male MeCP2 stop/y, wild-type and rescued mouse left 
femurs were used for scanning electron microscopy imaging described in chapter 
4, the proximal aspects of left femurs (n=5 per genotype) were used for 
histological analysis. Because of the limited availability of tissue samples in my 
study I have selected two important experiments as the initial histological analysis. 
Firstly, I have looked at the collagen content as this parameter has never been 
analysed in both RTT patients or animal studies before. Also since I did not find 
any difference in inorganic part (mineral content) I wanted to explore the organic 
part of the bone. Furthermore since collagen forms the primary organic component 
of bone matrix it was appropriate to start an initial analysis by measuring the 
collagen content first. Osteoblast is involved in the synthesis of collagen hence the 
results obtained could also be the indirect measure of osteoblast function. 
Secondly the results of previous experiments of trabecular thinning seen in Mecp2 
stop mice and significant improvement seen in rescue mice raised questions as to 
whether increased/decreased osteoclast activity in the bone tissue is the primary 
cause of under lying pathology. Alternate sections were stained with either Sirius 
red staining for collagen content (see section 5.2.2.1) or tartrate-resistant acid 
phosphatase (TRAP) staining for osteoclasts (see section 5.2.3.1).  
5.2.1.1 Decalcification of proximal parts of stop femur 
The bone samples were first decalcified in 12% EDTA, (pH 8.0, 5N NaOH) for 14 
days. The fresh solution was added every second day over the 14 day period. The 
specimens were then kept in the decalcifying solution in a refrigerator at 4°C prior 
to tissue sectioning.  
5.2.1.2 Processing of tissues for histology 
Following fixation by 10% neutral buffered formalin, tissues were placed in plastic 
cassettes and processed using a Leica TP1020 tissue processor (Leica Milton 
Keynes, UK) maintained by David Russell, Laboratory of Human Anatomy, 
University of Glasgow. The overnight processing programme took tissues through 
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graded alcohols (70%, 90%, 100%; 1hr, 1hr, 1.5hrs), amyl acetate and molten 
paraffin wax. Tissues were then transferred for embedding 
5.2.1.3 Embedding tissues in paraffin 
Embedding was performed on a Tissue Tek embedding centre maintained by 
David Russell, Laboratory of human anatomy, University of Glasgow. Molten wax 
was poured into moulds and bone samples were carefully oriented to provide a 
longitudinal (LS) sections on cutting. Wax hardens around the plastic embedding 
cassettes and makes up the finished block, allowing blocks to be easily cut. 
5.2.1.4 Cutting of histological sections  
Longitudinal sections of 5 μm thickness (150 slices in total) were cut using a 
microtome (Leica RM2035, Milton Keynes, UK) maintained by David Russell, 
Laboratory of human anatomy, University of Glasgow.  
5.2.2  Quantitative measurement of collagen in bone 
A variety of stains are available to stain collagen including, Masson’s trichrome 
which is one of the commonly used staining methods employed for collagen and 
collagen related pathologies (O'Brien et al., 2000; Lazzarini et al., 2005). Other 
studies have used sirius red staining because of its specific binding to collagen 
(Puchtler et al., 1973; Junqueira et al., 1979; Malkusch et al., 1995; Wright et al., 
2003; Hui et al., 2004; Goodman et al., 2007; Kliment et al., 2011; Huang et al., 
2013).  
However trichrome stain has limitation as it is not specific to collagen, in contrast, 
the sirius red stain is based on the application of a single dye that has been shown 
to specifically stain collagen types I, II and III and is highly sensitive in detecting 
small amounts of collagen (Junqueira et al., 1979).  
Moreover in a recent study (Huang et al., 2013) a collagen proportional area 
(CPA) images, stained with trichrome staining was compared with sirius red stain 
and it was found that the reproducibility of collagen proportional area image 
analysis stained with sirius red stain was superior to that achieved with trichrome. 
Moreover the mean CPA stained with sirius red was found to be significantly 
greater than CPA stained with trichrome and this was found to be consistent with 
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their morphological findings that sirius red staining detected more collagen then 
did trichrome staining. 
 In my current study I have used Picro-sirius red method of staining (after (Puchtler 
et al., 1973; Junqueira et al., 1979) to detect the percentage of Picro-sirius red 
stained collagen content in each bone specimen per genotype as sirius red 
staining for collagen is one of the best understood techniques of collagen staining 
(for methodology see section 5.2.2.1).  
After staining, percentage collagen content was calculated by pixel counting 
technology (see section 5.2.2.2 for details). Pixel counting technology is potentially 
a highly accurate technology that calculates collagen area however the reliability 
could be influenced by threshold settings, magnification and image resolution 
(Huang et al., 2013). In order to obtain reliable analysis, both during the staining 
and image analysis I and technical staff were blinded to the identification of the 
sample. 
5.2.2.1 Sirius Red staining for collagen 
After cutting, the bone sections were de-waxed with Histoclear (Fisher), for 15 
mins and hydrated through 100%, 90% and 70% alcohols. Nuclei were stained 
with Mayer’s haematoxylin for 8 minutes, and then slides were washed for 10 
minutes.  
Specimens were then stained in Picro-sirius red solution [prepared by adding 0.5g 
of Sirius red F3B (Sigma-Aldrich, C.1.35782) in 500 ml of saturated aqueous 
solute ion of picric acid]. This gives near optimal staining, which does not increase 
with longer incubation. Tissue samples were washed in two changes of acidified 
water [prepared by adding 5 ml of acetic acid (glacial) in 1 litre of water (tap or 
distilled)]. Specimens were then dehydrated in increasing ethanol concentrations, 
cleared in Histoclear and mounted in DPX (consists of distyrene, a plasticizer, and 
Xylene) (Sigma Aldrich). To standardize staining, care was taken that all sections 
were stained in a single batch (figure 5-6). 
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5.2.2.2 Region of interest and image analyses of bone sections for collagen 
content 
To assess total collagen content, bright field images were sampled using a 40X 
objective lens on an Axioskop50 microscope (Zeiss, Cambridge, UK) with Carl 
Zeiss AxioCam MRc camera (Zeiss, Cambridge, UK) and images were further 
analysed using Zeiss Axiovision v.4.8.3.0 software and colour segmentation 
plugin.  
Care was taken to obtain all images with same magnification, thresholding and 
image resolution. A demarcation, line was drawn across each specimen image, at 
the beginning of third trochanter across the whole bone section to standardise and 
specify the exact area from which region of interests (219.31μm x 164.56μm) were 
selected each, from both medial (femoral head side) and lateral side (trochanter 
side) per bone per genotype (figure 5-6).  
The Regions of interests were further analysed and quantified by using the Image 
J 1.47v, colour segmentation plugin. This plugin helps to segment (different 
colours) within the examining bone image. The Positive sirius red stained pixels 
were selected and quantified by using Imagej (colour segmentation plugin) with 
pixel area count and reported as a percentage of the total tissue area (219.31μm 
x164.56μm) specified in each bone per genotype (Malkusch et al., 1995; Kiernan, 
2008) (figure 5-6, Bi-Biii). The detailed steps of methodology are as below: 
Steps 
1. To calculate the area of red pixels corresponding to the Sirius red stained 
collagen fibres, images were opened in image j 1.47v (figure 5-1).  
2. Under the Colour segmentation, POINTCROSS tool was selected, in the 
toolbar section of image j software.  
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        Figure 5-1 Selection of image through image j Colour-   
         Segmentation plugin 
 
 
3. First cluster of high intensity red pixels was defined by clicking on the 
image.  
4. Subsequent clusters of white, blue (nuclei) pixels of osteocyte cells and 
remaining faint red pixels were selected by clicking on the image (figure 5-
2). 
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         Figure 5-2 Selection of different pixel colour clusters             
               
 
5. Under the data organization section dependant channels option was 
selected.  
6. Further on algorithm of K-Means clustering was carried out.  After this 
selection, Run option was clicked and an output image was obtained per 
sample.  
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 Figure 5-3   Percentage area measurement by Colour segmentation plugin             
                          
 
 
7. The subsequent output images gave the percentage area measurements of 
each defined colour cluster.  
8. The % area of red pixels corresponding to collagen fibres, relative to total 
tissue area, was estimated using a colour segmentation plugin in Image J    
(Biomedical imaging Group, EPFL, Switzerland 
:http://bigwww.epfl.ch/sage/soft/colorsegmentation/) using independent 
colour channels and the K-means algorithm (figure 3-3). 
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5.2.3 TRAP staining for osteoclast 
Alternate sections from the proximal femur longitudinal sections were stained with 
Tartrate-resistant acid phosphatase (TRAP) staining to assess resorption activity 
(osteoclast number per bone surface). 
5.2.3.1 Tartrate-resistant acid phosphatase (TRAP) staining for osteoclasts 
After cutting, the bone sections were de-waxed with Histoclear, for 15 mins and 
hydrated through 100%, 90% and 70% alcohols. TRAP solution was prepared by 
adding in 100 ml of distilled water, 1.15 g of sodium Tartrate, 1.22 g of sodium 
acetate. Solution was adjusted to pH5 by using 1M HCl before 5 mg Fast Red TR 
10 mg Naphol AS-MX (Sigma Aldrich, N-4875) was added. Specimens were then 
stained in TRAP solution for 1 hour at 37°C. Tissue samples were washed in two 
changes of tap water. Nuclei were stained with Mayer’s haematoxylin for 8 
minutes, and then slides were washed for 10 minutes for blueing of nuclei. To 
standardize staining, care was taken that all sections were stained in a single 
batch. A slide was treated with the same solution minus the substrate, as a 
negative control. Method of staining adopted from O’Connor et al (O'Connor et al., 
2009b). 
5.2.3.2 Region of interest and image analyses of bone sections for 
osteoclast number 
To quantify osteoclast number in histological sections, images were sampled by 
bright field microscopy using a 40X objective lens on an Axioskop50 microscope 
(Zeiss, Cambridge, UK). A rectangle area of 1.47 mm2 was selected as the region 
of interest below the anatomical point of femoral trochanter in each bone specimen 
per genotype. The TRAP stained cells were independently counted by at least two 
blinded reviewers, and each multinucleated and TRAP stained cell was counted as 
one osteoclast. Total numbers of osteoclasts were counted within the region of 
interest both on the medial and lateral side per bone specimen per genotype. For 
each sample an average number of osteoclasts were counted using the method  
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described by Sawyer and colleagues (Sawyer et al., 2003) and adopted by 
O’Connor and colleagues (O'Connor et al., 2009b). Osteoclast were defined as 
TRAP stained, multinucleated, light blue stained cells containing foaming 
cytoplasm lying close to an eroded lacuna or on the bone surface (figure 5-4). 
TRAP-positive osteoclasts adjacent to bone showing one nucleus or no nuclei at 
all in the plane of section were also included in the count as the osteoclasts. The 
number of TRAP stained cells was independently counted by two blind reviewers, 
assuming each TRAP stained cell was one osteoclast. Average number of 
osteoclast counts was calculated for each bone per genotype and total mean 
values for all three genotypes were compared. 
 
 
Figure5-4  Region of interest selection for osteoclast count in 
male stop mice 
(A) Low power bright field micrograph showing, the method for selection of regions 
of interest (ROI) for the quantification of osteoclast number. A rectangular region 
of interest (1.47 mm2) was selected below the anatomical point of beginning of 
trochanter. (B) High power (40x) image of region of interest) showing osteoclasts 
(black arrows) (A) Scale bar= 1000μm (B) Scale bar= 50μm 
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5.2.4 Ash weight density 
In order to confirm the density findings obtained from CT scan measures, I 
performed an ash weight density experiment. For this experiment, Left tibias from 
both male and female mice cohorts were place in Pyrex crucibles and dried at 
100°C for 24h in a muffled furnace at the Organic Chemistry Department, 
University of Glasgow, Glasgow, UK. Weight measurement of the crucibles was 
taken separately at the beginning of experiment by using the analytical balance 
(APX60 Analytical Balance, Denver Instruments). Weight measures were taken 
after the bones have been dried and ashed in muffled furnace. 
Dry weight measures were obtained (APX60 Analytical Balance, Denver 
Instruments) while the tibias were still in the crucibles to avoid any tissue loss as 
the mouse bones are understandably very small and fragile to handle, especially 
after being heated at high temperature . The specimens were then reduced to ash 
at 650°C for 24h and the ash weight measurement were taken in a same manner 
as dry weight measures. The ratio of ash weight and dry weight was used to 
obtain the final ash content (Kriewall et al., 1981; Keene et al., 2004). The ash 
content can be expressed on either a dry or wet basis: 
                  
     
     
   X 100              
                  
     
    
  X 100              
Where         refers to the mass (weight) of the ashed sample and       and 
     refer to the original masses (weights) of the dried and wet bone samples. 
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5.3 Results 
5.3.1 Mecp2 stop mice showed decrease in collagen content 
Sirius red staining was conducted as an initial experiment to assess any gross 
defects in overall collagen content of the bone samples from Mecp2stop/y mice and 
wilt-type and genetic rescue controls. The percentage college content values were 
derived by quantifying pixel area count of positive sirius red stain, localization in 
each region of interest per bone per genotype. Final values were reported as a 
percentage of the total tissue area (1.47mm2) specified in all genotypes. Stop male 
mice showed a significant decrease in collagen content compared to Wt mice (WT 
= 65.1 ± 8.6%; Stop= 48.8 ± 9.1 %; Rescue = 55.63 ± 11.4 %; n = 5 specimens 
per bone per genotype, p<0.01, one way ANOVA with Tukey’s post hoc test). An 
interesting finding of reduced collagen content and increased pale stained 
extracellular are in tissue sample of Mecp2 stop was also made as compared to 
the age matched wild type and rescue mice (figure 5-5).  
            
Figure5-5 Collagen content analysis in Mecp2 stop mice 
Bar chart  showing  percentage Collagen content in Mecp2Stop/y (Stop) mice is 
reduced as compared to wild-type (Wt; p<0.01);  n = 5  specimens (5 sections 
from each medial and lateral side) per bone per genotype. No significant treatment 
effect was seen in rescue mice. Abbreviations: ns = not significant; one way 
ANOVA with Tukey’s post hoc test). Plots show mean ± S.D.  
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Figure 5-6  Comparison of %collagen content 
 
 
(A) Low power micrograph showing position of (boxes) region of interest (ROI) 
selected for the quantification of collagen. Regions of interest are selected from 
both the medial and lateral side of each proximal femur at a site demarcated by 
the beginning of trochanter. A line was drawn across the section so that both the 
sections are selected at the same level. (B) Higher power bright field micrograph 
showing sirius red stained region of interest. (Ci-iii) Representative, high power (40 
x objective) micrographs showing representative regions of interest from each 
experimental cohort/genotype.  Images of region of interest were reconstructed for 
the quantification of percentage college content by using image j (colour 
segmentation plugin). (A) Scale bar= 500μm (B) Scale bar= 50μm 
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5.3.2 Osteoclast number did not showed any significant 
difference in Mecp2 stop mice 
TRAP staining was conducted to assess resorption activity (osteoclast number per 
bone surface within region of interest) but showed no difference between 
genotypes (WT=12.61±8.51 (n); Stop =17.48±6.13 (n); Rescue =18.90±4.61 (n); 
n=5 per genotype, p>0.05, one way ANOVA with Tukey’s post hoc test) (figure 5-
7). 
                   
Figure5-7  Osteoclast number quantification analysis in Mecp2 
Stop mice 
Bar chart showing no significant difference in osteoclast number between the three 
comparison genotypes (WT=12.61±8.51; Stop =17.48±6.13; Rescue =18.90±4.61; 
n=5 per genotype, p<0.05, one way ANOVA with Tukey’s post hoc test). Values 
refer to absolute number (n) count of osteoclast within the specified tissue region) 
Abbreviations: ns = not significant. Plots show mean ± S.D.  
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5.3.3 Ash density analysis of bone tissues in Mecp2 stop mice 
The analysis of mechanical (reduced bone strength), material (reduced bone 
hardness measure), structural (thinning of cortical and trabecular bone) 
experiments revealed an osteoporotic picture of the bone tissue similar to the one 
frequently reported in RTT patients.  
A surprising result was the finding of no significant difference in bone mineral 
density measures obtained after the μCT (see chapter 4). Decrease in bone 
mineral density has been frequently reported in RTT patients (Budden and 
Gunness, 2001; Cepollaro et al., 2001; Budden and Gunness, 2003; Shapiro et al., 
2010; Jefferson et al., 2011; Roende et al., 2013b). In order to re confirm the bone 
mineral density values derived from μCT, I performed ash weight density test. Ash 
weight density is frequently used to asses’ ash content. Studies have been done to 
compare the results from bone mineral density and ash weight tests. I also 
performed this experiment to confirm the findings of my earlier experiment.  
Left tibia was used to analyse the percentage mineralization (ash content) see 
above section 4.2.5 for methodology. Results showed no significant difference in 
percentage ash content measured on the basis of dry weight measures and in 
percentage ash content values measured on the basis of wet weight measures 
between genotypes of male mice (figure 5-8). 
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Figure5-8  Ash Content analysis in male and female stop mice 
(Ai-Aii) Bar charts showed no difference in percentage ash content in male mice 
cohort (dry basis) (WT= 62.15± 5.22%; Stop =62.57± 4.25%; Rescue =61.75 ± 
3.72%; n =6 per genotype, p>0.05, ANOVA with Tukey’s post hoc test) and (wet 
basis) (WT=41.54 ± 11.35%; Stop =40.88 ± 7.92%; Rescue =41.23 ± 5.36%; n=6 
per genotype, p>0.05, ANOVA with Tukey’s post hoc test). (Bi-Bii) Percentage ash 
content values in Stop female mice showed similar pattern of no significant 
difference, in % ash content (dry basis) (WT= 45.58± 6.37%; Stop =45.49± 3.78%; 
Rescue =49.55 ± 5.128%; n=3-5 per genotype, p>0.05, ANOVA with Tukey’s post 
hoc test) and % ash content (wet basis) (WT= 17.27 ± 26.27%; Stop=15.00 ± 
21.99%; Rescue =17.59 ± 26.36%; n=3-5 per genotype, p>0.05, ANOVA with 
Tukey’s post hoc test). Abbreviations: ns = not significant, Plots show mean ± S.D.  
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A similar trend of percentage ash content results was observed in female cohort 
tibias. No significant difference was found in heterozygous Stop female cohort of 
values of  percentage ash content calculated on either dry weight basis or wet 
weight basis  All data given as, mean ± SD (figure 5-8). 
5.4 Discussion 
The major finding of the current set of experiments was the observation that the 
collagen content is appreciably reduced in bone sections stained with sirius red 
from MeCP2-defience mice as compared to wild-type littermate mice. Sirius red 
stain was first described by Junqueira et al. in 1979 (Junqueira et al., 1979) and is 
a dye that binds to the [Gly-x-y] triple-helix structure found in all collagen fibers. 
This property of sirius red stain can be utilized to assess collagen in various tissue 
sections under bright field and polarized light microscope (Junqueira et al., 1979; 
Whittaker et al., 1994) and in cell culture (Walsh et al., 1992).  
In my initial analysis, to observe any gross changes in collagen content, I have 
used bright field microscope to assess the overall content of collagen in a 
specified region of interest per bone per genotype. The Sirius red stained images 
were further analysed by using the colour segmentation plugin of Imagej. The 
colour segmentation is an Imagej plugin that allows to segment an colour image or 
a stack of colour by pixels clustering. I have used the colour segmentation plugin 
to segment the bone cells from the extracellular content. The high intensity sirius 
red stained collagen content area was identified in each image per slide per bone 
by using Imagej software and the collagen content was calculated as a percentage 
of the specified area of each image (expressed in pixels).  
The results obtained showed mean colour area percentage of collagen in Mecp2 
stop mice to be 48.8% which was significantly decreased compared with the 
control group (p<0.01). This reduction in % collagen content was found consistent 
with the mean colour area percentage of collagen of 47.7% seen in histological 
sections of female albino rat (ovariectomy induced) models of osteoporosis (Naim, 
2011). The overall picture of reduced collagen content and increase pale stained 
space within the extracellular bone matrix found in my study adds to the 
osteoporotic picture of RTT bone phenotype. However bone histomorphometric 
analysis of collagen content in children and adolescents with RTT is unknown.  
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The magnitude of the reduction in my study was in the range of ~25% and thus it 
can be predicted to have a profound effect on overall material and mechanical 
properties of bones in these mice. Interestingly, there was a trend towards a 
reversal of collagen level deficits in genetically rescued mice (~15% increase 
compared to knockout mice) but this change did not achieve statistical 
significance. Hence, this study did not provide direct evidence that restoration of 
MeCP2 can results in improvement of organic part of extracellular matrix. In RTT 
patients bone anomalies have always being considered and investigated in terms 
of decrease in bone mineral density, while little attention has been paid to the 
organic part of extracellular matrix.  
As described earlier the organic (collagenous and non-collagenous proteins) and 
inorganic phase (minerals) both contributes towards the bone strength (Marotti et 
al., 1994). Collagen fibrils are stiffened by integration of the mineral phase. The 
presence of mineral phase increases bone strength; but in woven bone, which is 
constituted by unorganized collagen fibrils, the mechanical properties are 
decreased despite a high mineral content (Marotti et al., 1994). As majority of 
collagen content consists of type 1 form of collagen, my finding of decrease in 
collagen content are also consistent with the results of a recent analysis of 
biochemical bone marker, in which all the bone markers including N-terminal , 
propeptides of collagen type 1(PNIP), the C-terminal telopeptide cross links (CTX); 
and osteocalcin (see section 1.5.4) were found decreased in blood samples taken 
from Rett patients (Roende et al., 2014).  
Osteoblast plays a major role in collagen homeostasis as it synthesizes and 
secretes the C-terminal propeptides of the alpha 1 and alpha 2 chains of type 1 
collagen (Johansen et al., 1992). Hence the reduction in collagen content from the 
current study can be interpreted as the decreased osteoblast function in Mecp2 
stop mice.  
Interestingly, MeCP2 has been found to regulate the expression of RANKL gene 
(Kitazawa and Kitazawa, 2007) expressed by osteoblasts (Alvarez-Saavedra et 
al., 2010)(see section 1.5.4 and 5.1.2 for details of RANKL and its role in bone 
homeostasis) further supporting the potential involvement of MeCP2 in 
skeletogenesis. Also MeCP2 overexpression, duplication and triplication has been 
found to result in diminished ossification resulting in severe kyphosis, a distorted 
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sternum, spina bifida and dysmorphic feature  in male TTM20dTg mice (kyphosis, 
scoliosis).  
Interestingly, RTT bone phenotype, other than osteoporosis has also been linked 
to share features with a disorder known as Osteogenesis imperfecta (OI). OI is an 
inherited disorder characterized by increased bone fragility with recurrent fractures 
mainly caused by the defects in collagen synthesis (Smith et al., 1975; Camacho 
et al., 1999). Nonetheless the possible role of collagen defects, in RTT bone 
phenotype needs more attention. This current study has limitation as I have 
calculated the gross values of collagen content by using the bright field 
microscopy. In future studies a polarized light microscopic (Lillian and Whittaker, 
2005) examination to identify the collagen structure in detail can give further 
details. 
Histological experiment to count osteoclast number was also performed to analyse 
the resorptive activity of the bone (O'Connor et al., 2009b). Connor and colleague 
also looked at the absolute osteoclast number in their Mecp2 null mouse model 
and did not find any difference. They relate the non-significance of their findings to 
the small number of animals they have used in their study. I wanted to look at the 
osteoclast number to see if there is any significant difference in the resorption 
activity in bone that is causing all the apparent increase in bone fragility in Mecp2 
stop mice. The multinucleated osteoclast-like cells form pits on bone or dentine 
slice express high concentrations of 5 isozyme of tartrate-resistant acid 
phosphatase (TRAP) (Alatalo et al., 2000).  
TRAP is a histochemical marker of the osteoclast. It is also characteristic of 
macrophages and other cells of mononhitiocytic lineage (Alatalo et al., 2000; 
Hayman et al., 2000). This enzyme  partially dephosphorlylates the bone matrix 
phophoproteins osteopontin and bone sialoprotein, which have been implicated in 
cell attachment (Ek-Rylander et al., 1994). The TRAP “knockout” mouse has 
shown that the enzyme is essential for normal mineralization of cartilage in 
developing bones and for maintaining the integrity and turnover of the adult 
skeleton (Hayman et al., 1996). 
As an initial experiment to analyse the bone resorption activity I have calculated 
the number of TRAP stained osteoclast within the specified region of interest 
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selected per bone per genotype. TRAP is confirmed as a valid marker for 
identification of osteoclasts on the other hand TRAP activity is an osteoclastic 
marker of weak sensitivity. This may be due to known fact that synthesis of 
enzyme is not being unique to osteoclasts (Ballanti et al., 1997). Osteoclasts are 
heterogeneous with respect to cellular size and shape. They used to be 
recognised mainly on the basis of multinuclearity and cell width but since these 
criteria do not recognize mononucleated osteoclasts, this methodology has been 
questioned (Palle et al., 1989). 
Tartrate-resistant acid phosphatase (TRAP) is detectable in large amounts in the 
lysosomes of osteoclasts and its activity is now considered an established 
cytochemical marker useful for recognizing polynucleated as well as 
mononucleated osteoclasts in bone sections (Baron et al., 1986). At present, the 
number of osteoclasts is determined by counting the number of TRAP-positive 
multinucleated osteoclast-like cells (Takahashi et al., 1988). 
The results obtained displayed no significant difference of osteoclast number 
among the three comparison genotypes of male stop mice. However if we look at 
the analysis bar graph an interesting trend of 30% increased osteoclast number in 
stop mice and 50% increase in rescue mice as compared to wild type control mice 
was found indicating towards the slight increase in bone resorptive activity as 
compared to the age matched wild type control. The non-significance of this 
experiment results could be the result of high biological variance seen in tissue 
samples analysis (figure 5-4). 
Our results of no significant difference in osteoclast number were inacordance to 
the finding obtained by O’Connor et al. Similar to our finding they did not find any 
significant difference in osteoclast number per bone surface (WT= 6.34±2.43, 
Mecp2 null= 6.60±2.30) in their TRAP stained tibial section of Mecp2 null mouse 
mode. In another study conducted on five RTT girls revealed a decrease in 
osteoclast number and surface (Budden and Gunness, 2003). However this study 
had the limitations that patients and controls were not age matched and hence 
conclusion about resorption activity or rates cannot be inferred from these surface 
estimates. On the other hand Motil and colleagues study has displayed increase in  
bone turnover (increased resorption to formation) by age (Motil et al., 2008). 
Resorptive activity measures in RTT bone phenotype are still unclear and future 
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bone histomorphometric studies need to be done to fully understand the cellular 
mechanism of bone resorption in RTT patients. 
After the histological experiments in organic part of bone I also looked at the 
inorganic (mineral) content of the bone of male and female stop mice by 
conducting the ash weight density measurements. Although I already had obtained 
the bone mineral density measurement from μCT scans analysis, I performed this 
experiment to confirm and validate the finding of μCT mineralisation calculations 
as various report in RTT patients have reported decrease in bone mineral density 
(Haas et al., 1997; Leonard et al., 1999b; Leonard et al., 1999c; Cepollaro et al., 
2001; Motil et al., 2006; Zysman et al., 2006; Gonnelli et al., 2008; Alvarez-
Saavedra et al., 2010; Shapiro et al., 2010). 
No significant difference was seen in wet and dry ash weight density values of 
male and female stop mice and the results from the experiment confirmed the 
findings of μCT. In adults mammals 20% of bone weight is water, 45% is ash and 
35% is organic matrix (Carter and Spengler, 1978). On a dry weight bases, 
mineral content is 65 to 70% and organic matrix is 30 to 35%. In this current study 
Mecp2 stop male mice showed a 62% of ash content on dry basis which was 
comparable to wild type and rescue values and 41% ash content based on wet 
basis and consistent with the normal range. Compare to male mice, female stop 
mice displayed 45% ash content analysis on dry weight basis and 15% on wet 
weight basis, this apparent decrease in density measures obtained from male and 
female stop cohorts was gender and age appropriate (Henry and Eastell, 2000).  
Overall similar to male stop mice cohort, female mice cohort showed no significant 
difference among the three comparison genotypes. O’ Connor and colleagues in 
their Mecp2 null mouse model, had displayed a modest reduction of bone mineral 
density and bone mineral content values (O'Connor et al., 2009b) but results does 
not reach the statistical significance. Also a recent study (Roende et al., 2014) on 
bone metabolism of patients with RTT has revealed some interesting insights. 
Bone metabolism can be characterized by biochemical markers of bone formation, 
resorption, mineralization and turnover (Szulc et al., 2000; Jürimäe, 2010). 
Roende and colleagues characterise bone metabolism in RTT patients, by 
comparing biochemical bone markers levels in RTT patients with healthy controls. 
They found that both markers of bone formation the N-terminal propeptides of 
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collagen type 1 (PINP); markers of bone resorption, the C-terminal telopeptide 
cross links (CTX); of bone turnover, osteocalcin (OC); and of bone mineralization, 
bone specific alkaline phosphatase (B-ALP) were significantly reduced. 
Interestingly they also found no significant association between bone markers 
levels and volumetric bone mineral density calculations obtained from DXA scans 
of lumbar spine and femur neck of the patients. The difference of bone mineral 
density value obtained from this study and previous studies (Cepollaro et al., 2001; 
Motil et al., 2006; Gonnelli et al., 2008) could be because the Roende et al 
adjusted their analysis of biochemical bone markers for age and puberty while 
previous studies have only analysed biochemical markers of bone formation in 
RTT children and young adults less than of 25 years of age. Studies 
(Rauchenzauner et al., 2007; Tuchman et al., 2008; Jürimäe, 2010) on 
biochemical bone markers in healthy persons have reported high levels in early 
childhood, peaking in puberty and decreasing to stable levels in the mid-20s. 
Children with disabilities and limited mobility are at increased risk of osteoporosis 
(Aronson and Stevenson, 2012). RTT patients display osteoporotic bone 
phenotype (Zysman et al., 2006) and have been compared with cerebral palsy 
(CP) patients in past to analyse the bone mineral density values (Haas et al., 
1997). Interestingly biochemical markers (OC, B-ALP, and N- telopeptides) in 
cerebral palsy (CP) patients with motor deficiencies have shown a wide variety in 
serum levels (Henderson et al., 1995; Henderson et al., 2002) and no significant 
association with measures of bone mass as BMD z scores of the lumbar spine and 
distal femur region have been found (Henderson et al., 2002).  
Moreover another study comparing CP and healthy children reported no significant 
difference in both formation and resorption markers (Chen et al., 2011). Thus the 
reduced level of bone turnover seen in children and adolescents with RTT could 
be a direct effect of MECP2 gene mutation, although levels of bone markers did 
not differ between different mutation groups in patients with RTT (Roende et al., 
2014). This could be due to an overall general effect of MECP2 on regulation of 
growth and bone turnover. This is corroborated by my findings of decrease cortical 
bone volume, alteration in trabecular structure, reduced bone strength in Mecp2 
stop mouse model along with the growth plate abnormalities, decreased femoral 
trabecular and cortical bone volume and decreased bone mineral apposition rates 
seen in other Mecp2  mouse models (O'Connor et al., 2009a; Shapiro et al., 2010).  
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The results obtained from this study are quite interesting. As described earlier, in 
my initial experiments I did find a difference in bone strength and structural 
parameters in Mecp2 stop mice. In this current study, I found a possible defect 
(reduced collagen content) in organic part and not the traditionally considered 
inorganic part (ash weight density) of extracellular matrix to be responsible for 
bone fragility.  
Future experiments need to be more focused on the organic part of extracellular 
matrix in order to determine the possible mechanisms of bone fragility commonly 
seen in RTT patients. 
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Chapter 6  
General discussion 
  
The overall aim of the experiments described in this thesis was to explore the 
effects of MeCP2 protein on bone tissue using various biomechanical, radiological 
and anatomical techniques applied to mice in which the Mecp2 gene was 
functionally silenced. A secondary theme was to assess whether such features are 
potentially reversible by genetic rescue of the Mecp2 gene. This has important 
therapeutic implications as it would predict whether future gene-based therapeutic 
interventions are likely to impact on bone phenotypes. In this chapter I will 
integrate the major findings of this thesis, the significance of these findings and 
finally, I will discuss possible future experiments to extend this work and derive the 
maximum benefits from the results I have obtained to date. 
6.1 Major findings of the study  
My first aim was to see whether inactivating the Mecp2 gene in male and female 
mice will result in overt bone phenotypes. My study is only the second study to 
explore RTT-like bone phenotype in mice and the first study to investigate such 
phenotypes in female mice as well as to investigate biomechanical properties of 
bone. Female Mecp2+/stop mice are a gender appropriate and accurate genetic 
model of RTT yet they display a more subtle and delayed onset (4-12 months) of 
neurological features (Guy et al., 2007; Robinson et al., 2012a) compared to 
hemizygous male mice. Male Mecp2-null mice typically become symptomatic by 
the age of 5-8 weeks (Guy et al., 2007) and because of this rapid and severe 
disease trajectory are more commonly used in preclinical studies (Gadalla et al., 
2011). In keeping with this pattern, the results of my work revealed a more 
pronounced bone phenotype in male stop mice and subtle or undetectable bone 
phenotypes in heterozygous female mice. 
At the outset of the project there was no published literature on the expression of 
MeCP2 in bone. Therefore, an important initial experiment was to assess this in a 
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MeCP2-GFP reporter mouse line in which MeCP2 protein with an C-terminal GFP 
tag (McLeod et al., 2013) is expressed under its endogenous promoter and 
regulation. In male mice the MeCP2-GFP was observed to co-localise with DAPI in 
the nucleus but was absent elsewhere. This is consistent with MeCP2 displaying a 
similar nuclear-specific expression pattern as reported in brain neurons as well as 
other tissues. These experiments also showed heterozygous Mecp2+/stop mice to 
display punctate nuclear GFP fluorescence in ~50% of nuclei and no detectable 
MeCP2-GFP in the other cells. The heterozygous Mecp2 stop female mice in 
which one Mecp2 allele is inactivated mimic the mosaic expression seen in human 
Rett syndrome (figure 3-8). 
Having established the presence of MeCP2 in bone and the efficient silencing of 
the gene in the Mecp2-stop mouse line the results of my subsequent anatomical 
and biomechanical phenotyping revealed that Mecp2 stop male mice display a 
range of abnormal skeletal phenotypes that shares many of the features seen in 
clinical cased of RTT. Morphometric analysis revealed that the long bones of 
Mecp2 stop male mice are lighter and shorter as compared to the age matched 
wild type group. This finding correlates with the growth retardation pattern seen 
commonly in RTT patients (Neul et al., 2010). Male stop mice are also known to 
display skeletal dysmorphic feature of kyphosis, which is comparable to 
pathogenomic ‘S’ type of curvature seen in RTT patients (Ager et al., 2006; Koop, 
2011; Riise et al., 2011). 
One of the major finding of the current study came after the biomechanical 
analysis of male and female stop mice. The robust deficits were seen in 
mechanical properties were profound (39.5% reduction in stiffness in the three 
point bending test; 31% in load and  12.3% reduction in micro hardness) and could 
explain the weakness in MeCP2 deficient bone that accounts for the  increasing 
occurrence of low energy fractures reported in Rett syndrome patients (Roende et 
al., 2011b). Frequent findings of reduction in bone strength (brittle bones) and 
hence increase incidence of fracture has given human RTT bone phenotype an 
overall osteoporotic bone phenotype picture (Haas et al., 1997; Zysman et al., 
2006). However, the current studies do not discriminate whether the observed  
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defects arise from absence of MeCP2 protein or MeCP2 per se (ie. a primary 
pathology) or whether global silencing of Mecp2 throughout the body results in 
endocrine or systems defects elsewhere in the body that results a secondary 
pathology within the skeletal system. This question could potentially be address by 
using bone-linage specific cre lines. In terms of the potential secondary pathology, 
it is important to consider that the male mouse tissues used in the study were 
harvested at a time point at which the Mecp2-stop mice where showing fairly 
severe and advanced clinical signs (tremor, abnormal breathing, reduced 
locomotor activity and general poor condition) and these non-bone-related 
phenotypes may be an important factor. In contrast, the female heterozygous 
mice, despite being tested at a much later (many months rather than weeks) 
display similar non-bone phenotypes, albeit with much reduced severity (Guy et 
al., 2007). 
Another important finding of my work came after the structural analysis of cortical 
and trabecular bone. Robust significant differences were seen in Mecp2 stop 
mouse cortical and trabecular bone including a pronounced 54% reduction in 
cortical thickness, 30% in bone volume, 20% in total area, 38% in marrow area 
and 30% in trabecular thickness. Such findings are consistent with what is 
expected in an osteoporotic model (Seeman, 2008b).  
Female stop mice bone phenotype results remained consistent with their overall 
subtle bone phenotypes and didn’t show an overt difference in morphometric 
measurements of long bone length and weight measurements. Within the nervous 
system there is evidence for both cell autonomous and non-cell autonomous 
effects of MeCP2-deficiency including morphological changes in dendritic 
architecture (Ballas et al., 2009). Whilst it is clear from the results of the current 
experiments that various bone phenotypes are more subtle, absent or below the 
level of detection in hemizygous females compared to equivalent measures in 
males, it is unclear whether this is indeed due to the fact that only ~50% of bone 
cells are expressing MeCP2 or whether dysfunction in other systems are 
contributing to the subtle phenotypes. Nonetheless, a similar significant reduction 
(14%) in micro hardness and a trend towards reduced biomechanical properties 
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 seen in female mice that are heterozygous and mosaic for the mutant allele, 
demonstrate that the bone deficits are not restricted to the more severe male RTT-
like phenotype but are also seen in a gender and MeCP2 expression pattern 
appropriate model of RTT.  
An important finding of the current study and one with therapeutic significance is 
that the bone anomalies observed in terms of cortical bone material and 
biomechanical properties were rescued by delayed postnatal activation of the 
Mecp2 gene. Male rescue mice displayed a robust improvement in mechanical 
(stiffness 40%, ultimate load 10%, young’s modulus 61% and micro hardness 
12%) and structural bone parameters (trabecular thickness 80%) as compared to 
Mecp2 stop male mice. Similarly another major finding was the rescue of female 
bone phenotype in female stop mice. Female rescue mice displayed a significant 
improvement in bone material properties (micro hardness 19%) and a trend of 
improvement in mechanical properties (stiffness, load) as compared to stop mice. 
These finding of rescue of bone phenotype in stop mice were consistent with  the 
improvements seen in multiple non-bone phenotypes seen in the Mecp2Stop/y  mice 
after delayed activation of the Mecp2 gene including survival, normalized 
bodyweight, locomotor and behavioural activities (Guy et al., 2007; Robinson et 
al., 2012a). 
These results were quite significant as they suggest that the bone anomalies seen 
in RTT patients may be at least partially reversible using gene-based approaches 
currently under development (Gadalla et al., 2013; Garg et al., 2013). However, it 
is also possible that significant amelioration of bone phenotypes may also be 
achieved by using pharmacological strategies (Gadalla et al., 2011; Garg et al., 
2013). In order to apply all these therapeutic intervention most important aspect is 
to identify the mechanisms by which MeCP2 deficiency results in altered bone 
mechanical, material and structural properties. In my study I have found that 
MeCP2 is expressed in osteocytes (figure 3-8), but the protein is widely expressed 
throughout the body and it is possible that metabolic and endocrine factors can 
influence the bone homeostasis (Motil et al., 2006; Motil et al., 2011; Motil et al., 
2012).  
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A surprising finding of the current study was the absence of any significant 
difference in ash weight density or bone mineral density (µCT) in stop male and 
female cohorts. Our findings of no significant difference in bone mineral density 
(BMD) in Mecp2 mice were similar to the one reported in a Mecp2 null mouse 
model (O'Connor et al., 2009a) while differs with other animal study in which bone 
mineral density were found reduced in Mecp2 null mouse model (Shapiro et al., 
2010). These are the only two animal model studies conducted in past to explore 
the RTT bone phenotype using the  Mecp2 null mouse model. The relationship 
between RTT bone phenotype and bone mineral density values in animal studies 
is still unclear. 
Reduced bone mass is commonly associated with osteoporotic phenotypes and 
indeed these have been reported in RTT patients (Hui et al., 1988; Leonard et al., 
1999c; Cummings et al., 2002; Ager et al., 2006; Flynn et al., 2007). Several 
clinical, density x-ray absorptiometry (DXA) studies (Haas et al., 1997; Leonard et 
al., 1999a; Cepollaro et al., 2001; Motil et al., 2008; Shapiro et al., 2010) in RTT 
patients have shown low absolute values of BMC (g) and or BMD (g/cm2) 
compared to age-matched controls. The problem with use of DXA scan for 
assessment of bone mineral values is that the size adjusted absolute DXA values 
of aBMD (g/cm2) may lead to interpretation of a relatively lower bone density 
among RTT patients than is actually the case (Roende et al., 2011a). Nonetheless 
these findings of bone mineral density from both µCT and ash content analysis are 
very interesting. They points towards the further need and importance of 
exploration of other possible factors (e.g. cellular dysfunction and alterations in the 
extracellular protein matrix)  involved in the robust reduction of bone strength and 
structural parameters seen in Mecp2 stop mice. Furthermore reversal of bone 
integrity (bone stiffness, hardness, trabecular thickness) seen in rescue mice after 
the gene reactivation leads to assess the mechanisms by which bone structure 
and properties are dynamically regulated by MeCP2 levels. As stated, it is also 
necessary to assess whether the influence of MeCP2 on bone homeostasis is a 
primary or secondary mechanism.  
A number of studies have been conducted to investigate the role of specific genes, 
gene pathways and biochemical networks involved in the regulation of bone  
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homeostasis (Elefteriou et al., 2014; Quiros-Gonzalez and Yadav, 2014).  
Studies involving leptin and neuropeptide Y2 have disclosed unrecognized 
interactions between the central nervous system, peripheral neurotransmitters and 
osteoblast function (Allison et al., 2007; Abdala et al., 2013; Elefteriou et al., 2014; 
Quiros-Gonzalez and Yadav, 2014). Several reports suggest that MeCP2 is an 
important regulator of neuronal gene expression (Skene et al., 2010; Guy et al., 
2011b)). Neurological studies suggest that MeCP2 can affect osteoblast function 
by altering osteoblast chromatin structure as already seen  in brain tissue or by 
altering cell maturation as observed in RTT neuronal tissues (Budden and 
Gunness, 2003; Chadwick and Wade, 2007). However, the precise role played by 
MeCP2 in the nucleus remains unclear (Chahrour et al., 2008; Skene et al., 2010; 
Guy et al., 2011a; Li et al., 2013a), but it is generally considered to regulate gene 
expression.  
Another important finding of my studies and one which may relate to aberrant 
gene expression is the effect of MeCP2 deficiency on collagen content. As 
collagen is the most abundant gene product and structural determinant in bone, I 
conducted an initial analysis of collagen content and distribution using sirius red 
staining. The decreased levels (25% as compared to age matched wild type 
genotype) of intense sirius red stain observed in the MeCP2-deficient mice is 
consistent with reduced PINP (bone formation markers) levels in human RTT 
(Roende et al., 2013a) and the patches of reduced staining resemble those 
features characteristic of early osteoporosis (Leonard et al., 1999a). Whilst my 
work suggests that deregulation of collagen may be a significant potential 
mechanism underlying RTT-related bone phenotypes, further studies would be 
required to assess whether altered collagen level or altered balance of different 
collagen subtypes may result as a direct consequence of MeCP2 deficiency.  
In addition to structural protein, we also investigated the resorptive properties of 
the bone in terms of TRAP staining. The lack of any difference in osteoclast 
number between genotypes is consistent with a previous report (O'Connor et al., 
2009a) and suggests the possible absence of any primary defect in bone 
remodelling.  
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My findings of osteoclasts were also consistent with the bone histomorphometric 
analysis performed by Budden and colleagues (Budden and Gunness, 2003). 
Although no difference in resorptive parameter (osteoclast number) was found, 
conclusions about the resorption activity or rates cannot be inferred from these 
surface estimates. 
Overall, based on all these major findings of my study it could be said that Mecp2 
stop mice display, osteopathic features of RTT (reduced bone strength, decrease 
in cortical and trabecular thickness, decrease in collagen content and tendency 
towards spinal curvature) which are also similar to those reported in collagen type 
1 genetic disorder (osteogenesis imperfecta; brittle bone disease) (Dogba et al., 
2013) pointing towards the possible importance of collagen defects in RTT. The 
RTT bone phenotype has previously been linked with osteogenesis imperfecta 
(OI) in past (Loder et al., 1989). Indeed, one patient in this study who suffered 
from increased rate of fractures had originally been given a primary diagnosis of 
osteogenesis imperfecta before the Rett syndrome was diagnosed. 
Animal’s studies and studies in human subjects suggest that skeletal fragility in 
osteogenesis (OI) is due to the defect in collagen synthesis, whereas the 
abnormalities in bone turnover and mineral are inconsistent. These findings of 
reduced collagen and no significant difference in bone mineral density were similar 
to the one I have observed in my analysis of skeletal phenotype of RTT. The 
collagen abnormalities seen in OI are the result of the two type 1 collagen genes, 
mutation COLIA1 and COLIA2. Over 200 mutation types have been reported. Two 
main classes of type 1 collagen mutations have been described (Seeman and 
Delmas, 2006). The first “null allele” mutation affects the pro-alpha1 or pro-alpha2 
allele that impairs transcription and mRNA stability and produce low amounts of 
the secreted heterodimer. The abnormal heterodimers are incorporated into 
matrix, resulting in a quantitative and qualitative abnormal bone matrix (Seeman 
and Delmas, 2006). These results of quantitative abnormality of bone matrix were 
consistent with my finding of quantitative analysis of Mecp2 stop mice showing 
reduction of 30% in collagen content and a recent study on bone biochemical 
markers (Roende et al., 2013a). 
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Whatever the mutation in OI, there is less bone synthesized (Seeman and 
Delmas, 2006), a feature that may parallel the bone phenotypes seen in RTT 
(Budden and Gunness, 2003; O'Connor et al., 2009a). Moreover abnormal 
collagen fibrils may be unable to provide nucleating and scaffolding sites for 
mineral propagation. Such mechanism point towards a hypothesis that low mineral 
density seen in RTT patients could result from a direct alteration in collagen 
homeosynthesis.  
As mentioned earlier, although RTT-like bone phenotypes are frequently linked to 
an osteoporosis bone picture (Zysman et al., 2006), the biomechanical, structural 
and histological finding from my study has features consistent with both 
osteoporosis as well as those of OI bone phenotypes.  
A mouse model having well-defined genetic mutations on the COLIA2 gene 
produces aplpha1 collagen homotrimers and non-functional pro alpha2 chains. 
These oim/oim mouse modelling human OI, displayed a bone phenotype 
characterized by spontaneous fractures  and limb deformities (Camacho et al., 
1999), both of these features are commonly reported in RTT(Guidera et al., 1991a; 
Roende et al., 2011b). OI, oim/oim mouse model (Camacho et al., 1999) also had 
displayed mechanical defects (30% decrease in stiffness, 20% decrease in 
collagen content, reduced trabecular thickness and an unchanged mineral content, 
but with a decreased mineral crystallinity). Other than mineral crystalline results, 
all the features of RTT bone phenotype in my Mecp2 stop mouse study were 
qualitatively and indeed quantitatively similar (39.5% reduced stiffness, ~30% 
decrease in trabecular thickness, 25% decrease in collagen content and no 
difference in bone mineral deficits) suggesting that RTT bone phenotype shares 
common features with OI bone phenotype and that specific material properties 
such as mineral crytallinity and collagen content commonly seen in oim mice, 
could also be indicative and possibly predictive of bone fragility seen in RTT 
patients. Leonard and colleagues (Leonard et al., 1999a) did mentioned these 
similarities between OI bone phenotype and RTT bone phenotype but since then 
not much attention has been given both by human and animal based trials to 
explore further qualitative and quantitative dysfunction in organic part of 
extracellular matrix as a possible causes of bone fragility. To investigate the 
mineral crystalline structure directly, I have already initiated synchrotron X-ray 
nanomechanical (SAXS) imaging of mineralized fibre composites on Mecp2 stop 
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mice humerus. I have performed this research experiment at MAX Lab at Lund 
University (Sweden). Results and analysis are in the process. In situ synchrotron 
X-ray scattering and diffraction, in combination with micromechanical testing can 
provide quantitative information on the nanoscale mechanics of bio mineralized 
composites of bone. In bone carbonated apatite forms a composite fibril with type 
1 collagen of diameter ~ 50-200nm, which forms plywood-like lamellae in the bone 
with widths ~5-10μm that in turn form cylindrical osteons at the scale of ~100-
200μm. Due to this well known hierarchical organization the structural and 
mechanical properties of the mineral/protein composite at small (submicron) 
scales are crucial to the mechanical function of the entire organ (Reznikov et al., 
2014).   
6.2 Significance of the study 
Given the very limited previous attempts to explore the effects of Mecp2 on 
skeletal tissue, my current studies brings significant advance understandings that 
Mecp2 has a role in skeletal tissue regulation since inactivation of Mecp2 resulted 
in RTT like bone phenotype in stop mouse and reactivation of Mecp2 resulted in 
improvement of some of these defects identified in stop mice.  My study is the first 
study to use female stop mice which is a genetically accurate mouse model of 
RTT, and the results obtained from stop mice bone phenotype analysis will 
contribute towards the pre clinical trials of gene therapy intervention.  
Fractures due to osteoporosis are a major cause of long term dysfunction and 
even death (Heaney, 2003) in individuals with physical and mental disabilities 
(Gray et al., 1992; Lingam and Joester, 1994). Lack of soft tissue padding, 
inappropriate postural reactions, and lack of bone strength as major contributors to 
fractures and these factors are common among individual with RTT. For these 
reasons a thorough knowledge of mechanisms by which Mecp2 regulates and 
participates in bone homeostasis is required. Biomechanical and structural 
findings from my study will contribute towards the better understanding of these 
parameters and their link with MeCP2.  
My study results along with other recent studies (Roende et al., 2013a) have found 
a defect most probably linked to bone formative factors (decrease in collagen 
content and no difference in osteoclast number) rather than bone resorptive 
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measures. In this scenario, use of pharmacological antiresorptive measures 
seems less useful by further decreasing the activity of osteoclasts and the 
osteoblast. In contrast anabolic bone treatment stimulating bone formation may be 
more relevant, but caution should be taken due to possible medical side effects 
regarding risk of inducing uncontrolled bone formation in childhood (Tashjian and 
Goltzman, 2008).  
Also my study is the first study to provide initial quantitative analysis of collagen 
protein in RTT bone phenotype. Majority of the clinical trials in past have been 
focused to explore the inorganic part of the bone and not much research has been 
done to explore the organic part of the bone. My study highlights the importance of 
more insights into the collagen as underlying mechanism for the RTT bone 
phenotype 
And lastly the most important significance of this study is the use of adult male and 
female rescue mice. Reversal studies (Guy et al., 2007; Robinson et al., 2012a; 
Gadalla et al., 2013; Garg et al., 2013) in stop mice have shown potential 
reversibility of RTT-like phenotypes. In this study I have shown the first evidence 
that RTT bone phenotype can be prevented/ improved by genetic manipulation. 
These data in rescue mice however at the proof of concept level should have an 
impact on the future therapeutic approaches not only just for RTT bone phenotype 
but for better bone health in other related bone pathologies (osteoporosis, 
osteogenesis imperfecta etc) for which gene based therapies might eventually 
have therapeutic potential. 
6.3 Future studies 
The nature of this project has been to explore the consequence of inactivation of 
MeCP2 on bone tissue using an animal model of RTT. This represents a logical 
trajectory in reaching the ultimate goal of exact mechanism by which MECP2 is 
linked with the skeletal tissue: 
 In my current study I have used a functional knockout mouse model in 
which Mecp2 is silenced throughout the body including the nervous system. 
In order to discriminate where the bone phenotypes I have identified result 
primarily from local intrinsic bone dysfunction or whether central (nervous 
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system) dysfunction result in secondary bone phenotypes, experiments with 
different mouse cre lines may be informative. For instance mouse lines 
have been developed in which Mecp2 is activated or inactivated only in the 
nervous system or only in peripheral tissues or other organ systems 
(Alvarez-Saavedra et al., 2007; Alvarez-Saavedra et al., 2010; Chao et al., 
2010; Nguyen et al., 2012). An analysis of bone measures in these models 
would be highly informative. 
 The role of collagen in the pathogenesis of RTT bone phenotype has not 
been explored yet. Basic validation of altered collagen level by techniques 
like immunoblotting would strengthen this conclusion whereas a better 
understanding of collagen (matrix) structure in bone from RTT model using 
approaches such as Small energy X-Ray (SAXS), a nanomechanical 
imaging of mineralized fibre composites can provide useful insights about 
the exact structural changes that might result from MeCP2 insufficiency  
 In my current study I have used an adult mouse model, in future, animal 
studies need to be done to explore the possible effects of MECP2 on the 
bone mass formation and later on ossification of bone, using the embryonic 
and early postnatal murine models. These experiments will give a better 
understanding of the exact time points over which the deleterious effects of 
MeCP2 deficiency start impacting bone health/properties. This will also help 
in the development of future therapeutic strategies and time point at which 
they should be implemented. 
Based on the findings of this study, the reduced bone size reduced mechanical 
properties of bone, altered structural parameters and extracellular organic deficits 
in an adult stop mouse model points towards the fact that MeCP2 has a general 
role in regulating bone growth. Improved knowledge of how it involved in bone 
metabolism is important to assist directions for prevention and treatment in order 
to improve bone health in RTT. 
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